var title_f16_43_17072="Local anesthetic block MP joint";
var content_f16_43_17072=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F80531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F80531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Local anesthetic block of the metacarpophalangeal (MP) joint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 356px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The wrist is placed flat on the table, palm side down. The point of entry is in the web space between the metacarpal heads. Ethyl chloride is applied to the skin for anesthesia. A 5/8 inch, 25-gauge needle is inserted at a 45 degree angle, 1/4 to 3/8 inch deep, and 1/2 mL lidocaine is injected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_43_17072=[""].join("\n");
var outline_f16_43_17072=null;
var title_f16_43_17073="Hip prosthesis PI";
var content_f16_43_17073=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F65030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F65030&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hip replacement prosthesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 474px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anatomical Chart Co. Copyright &copy; 2008 Anatomical Chart Co.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_43_17073=[""].join("\n");
var outline_f16_43_17073=null;
var title_f16_43_17074="Aging pleural hematoma CT";
var content_f16_43_17074=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Loculated pleural hematoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Loculated hematoma in left paraspinal location after cardiac transplantation. Low attenuation with several specks of slightly higher attentuation material indicate an aging hematoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_43_17074=[""].join("\n");
var outline_f16_43_17074=null;
var title_f16_43_17075="Patient information: Breastfeeding (The Basics)";
var content_f16_43_17075=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15451\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/38/25191\">",
"         Different holds for breastfeeding",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/62/41967\">",
"          Infant's latch-on for breastfeeding",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/13/38111\">",
"           Hand method to release breast milk",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?33/34/34338\">",
"         Patient information: Diarrhea in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/38/44642\">",
"         Patient information: Ear infections (otitis media) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/62/22498\">",
"         Patient information: Jaundice in babies (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/49/26386\">",
"         Patient information: Poor weight gain in babies and children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?17/25/17813\">",
"         Patient information: Breast pumps (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/19/1333\">",
"         Patient information: Breastfeeding guide (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/61/37845\">",
"         Patient information: Common breastfeeding problems (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/54/31588\">",
"         Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/0/25602\">",
"         Patient information: Weaning from breastfeeding (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Breastfeeding (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/breastfeeding-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H477147810\">",
"      <span class=\"h1\">",
"       Do doctors recommend breastfeeding for most babies?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors recommend that, when possible, women feed their babies only breast milk until the baby is 6 months old. Breast milk has all of the nutrition that babies need until they are 6 months old. Breastfeeding can also help prevent babies from getting ear infections, lung infections, or diarrhea.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H477147817\">",
"      <span class=\"h1\">",
"       When can I start breastfeeding?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most women can start breastfeeding within a few hours after giving birth. For the first few days, most women make only a small amount of yellowish milk called &ldquo;colostrum.&rdquo; Colostrum has all of the nutrition a newborn needs. Most women start making more milk after 2 or 3 days.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H477147824\">",
"      <span class=\"h1\">",
"       How should I hold my baby during breastfeeding?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are different ways you can hold your baby during breastfeeding (",
"      <a class=\"graphic graphic_figure graphicRef60405 \" href=\"UTD.htm?24/38/25191\">",
"       figure 1",
"      </a>",
"      ). You can try different positions to figure out which way works best for you and your baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H477147831\">",
"      <span class=\"h1\">",
"       What does &ldquo;latch-on&rdquo; mean?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Latch-on is another word for when a baby makes a tight seal with his or her mouth around the nipple and the areola (the dark skin around the nipple) (",
"      <a class=\"graphic graphic_figure graphicRef69241 \" href=\"UTD.htm?40/62/41967\">",
"       figure 2",
"      </a>",
"      ). A good latch-on helps the baby get enough milk and can prevent the mother&rsquo;s nipples from getting hurt. But even with a good latch-on, it can be normal for women to feel a little pain when a feeding starts.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H477147838\">",
"      <span class=\"h1\">",
"       How often should I breastfeed and how long should a feeding last?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A woman should breastfeed when her baby shows signs of being hungry. A baby can show that he or she is hungry by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Waking up from sleep",
"       </li>",
"       <li>",
"        Moving the head around as if he or she is looking for the breast",
"       </li>",
"       <li>",
"        Sucking on his or her hands, lips, or tongue",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Babies can breastfeed on different schedules and for different amounts of time. For example, some babies finish a feeding in 5 minutes, but others might take 20 minutes or longer.",
"     </p>",
"     <p>",
"      Doctors recommend that women finish breastfeeding on one side so that a baby gets all the milk from that breast. Then, a woman can see if her baby wants to drink from the other breast.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H477147845\">",
"      <span class=\"h1\">",
"       How do I know if my baby is getting enough breast milk?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can tell if your baby is getting enough breast milk by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Checking his or her diapers &ndash; By day 4 or 5 after birth, babies should have at least 6 wet diapers a day.",
"       </li>",
"       <li>",
"        Checking his or her bowel movements &ndash; By day 4 after birth, babies should have 4 or more bowel movements a day. By day 5, their bowel movements should be yellow.",
"       </li>",
"       <li>",
"        Having your doctor or nurse check to see if your baby is gaining weight",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H477147852\">",
"      <span class=\"h1\">",
"       Does my baby need any other food or drink?",
"      </span>",
"      &nbsp;&mdash;&nbsp;For the first 6 months, most babies need only breast milk. But your doctor might recommend that your baby take a liquid vitamin, too.",
"     </p>",
"     <p>",
"      When a baby is 6 months old, he or she can start eating and drinking other foods. Ask your doctor or nurse which foods you can feed your baby and when.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H477147859\">",
"      <span class=\"h1\">",
"       What problems can happen during breastfeeding?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some women have problems during breastfeeding that can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Swollen, hard, and painful breasts",
"       </li>",
"       <li>",
"        Painful or cracked nipples",
"       </li>",
"       <li>",
"        Breast or nipple infections",
"       </li>",
"       <li>",
"        Blocked milk ducts, which can cause red and painful breast lumps",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H477147866\">",
"      <span class=\"h1\">",
"       How are breastfeeding problems treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Breastfeeding problems are treated in different ways. Treatment will depend on the problem. For example, women with swollen, hard, and painful breasts often feel better if they:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Use their hand or a breast pump to let some milk out (",
"        <a class=\"graphic graphic_figure graphicRef73810 \" href=\"UTD.htm?37/13/38111\">",
"         figure 3",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Use an ice pack or take pain-relieving medicine to treat the pain",
"       </li>",
"       <li>",
"        Take a warm shower to start their milk flow and let some milk out",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Talk with your doctor or nurse if you are having problems with breastfeeding. Most breastfeeding problems can be treated. Some women also find it helpful to talk with a breastfeeding expert called a &ldquo;lactation consultant.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H477147873\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse if you have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A blocked milk duct that does not get better",
"       </li>",
"       <li>",
"        A fever and a hard, red, and swollen area of the breast",
"       </li>",
"       <li>",
"        Blood leaking from the nipples",
"       </li>",
"       <li>",
"        Pain that lasts for the whole breastfeeding session",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H477147880\">",
"      <span class=\"h1\">",
"       Do I need to eat or drink more when I am breastfeeding?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Women need to eat extra calories and make sure that they drink enough fluids. Ask your doctor if there are vitamins you should take, or foods or medicines you should avoid.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H477147887\">",
"      <span class=\"h1\">",
"       When should I stop breastfeeding?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women choose to stop breastfeeding at different times and for different reasons. But doctors do not recommend that women stop breastfeeding all at once. Instead, when you decide to stop breastfeeding, you can drop one feeding every 2 to 5 days, or breastfeed for fewer minutes each feeding.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H477147978\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/62/22498?source=see_link\">",
"       Patient information: Jaundice in babies (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/49/26386?source=see_link\">",
"       Patient information: Poor weight gain in babies and children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/38/44642?source=see_link\">",
"       Patient information: Ear infections (otitis media) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=see_link\">",
"       Patient information: Diarrhea in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=see_link\">",
"       Patient information: Breastfeeding guide (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=see_link\">",
"       Patient information: Common breastfeeding problems (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=see_link\">",
"       Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/0/25602?source=see_link\">",
"       Patient information: Weaning from breastfeeding (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/25/17813?source=see_link\">",
"       Patient information: Breast pumps (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/43/17075?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15451 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_43_17075=[""].join("\n");
var outline_f16_43_17075=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H477147810\">",
"      Do doctors recommend breastfeeding for most babies?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H477147817\">",
"      When can I start breastfeeding?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H477147824\">",
"      How should I hold my baby during breastfeeding?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H477147831\">",
"      What does &ldquo;latch-on&rdquo; mean?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H477147838\">",
"      How often should I breastfeed and how long should a feeding last?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H477147845\">",
"      How do I know if my baby is getting enough breast milk?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H477147852\">",
"      Does my baby need any other food or drink?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H477147859\">",
"      What problems can happen during breastfeeding?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H477147866\">",
"      How are breastfeeding problems treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H477147873\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H477147880\">",
"      Do I need to eat or drink more when I am breastfeeding?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H477147887\">",
"      When should I stop breastfeeding?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H477147978\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15451\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/38/25191\">",
"      Different holds for breastfeeding",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/62/41967\">",
"       Infant's latch-on for breastfeeding",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/13/38111\">",
"        Hand method to release breast milk",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/25/17813?source=related_link\">",
"      Patient information: Breast pumps (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/19/1333?source=related_link\">",
"      Patient information: Breastfeeding guide (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=related_link\">",
"      Patient information: Common breastfeeding problems (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=related_link\">",
"      Patient information: Diarrhea in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/38/44642?source=related_link\">",
"      Patient information: Ear infections (otitis media) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/62/22498?source=related_link\">",
"      Patient information: Jaundice in babies (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=related_link\">",
"      Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/49/26386?source=related_link\">",
"      Patient information: Poor weight gain in babies and children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/0/25602?source=related_link\">",
"      Patient information: Weaning from breastfeeding (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_43_17076="Notalgia paresthetica";
var content_f16_43_17076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Notalgia paresthetica",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A hyperpigmented, lichenified plaque is present on the right medial upper back.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_43_17076=[""].join("\n");
var outline_f16_43_17076=null;
var title_f16_43_17077="Chlorpheniramine and acetaminophen: Drug information";
var content_f16_43_17077=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"18\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chlorpheniramine and acetaminophen: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/10/43172?source=see_link\">",
"    see \"Chlorpheniramine and acetaminophen: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Coricidin HBP&reg; Cold and Flu [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F150026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkylamine Derivative;",
"     </li>",
"     <li>",
"      Analgesic, Miscellaneous;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F150018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cold/flu/muscle aches: Oral: 2 tablets every 4 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F150019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F150020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution. Limited, low-dose therapy usually well tolerated in hepatic disease/cirrhosis; however, cases of hepatotoxicity at daily acetaminophen dosages &lt;4 g/day have been reported. Avoid chronic use in hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F150011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Chlorpheniramine maleate 2 mg and acetaminophen 325 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F150004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F150012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of congestion, headache, aches and pains of colds and flu",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5118634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F150024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F150023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F150009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Acetaminophen may increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F150016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Coricidin HBP Cold/Flu Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-325 mg (24): $4.85",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F150014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, &ldquo;Potentiation of Oral Anticoagulant Therapy by Acetaminophen,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/43/17077/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, &ldquo;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/43/17077/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, &ldquo;Potentiation of Warfarin Anticoagulation by Acetaminophen,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/43/17077/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, &ldquo;Interaction Between Paracetamol and Coumarin Anticoagulants,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/43/17077/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &ldquo;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&rdquo;",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/43/17077/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &ldquo;Warfarin and Acetaminophen Interaction,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/43/17077/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, &ldquo;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/43/17077/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, &ldquo;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, &ldquo;Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),&rdquo;",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, &ldquo;The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,&rdquo;",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/43/17077/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8861 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9F1D191359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_43_17077=[""].join("\n");
var outline_f16_43_17077=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150017\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150026\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150018\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150019\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150020\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150011\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150004\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150012\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5118634\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150024\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150023\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150009\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150016\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323061\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150014\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8861\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8861|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/10/43172?source=related_link\">",
"      Chlorpheniramine and acetaminophen: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_43_17078="Zephyr Endobronchial Valve end view";
var content_f16_43_17078=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76276%7EPULM%2F64484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76276%7EPULM%2F64484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Zephyr&reg; Endobronchial Valve, end view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Views of the Zephyr&reg; Endobronchial Valve vents showing an open valve during expiration (panel A) and a closed valve during inspiration (panel B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Strange, C, Herth, FJ, Kovitz, KL, et al. Design of the Endobronchial Valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reduction. BMC Pulm Med 2007; 7:10. Copyright &copy; 2010 BioMed Central Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Zephyr&reg; Endobronchial Valve, side view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAVIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD364fdKYUJHAHSpbWMKMMw3CqsqsJFcn5t2efarLYbaWx84zXXaysec7N2LqOQwBGM9KcXC5JqnOGYrtbgd6aUcjBOc9DWfIVzWNAFTk1VkyXPJzikDMg6A4FM3NISeKIxsPmvpYZK4WPbn2qW0RWX1yO9V3K5ZT8zevpU0UqRKoAzxVSbsRy66jp4djhwQBTlQHkHJIzmiWdXXCgVSluNhCCktiloWyQOCfzqeKZRwCKyJGYrnjApY3ZBkcg03G4r22NeSdV6CqknzZOcZ5rPkldn+9wO1SrIzRkHGKFGxXNcu2jqFIP50hKrKcHjNUY9wHvTh5hbnpVKJk5WNhHG0c1HJKDwD+NVoASRuPAqeZ0UY21k42ZopcyHYyvOc1TLsJOOxq4kyspwRVfALY/iPNOPmDuWo5weDwainYN0NNKDuetR+WQOvFNJBd7MrOpyafEpYjmm4JkNSr+6w36VTYLQs+Upjx3qq8PJyanEje1QO4Gd1EbhJld4wrDBq1Cq4qk+8uO4q5Eu1RnqapkJsc8aAEk1VmiDcrUszbcmo0kU/epbF3vuRxRYPNXBEmKjUfLnNOEmT1FDHew8wqAfeoGhx61YWUDOcH8ajaYHpRqLRkaxc8nIqwkYA6cUiupPzZqTzVA4pNsdhVjHpS7V561H9oweKY03JOKWvUEMuIlGcCmQgDmleQt1pEYDHFF9Qkrl1WCjrTHcAGq7Sjn9KheTOc0XEnbQl3j/ACaKrbjRU3HcW4n2upHfgCmzzPLBsb74PBHaozfQO+Du3jjBWqou2aUJEo4PJxzmtrGLZZ+33OzBiJxwCBVyC8llUAIR3yarW6ykDkkHqKkaSSMFRggAkn29KLIqzLQuJCFZlwoplxK4IWPAycmqM11PIpEaKB2zUaXc2w7osso4xSUSnKxedgictliagebBABB+lVS0txg7Sh9DV61tcIMjLGm49yea46G4AIymR60yZvMb92CQDV+OAbemD7UsUKgAED6mpdkO7ZUSMsnTip0gLJux8oq6sKhOD+FPiUKxHQY6VDnbYuxni2BOSuBUU0BB+Xn2rWlK7MVAQpPNOMrkyRnfZ5CMkEVYjXalXsJtxVebAHBp81yGReYVPA5qGad9+DyKdCmX65FTtDuA45puyKSa2IVkQLnoaZE/zEg5zVsWu5TwKUWuwdOaltMav1K6TgEhgamd/wB0NoqvOpUk4xToWBWm0UVZpJFYEZGadE7Ny+SK0BCrp0qtIhTjFNNMVg3EjK4x71XlchzxUgBJ46UrDf1AzTE9UUluMONy5q19qRsbf50v2Qt2PSovshBGBSeoo3Qk0+49cVCqAng0TQkfWp7OLkA5zRYa1GL5ijuabubPINagiGKjaAHvii47XKgLAYp6KWGKn8nHXP1qVUAI5FA1GxAIn69qY6MvetCFA2QSMU2eLnoKSlrYGmZjk4xupImYuAelSumDToo/m6cU5K5K3HCPccmnNDjkdanRBjrTnIHWptYspOhpqxGp5CO1OQ5xnFIOhCITjtRVwYwOlFPlEU4bWFkz/F60sVjiR2BAUntSR3Ea55HXOKlhvYxgcc1bbWxne7JRb7OlVVTcXDKNwPany3p3H+72pbdlaQOSAcHpU3fU03KyjZKQfyq5BAu/JXrVOaNhM0ijJz9ale6eFQNh3fSrfkZXtuWJoAJuAcmgAJgkCoReeYOcg1HLcDacg5qdUtRxa6FszhVOMH6VD5kj8qAB6Vnpcjdj7vNaMcy7RgiixTd0Kbp1wD2p8dwS5yM1FM60RnepO05H60rImzJTI240EOw461A10iHJKKB3JrznxT8SZLMXUVig3RttiYD7x71Eny6lpN6I9MYyqcHtUZEjD5unavH/AAP8Xp7nW0tNeIFtM2zewA2N25r2WeUsARgqeRjuKqMuliXHl3G242kcipi/I2nOKqoBncTgUSSDn3pyNE9DQWZQMNimm4XGBWW0pUdCahN0Ae4qeQLmhM4J5GaYqgYYZH1qmGZyCDx1qcyOw+UcdKYjUt2/d89RUUy5NUlkkQHGaY1zIpy3OaSWo7lnbzSomCMVW+08jsamjlzyOuavchpM0olGzpUEy4YjpSLLgU1pFbris1dMb2Ks8eSOO9SRIFwe9PJ75BxSq2ecVdwSsSI3Y0pUHmq7vtoSQk/SlYaJWUEYqILgnAqbdQMEmi9irDYiQwqaU5WonYKDjrVOS49/wpWvqBJIMEmhCBmqpuT0pQ+Rkd6q7FYsmTHAqKSU56nFQM2DzxULOSeKlsXKWDLzz1pyyHjmqZDEZpyFs+tSUXjOc0VB+NFOwGH50jxlgrBT3Pemr5rtkPyBwK1k08+WAVyB1zUv2HEisqBR0IrpsjnsZ/2naFUvk+nrVmObOWBCk9s1NHYRySqGHOMA0p00xuAp4paD5pFm2ulCDfwx6CobmeN23N34xTGtjGnXJPOe9UU8yTOD09RUpagXGCHkNg9QKpsxVhkg596I4nTl2BzxUWtX+n6HprXV6wJPCoCMscdKqVluKOmxL975Q3J/SrlnBIT8hA6YJ5zXkd38SnuL9IbSJo1LYEUal3Pp0yc11/h7xVYM8VpqV7eWF1IR5ZuUaMs3b7wwaTTSuaxjc9BtbdfNUTbmzkU69jEciLkkZzj2qmb2S0uIINTK7pMCG7jHySHsrehq7chn2sSSRmudXbNZJR0MnUIswTrGACQdvHrXj+hWMdxrWnTXUeYi8uQw6lc5H4HFe2SoXgVwOQ5zjrgV43qV1JY6hqFuyk+ReC9X+8N3Dfn8ta2urBGXKyl4u8L28s0l1Y26K4J4VePr9a9E+FGsTajoTWN6d11Z8f7ydj+HSoRZoyLtO5JVGG9cjOa53wvcN4c8bwGY7be4Jgcnjgng/nim1eNyJrmR7AbbAJPSq7RqG6HNar8KelVHCh81EZX3JbtoUmTJK9qUWKNjJzUsjDOQKlSdcU7voNMalmE5X0pY4wGx0NTCbK9KhWT584qdWF10JCqg88mmtAG5wPamzSEkYApRMQCKWpWgn2NX5IHNM8gJwMcVKs7FcDioppG5yDVK5NlcqzvjgcdqgWRscZqWVSx/CiKHPApisNVnPJzmrEcm0c1JDDtGD3pky7RQGw2VwxBHFMV9rc9KkVAw5phQrxTGSfaBSLOOai2n0pvlkjuKloY+WbIJFU2QuwOeasvH8mDTooelICmYDn71SIjDqeg4q+YRt5FIIgabjcE9Si6HAzTVU9O1XZY+gxUezipGyNcg81IoGRmpAgIzSAdMVdhCbaKl3H1NFQK5YLqFYk9+BTEkUMFLck5rEaK8kO5M4680iLMD5jfexitVEjmsa0jeWylTyDV8YdcjpWHAZpMcZPQ+9Xw06gKCBTlEakOuyoChce9ZpwrMoAAPXApus3sWlWD3l3koCBgetc/ovimDU9Rkjj24I3Bc9qFpoTuzo9qsFHJ714h8adVuLjXmsLfO23jAVB3JAJ/nXue9WGAQFFeKfESAR+OpXUZW6gDoT6gD/wCJNNPXU0glex6D8O/DVloGi22yBVvJI1aaXH7xmIyefxxiusurG01K0ktb+3S4tmUhkkGRzx+H4Vz2jaol1p9tOuTvUE+3AFba3qq3TrgU6jvuJXuzmdKgktUu/COqtI9q0fn2Eshy/lA8jP8AeQ4/Aiun8N37zW01pfMPttidjn++p+649jWb4ltX1WwSa2cRX9s3nWsv91h2P+yRwap6ZcjXGW809ha6taKYrm0l+vMb+2eVcVirNG97qx1e7y9wP/PIsc+5xXmHxCsUstcgv3VZLa6t5IJIw+05xwT9Dg/hXezagLeGcXsU0EhRUAKFx68EZBFefeM999PvXcltbQlgzKQX9SM/X9aqF02zPlkza8LSPeeFNKmZtxCKjN67SVz+grnfiJaP9kS7izvjIbI7EHiuv8JWb2vhXT7aYbZQgZlI6Ekn+tSajYrcwTwy4ZJAy4P1qW9RvfUv/D7xKPEXh2GVj/pMQEcy9wfWujI4rxzwDo2qeFvEFzf3UkcelswhdGb5nyeCB7V7QwUqCvQjIxTceTQxKe3cSBTo4CGPWlDYfHSrkTKRz1NQ3YuNmhgiOzHSq7xkc5q1NKqg1T37+59MU43FoNB560ZBal2inxqoPPSmO5PCo2UssQKk4xTkKqMCgvuGKi7GjNkUluKkRQtTlNxyKbINq1dwHoMjPtTJE3E0xJNtL545zikm7gIqhcjtTtox0/Gq8k47YzTRN6imBcCA4prhVzVfz+KieY896TdguPd8cdqVJRmqLSMTjinxjjJNAXNESq/HFSDp1rM3ADjr607z8DrVNgXJCGbpzSBRVLzWz0qdJODUDJWIFM3D16VCzn8KaDuPFO4mT76Kj8s+9FIkutIgwOg6YqMNGy7RgDnnHSseXUcEhhkrnFRy3wKHywRIOtbcrIv0NpZ4oFOOCOKrzaio+tYTTSMMs3yqOgqBXeTleM+vWtFDuQ2y14ib+09JmtcffBAyM/Ng4rxHwyt7b+IGtIgVv4GygJxnB5X8RXss0pgGFB+przDxpG8HimDUbJSJG+cAd2Xt+IyKajZ3FFtPU9Usro3FtHLgg4IZT/Cw4I/OuD+J1uyxWGp7A5tZACPUdcH9a7Kz1KxuI7aWyfbb3EYCDHTAyuffqCe+Kw/iI8f/AAjFwpI3OVC+uRyaUo2N76kPga6jCz2iPvjicvGc9UYZFdZEWLN1Y78ivOvhjKrak6pwBCisMd9pr0hVKbDjpz+dRW2NErSL1s4ZIlIxwc/rVTXvDcGoX6X1hLLYaoigrd25w+P7rdmHsc1at0ysb5xzkitKKUBs8N8uPxrnjoWcRqd/440W0lnZNL1e0gzuARoZ2ReT04JxVnVIorzSra7jZvs9zBHMCw+ZUcBlJz1xurotXbzLARqQBPMIGz1IY/MP++QfzrmPH/izTNF1K20+Swuvsg2W8l1GAILbcAFDH2GDj0raE76PYI+pp2Ws28l21peEQXwVUAPCTH1Q/lV+4Uq/zcYbB9q8R8e3niLSdRe5mZJ9FhmSBo1IzGdvysD155IPtXpngjXP7b0xknkD3NuFJcf8tY2HyuPyINZOEkrhK1zP8d2E91biSB3wBuwp4yK6/wAFaydS0CJZci4g/duD14HWmx7VVgyB2HK7ucVzOl3Nzba/JEmQdmEXGAQMkL+RroXvxv2OWSSdzujIxfnpVyN8Lx2rO06eK/i8yLIbPzIeqmrQDAkGsmhxZFczMXAzTrUMxpzxgkEjmpoBtkGKG9C+VEnkkc1HICoFaKL8oqvdKMe9RGV2KUSkbgg4NPWfI61XmUk/KOaREbANU0NE5uAvrUUs4YHrThCWHIFNaDae1HKBFvJ6U1mfacZ/CpGjx61PHGGxTs0EXqZ6o5bOKmVCoya0UhGD8oprRDb0oRVil1oWI7atGMbc8UhIHFTICukOR2zT/szKKsQlRT2cEc9arQRmSIcmkCE9Ksy4JJFOiUDnFS2h2K6xFsVJ5e2rq7RSSFMY70LUDPYZ+lTRR5IxikYgHFPifnrT0QmTiLjvRTftJHGBxRUXQtDnEtQ0gHTPApzabKrl0dtpJyKvMFUY9qmglfACjJrr6GSWtzPitAwwwIPpUyWagnjPHarBO18sOSM0qygZwce9O4upi6pbbLdmJO0VxOtWy3Fo8kQ/fwHzV/Dk13+qEvEykDbXBam0lrcMygFT2I7UasTRzt/cS6JcLLGpNhcrvj2/w55x+dY3iXxHd6laJGu9gOFX1J713mlQwX2jyWt4glRZMbT1APQj0rzrV0fRNcuIrZ/kjLIARnKnsa0TUrJlw+LmZ2nwn0y4tbeS6vEKSyvwrDBAxXosrjaOeK8g8O+K7ya5WANIbhAWVWHBXHP147V6Lpupi/gR2Xa2OeMKfp/P8awxEWttioybZ0FmxklCbzuPA/Kr7boP3bgiQsBXPPP5coKsMggj2xW7ZXsV9DDFMD5seWL9M+9c0djoe5n61diGGzmJKpbTrLIcZypbb/Wq95aw3GqatpF+iywaqi3Cgjj7oUj6gr+oqXUrbz7a4gkOY3gKE+5PUfoaoS3+NK0bVS5kubUiKcYxjJ2tn/gS/rWkVeOhLdjgdOmTTdQl8NeIoxJEsZt2HOLq2PKkH++nBB68VneCtSHh/XDatcCaGwdoxIBgS2zHrjtjg47ZNdj8YfDzXUUN/p7KtzauGR8/wtgj+YrzaCY3FzmWIQarBkSRFcbx3/OuinGNWN3uRqnbofQjFQ6uh3RkZBHcetZ+q6cRe21zbkiQHAI4AYjK5+uCKyPAerLe6S9lJnzLUDYG6mM9Py6V21mn2jTZEUhJwdqt/dYcqfzFc0JuF4lVIIxZYzJFHqWnuImkGWGML75Hr2q7p2uR3DiO4xFP78ZqHSnFrq17ZE5hlC3UQYcAPyw/Bg350mo6Ejl5IBjJLFff2NaKSlozPltsdCRnkHI7Glj4INcbHf3ukSpFKRJF6Nya6vR9Ttb9F2MBIf4GOKiSsWncvCV9uMVDI7txkZq46hR6VGuM845qUyZK7KZjJHOaljiGKnkAHpUJkCnqKdx2FKheKhZcnNEsw9ah84Zpc1gS6COSM4FSQzbQQQMVVll5qASndgVXNcLWZtCZfWoJLjBPIrPMr+uaaSWTJ61N7MZae45+9TfO3cE1QZX7GpIw2Bmk23sCLok44oMuByahQEmnGM55pXZXKhDLlulTRyfKKh8rninhCAOKWpJMZcfjUbSEikYZxTkjLdasCLnPSmuxA4FW2hwKheMgUhFRpG3HrRU2wUUwIFlUzDcVHNW4ZUVCc9D1NcpawzKQ8xbdnOavbpJI9ufyroSMToDLCytkgkVTyhfAP4Vl/vEjwQSTUSTyRtuORz0qkiW7GveLGY/nNcb4pEWxmUjjoK2p7t7kkD5BXO6zbZtmZiXYZ6etNIXNcxfDuoImoNC5wJOvp1riPGbKviy5tZdyiVi24enGf0rSvBLalpI1KOp3A/SpPGltDe3On6sMFLmMHOOjAYI/L+VFNXkaR2Oe0bQpEuNWhtrvzJLKTdBIHKueu1gPwznscV6x4X1l9bh09raKKBZcrJGBhROo+YA/7QwwBrzW1ujp3iuKY4EcypHJn3VeT+NdHbKdC8ULbEmHTtW2tCeghuB93n6/KfqKupFc3Kyou92egyN85Vgc989QaYJWjbCNjapAIPGaJ3EqidVAyTDMpP3JR1+m4cj8RUYHyemODXn2tobo3Ib2O5t2iuCFfKKjetZH2Xz4vEukOQhwZY2OP4huH/jyn86ZGu1yGBxu646VHb3Rt/FlnMxAF1FLb5YZyyMGA/LdWlD4rBLY0rSWLWvC9sJVw0tp5Ug67uMf1/SvN9V0KbV4hcWhKa9Zt5TNwPNKep9cYr0Pw9bmJLiADiCV4xj+795T+RFZ00P2XxRJMi7Yr5RJtPaVP8Qf0pRk4Sdgcbq5wfhLXzZ6mkk4MV1C5WeEjBK5wcfzxXscd3lVe3cNHIAyup4buDXkPiaCDWr6R4G+za3A7CN+gnUH7rf7VTeDfFj2chsb1GQq2JIT2Pqv9RW8oc3vpGTm17rPVfEgSCTTNWiP7sSmFx7Pg/ow/WuiX541ZTkEZrHhVNc8MXtnC6s0kXmQN1ww5B/MD86v+FbxdR0C3nbAfHI7j2rlvyysXbQW7tIZ0xKgbPHIrnr/AEG4tm8/Tn3Y5Kk4P4V2zQLJHxjOKz33Rna/I6Vop3JOUtPEd3bqVvlZlXg7h81b1hq9veIDBMNx/gJ5FM1PT4L6I70DNjr3FcbfeGriBzcWE0gdecA8inZNBsd+0zmo2dj3rjdK8WyWMiwazGSucLIF5/Gu1s5rbUIRLZSLKh9OtZ8o07leTd1qMBu+a0Ht+4qMQ855zScSkQRxFuTUhtwoBB5qwq8c0u0dqtRViZS1K+wdDTjCOwqUrzmlT3osBAIMnpTnhAGcVYwe2MVHKw70wsQqnIAqXy8jmmZ9KniIPBqeXUOYdHGAO1RyLyanIXGcionYc80x20IduKswgelVBJhutTJJz1pMRZYc8iq0uCDTpJcdTVd5N3WpbsAwjmik3j1oo5gK6RRsTnJGAKmSyVSf7tU/tIEXyYyKntL0nPmcZrqvcxehKtuhj+b7x6c1DJpcco6c96c0ga4UqeMdKsiZVbJ/nT2JauVDo8MYGBz696oappqG3cfoK15LlX6HnpVK6l4wSDnrTuyfI8u17S13ED8qwLVWu9FvNKlJ8y1lE0Oeu3vivRddRXRtuPevI5r59P8AFBcnETbkYeoNKG5otEWrSwa78Rw2jRmXzY1KjPouf6V2er6QviLweqxswuMkDPHl3CDOPoy/qK4u2vW0zXLW8xua3EblevYcV6ZpjLFql3BBza6jGl7AT1OMnA9xzSryd/Q1prRnP+DfES3Vk9xqIkSVAtpq64+ZSDiK4A9cjB9wR3rrmia3uJIZNuU/u9DnkEex61wviyI+HNcTxDbQiSwvENvfwleJFbrnHTOMg+orqPDNzHdaatuJ/OFunm20hPMtsxJ2/wC8pHA7fMO1RUjzrnRd7OxoyuGUZ6A1neImNvYWeoRYC2V3FMwPOFY7Gz+DVoMgboCVNQajaG/0y/sk/wCW1s6fjtyD+YFYRlaSG1fQ2IybfXGLfLb3SAZB4yOAR9MCoNcgaWNvLUfarVlnQH+IDqPxU1m297JqPhXSdS27GQKHGc4J+Rv1ANaqSxXMmyTKzJg+ZyAM9AfT61dZWncqL0PPtT0/yPFMzhSyz4kjU5yCfT3o8T+Fnu41uoVMN8qjDngE9gT/AF/Cut1e1dplnQf6bbMJEB7+x+vStjTDJqenm6to1mTkPCeHX1H1rWFS+tzK1tLHm/gTxpdaDqYt9QRhsbMsROMk8Er/AIV6Z8PbtXn1O2iBERkNxBnvHIdwI9uo/CuH8beGbfUIxcWeYrmPkFlwwx6+tct4S8T32h6xi6aXz1Xy3Qn7yZ7fzq6tONRc8VqLmtofTCyeWuGPNRXGyZcEA4Oc1z+manfXdpFdW7RXNm4yJD/Kr8t6YhvmWJlPPcGuUodLEVwd2femxxiUHI/GiK+SX7ltkY5w5pftsahttq+R230XdwsZ2raBbXwJkjAfsRXJtpmoaHL51g7Jg8AHCn6iuym1N9xK2+B6Fqg/tGNplW7gIiJ+bHPFVzMlq4uh+JItRH2e4xDeLwUJ6mtgMB1ryDxR4jsH166/sm1eO5iwImOVyAOTj612fg/xKuu2RzgXMQAdfX3FOUJKPM1oRCV3Y6p3GCeKiEp9arSSsoINRCQkgCo12NC80/HPFRicE8fnUYRnBwTT1tzjJo1YXJPN461GzknGc0FCBwcUCPJpWY0xAxHFSxuR1NHlUFBjrzVpaECtNjqetRPMT0PSmOp7GlSMnknNT1LWwhYs1SqxWnpFnrSTLtFUxWIpJOvPNCfMRkVXzl6twjkVDEN2D+7RVjZRSshnPW9lICWlJUgdB0qZvKUYZ8HvT54HnXaJSuOw71mvplzsZQ+T6muzdaGD0eo65vzFJm2G6mGW5jiM0xOOoFJHps1u64Ib1xU0kMsnyZP0pJMTKpupJlBHGaV/OaPBYg1dhtCVAA24qaezmG0rzWhF7HLarFNDbyO3IwT+FeS6nAbi+d2H3fmBHY17T4mLQ6ROZRtOMCvJIU3SSk9HcKPzFQk0zRS5mU9VBW5ue5XbGFJwSQAK9C8JXTXehx2Z41HTsXVqCeXQ8vHn36iuGtbYXmo4x8plJOepyeK7AWs41WS/08EGwVdxH8Y7jH0qp2k+Vmi9yDZ1+sRWd9YsJE3afepskUDlM9GryPR2vvC+vzaJNgyxOZLVm+UMDztBPZhz/vCvaIol/szz4wvkyZxg5GGwSK4P4jaCNc0QzWy41LTR5kRXq8XVl9yOorCnL2c7PZlv3onQ6ZdR31slxGeGAJHuQK3NOUCbAiyzcbsZxz0/GvNPBGt50xLyVgluZBFKx+6k3Ug+m77w+pr0Zb06eiSSeXt27gQ4KsD0OR2qatL2crx1TKhK+jMzw/bJ5/ifw/IGTyZneIY4CSDemD7HIq54YhvrzTzeWiI8U0IhuI5cbcjndn161D4fvEW91nXp0C2sqea0h6rGibVz7seQKt+HPPttBghlheMy4O3GPm75Hb0qqyvFdxx6tjrmDzEQkIvkDa2F5ZT0H4H9KZpatbXUl5a3BE7AK6uuMjtlehHoRzUio6GZ3UOASPlOc46YqAxSXVvuYeWWHAU4Kf8A1650ndsrRmzrD22o2W28tcTOvDD5gPxrz7xF4JF7YAxTj7ZF/qZiMYH90+tdskFxHbqsN7Is2MsWUFT+FTW090jBbqOG4TsyrtbHrWsXKLumZtI80+Ffia70PU7nRta8yKJhhkY/6pv72PQ17DaTK/mLGm6PPeuF8V6Pa6nqtre2Ns6XcGRPN2ZSPu+5rDvfE+o6HAYbS+iHln7kgDYHue1a1LP30Eabex7DGyL/AMsyCfTFKFzkkD6V5V4d+KkUsixa3CqxnpcwcqP94dq9LtrmK4gSe2lWWBxuV0OQRWOommtGTSIuegqtLEjA7l5+lWdwIphFK9hnlPjbSFh1WK7jXac/NgVzmhX0vhzxkk5DC3kba4PTaeteteJrFbyzYEfOvORXB6npn22zBZP30Y+U9zj/AArenO65JGU4295HqzxJIivE26NwGU+oNQiL565n4Za59usJNMuWIuLbJQMeqV2yxjOQM1k4tOzNE+ZXGQJxipzwKkjTg9qZIPmIpiICoNLjHSnAgcGmuwxxQFh3GB61E7flQZBjk1XkkAPBouJk2AaepC1S80c05JQc1FzS+hoI4xUE7g1Ar4Gc1HNJ0NO4JaDe/FWYDjGeaorKdx44qeN8HrUskuFzmiq5lXPWigCtaxMjZLZBNTFj5vBFV7NJHTO7p2qSaDnAY7q6E7Mwl3Lb7OSuASciqUqYnyOtVmM6DABbaccelJBd73bIwRxWiIvcu2ysrlnGavxOrxcjHNZrz54XqOuKtxJvAPShhfWxyfxJuFi07auM/eP8q8mtl8uCEnI/ebz36ZNd38TpGe7FtFyuQuf51w+p5trYBM5EbHH14qFK8rGlNauRo+ErNZrmKYhsKwJP4E/1r0fwZp/n6XeXGPmuLh8kj+EDFcR4RhK6S8kYOwyMvr0Wuw8P6oLfwvBZwbmuSWVuOAGbOSfpRGVpSaLqbJEfh27dtGls2AJimaMAn05/lQLedhJPG7oo/eI+3OfrTbOLKyyrAskSttCAnccnLvx74H0FWRfK8yWwtpVdWKhyNoCE5IIrmqO7No7Hm/jDwrfWZuNT8LTTpFcY+12kQO1z2wvRh7Hp2rltN1G6imSK6LIAwGyG3csP+Ang89RXvcyeRFvKB0U9EwBj2BrEfWAb/MVrebzwStrxj3Y4H5VtCvJKzJ5epj6GNX1q1jfUbIaXpkbhikshMly4OQz+w6hfWu8nneRRtliEPlnfcyLklvp3+tYWqQXF3PDJbqUg4Z2kJYgdcKvb3J/CqksSFm2OQoPAzkdKiU3LcZtPqiDEdvCSoODIxxk+w9KdHcZBJYYxjb6Vk2sajDKeh7nNaMACqM85qQL8ksm3KDAwKs2ch8i5k4GxcVVZ91tz09qks1DaPdfLuJJ474xTW4xfFStp3h+0S0O26ugFB92GWNZtt4T0ttKFnJZxSNL/AK6Vxl3Pc5rX8clWttDnwduePbIFWNOcvIgbBGe30qaknyor4dEeS+Lvhd/ZSvfaAzqmDvhJyAPasv4d+M7jQL82d6GawLfvY8/cP99R/MV9DOivHhgMEV418SvAB8yTUtJXbIPmwOmaqjOLbUinG56tb3CXUMc1vIJIpF3KynIIqZXz14rwD4deO5dAuf7O1XebXdtkjxzEc/fX1HtXu1tcw3VtHPayLLBINyOpyCKTSTsZ7aDLwjyyx6DrXI3kJiu2APBPArq7p8BgeVPBrnLwb5QpGXVupoTsJq5xktw3hvxPaanDkQSH5sd1JwR+Fe1W0yTRRyxHKSKGU+oNeUeLLBbjSZ1HMkREq/QnBrpPhPqbah4bNvIS09k/lnudvOK1qe9FTMo+5JxO93YGc1A8nzdaVhtH+NVXJJrIse8hNRSSECnYzSPH1zQIrO561AWZmPP4Va2Z4p6QY5xQadCsse7Bwc1IsZXHarcUYxSSIMHmhxsQVm4qMjOev0p0pKtRGM8+9IpMYI+/NPUAVYCDFNMdDJKzEbjyKKkKcmilYB1sgG7DdP1qWVQ23HGOtVgNhV1xt7+9SvdKVU9PUVuYiPIuRxg1TbyhJuHXnIq3c4xkDJPSsu4t5JchAQc9RWsDNuzJ/tCJlxyTwKWPVAm4lSNvPWqcdtIg+fk/yqlrJa306YvjJGM1T2Ju2zitRum1LxBI/wB5EyefWuf8VnZIRzyUTjt3P8q6jwrp0t1G84UfOxGfxrE8S2Zk1n7OGyfte3pwCqgf1qI2TubRujsfD9obPRtPEsYXejyNk4+8elXZYY4LTfGDGDkRxr96Q/U/qa0pMGOPeNywKFyBjJ9BVedGc+bIqq+MAL0VfauZK15Pc6ZvmaSM+0Yx+V5sUbMkexiGI75+lWl1XYqxpFuI6bmziq4gLdST16iiNETJCgGs5O+pSVkWTeXMy87VAP3VUY/WlMzkfOwP4YpisAuearzTBQfWknYZYlu2uJSrMDtA4zwcVSuMkMzDq2Bio0lZbnfgDK81JcIcKxGVzgVSehLRLZx7SMAcHGR3rRjVse1V7UcLkAZPary9OOgaquIZ5gMO0Vd8OMGjliPcn+VZcpOSVOOvFaXhwjzmYLg4yaaEW/FMO/wTZytw8LIc9e+Kj0fLQxNnsDVjxHcoPAqhhkyMEA993/1qraIdtpByDxWdT4TdJNm6rZUZo8pJAyuuVbqDUStlaljfjPpWCLPHvir8OmkU6noyYmQ7ti8H8K43wF43uvDt01pdpI8JOJLY8ZPdlz0Pt3r6UuY1mjZWIweteTfEjwLbat5k9ughvV6SqMbz2LY/nXTSnzK0jKcTs7TUbTVbCO7sJlmtpBwy9QfQjsfaqU43yO4+teGeHNe1XwbrTW1yNrE4ljY/JOP5BvRu9e06VqVtqtmt3ZSFom+Rkb70bd1YdjVSXKTYS9RXgQMP9YfKb6MMfzxWJ8KrltM8bT6fIflu0ZOv8a8j+RrorqIvZSAD5lG4fUVxGqSHTfFllqUON/nJKOOoJGf61tS96LgYVHZqSPeXXIqnIoz05q8zq6hlxhhuB+tU5W9O1YXLYqgDtTJmABqF5CKqTSMWIzRcGifzBnpTxJxz0qkiMT1zU6hgoBFAicSjPAqKRyfx61HnnrUsa7qZXKQcseQaljT0qQRY5OaR/kAxQiZId+NGR0zUBkJ705SSeaTAQscniinEHJoov5AO2xhAmRtIqpNGAgxziqwZ9zbsgjoKnj3bSSCR6VvYwTHxnKHd1Bq3DLHHGc49aoPuIwOKnt4jKoVhx3NaRRNwlmjZ+DgHiue8dsBpBRchmB6V0U9tEuOeV5rlPGEu+aGFehwDSne2g4q+hY8Nxx6do1uhH70qDgdq5CxgfU/FNrH94m8uHII4GG6/pXSyXccFo00zBYY1JkPoBzXiU3iq7ttcnvtOleEtKzpz0DdR9KVCPM2bySWiPomWJAFVACF7j19ay9TfZyV4HGc1534a+Js3neXqapIjfxAYIr0AXttrVqWtSG2/MQeorKtTlEcJWdinHcFXGOF6U/zF3YyD+FVnQo5BxxSuuFDdMda5rmxLLKSuFHQVW5zlu3HNPjLZxkfiKkKhWBI5yOtAFZs7s9lHpWhEVliGc56/lVOUNklsZx2qzaPgBDgE96pCZcgwQOD1HWr2Nic9jms+2wrkFs81eGWTnpmmIp3Gdh2nBzmrmjAw20kjHkKTVO6TLKM8A84q9cBYdMKDhnwOKcewWK3iGZ/7LsbUPkM24j0q9pb4cqOFAGKwLmX7RqcaI+6OFefrWxpzbJhk8HipxGr9C4K25u7/AJODipYpOCDzVYDPAp6Ag1yamxob+BwMVmXoWQkN3GKtMxC9sfWqVw2XJ/vY/CtIETOD8ceELXXbF0mARxkxygcxt6+49RXl+gaxqXhLXWsb8fvkOCM/LcJ259fQ/ga+gJOdwz1rz/4g+FotXsMxqBcxAm3kHBU5zsPse3oa6Yz6MzOo0jUIdTsY57Zg0UnPPUeoPuK5nxNarLpx2jLRkrnGCMHPX8a4v4f+IZ9NvHtb0FBu2XCsMbTnCyY7ehr02+8ppJorkgJLGWU9sgYP6Gt6N4VLdzGtD3DrvB2oNfeFNNkZ9zrH5Tn1ZTtP8q1CRXFfCm5WbS9QtEY5trgZB7bl/wAVNdqyc9awqR5ZNeZUNUmQS4HOahC5appF556UkSYIzSiORLHGPSpJUAXOKRWqVzlcVRKMyXI6etTwNTpYwRToY+BgUxvQcWyMYqCfoKtNHxxUEkeR70mrkldVyc4qwi4GcU2NMHk1L2pxXcHsLiikyfeitLInmII9jMeOelO4EpH8GKqygSEshwwqJPOwMhiSa1MdVoaCoGcgDjr9KuQBQnbNY8f2nzPmJAxVlbqML94bqbFs7luaFeWI61wXiKLOpggng12b3ZdOOK4bV5j/AGgcnnBFJu6BRSaaOc+I10Lfwdc7WwXdVOPTPP8AKuN+E2h2l/PNfX8fnOM+WjjKj3rf8fhpvDksWc5kX+tWPhXF5NvNCf4QCPxrON1FtHRF/iafiLwfpl9HmOBLefHyyxjbg+4rk9GlutB1U2txLsuVO6Mk4WQeh9jXq0wB61yvirQ11aDMXy3cXMbDqR6ZqaVSz5ZbF8tzdtJYtUgSaNkwVz7g+lIqkFw4+UjrXnuia7LZXRiZGju1yJYj/H/tCvQ7G9hvrcEnDEZHFTVpWd1sOMuhFtG7HftQylgcnGKnki2kEcj1pm0YzjoawLIwnGWAwBjrSR/KwwMkelSy/M5K/lUbKyMzZ6+namhM0RgsGAwW/SryD5eOvesy1l8xAWyG6VoxsNlUxESL5lwQ3T2rQSxbUJPKjYKsXzOSe1Q2qjdk1g6lqUqXl4IJGUKmzAPU+9OCu/QpD7a2jh1G6WKQShXKll6ZrTVCCrA8is3R4mjgXI5IySK1F6Gs5u7NEa1vJ5ke7PPerKYOMViW8/lnnp3rUglVx8pHHNYSWpRadcgEVlTH964weDWyMOn1rH1ECO7YgYyKKbuTIidsoOee9U7hFZSrqCrd6bLcKi4z1459agE4clc5K1sZnl/jzw9dWuqnVtNjMhUfvYh1kXvj1PaqVh4uD26QXfmNborKspGTESMBJPb3r1u6gE0Z3AEdSK8n8beC7q3nfUtGulgilPlzI52g55+h+hrenJtruJpNanoPwPmSXV9YSCVJYJII5Mr/AHgef51648XB4r5l+G+vx+GdUtzCxiF9B5btIuB5gbBK8n5civozS76Se02XBBnj4cr0Poaqom5OUtzOLSsh00fNRbeSKld8k5qLPOazTTHIUDHWlL5FR7gDSbsmi4kPJzUsbAY5qqSaQuRkDNFxvYuFxjrzUTuMVUZ2PekBJ4ochWurolL5anK9V9r0u1qV2KxPvoqDDUU7sLIgQfOpGMHtWhCyOo3AZFVA6bgR1BqK5nAOxDgjn8K3baItfUt3VxGgIBFZYVS/XAzkGoWMj44yPWpYopQeelWmyWknYe03lgkcjpXKaipluldSPvdRXS3MTPE23I4rnLgGB1DA5DUkNaaHKfEOPyvDrv6SJn8zUPwvug1xMrEcrxVz4oqq+EJnBPMqdO3WsD4WSA3DEAdCM96lP3GaJanqd2euDVVlHf8AOnXMoxzxUaHP41zM0juYPiTw/FqS+bHiG8Ufu5hx06A1zmmalfaddPa6ihguVYYP8Ew9Qexr0ZyHiK4ziszUNLtNQi8m9Qsn8Lj7yfStKVblXLLVBKF9Szper29yqxsSkwHKsOfw9q0ZITszH84JzwK871nR9U8OqJYQb/Sid2UHzp+Patvw34pMtujKTLCTjb/y0X6itZ4dSXPTZKk1ozo2CqAAPmPWoXBYN6d60YZbe+xKjbW9xj86huoWiJ3DhjxgVzWszRW6EFuQGAJrQV/kFVBDskVSPerRXAPSmKxejbZC7k9BmuIsQb1ZrgnBklJ5+tdPrFwbbw/dyjqsRIz9K5Lw/vFlb7v4uauOkZPuNI62zXEOOlWGODkUy3/1Q+lDMc1zdTRAP1p9vIylWXGfrUWc+xo6fdxQ1djN+zuA+BnLdar60p++vUjvWbDIVk3LncOM1l61r121xJDbxB1g+V3PCqeuM+uO1SoPmugbvoyw9uzs2QCG5A98VVEW2USRdWPIY1Q0/wAVWl3IIBPbSSY5MMgbb9RWw0e5mdTkMM4B9q1SsRJWJhyCAehzWfrVpDdaXMsqkiNkf6gMP8auW5YCMH0AouMtb3MTZIMbAflW1KymjOfws8T8bgrpuneTE0ctjJcQBwPvfvAw/RiK9U+HXiX7fZ2d0XXEqiGYZ6MOBXD6tZ/bLp7WUtva5lwo6AmIN+uMVieDb99H1xrGTMVtc/KT/cYHnH863xDXO0ZRTcE+p9OFOec9aa0ZGfSoPDV5/aOlxu5/fR/u5B/tDv8Aj1rSkUYrmUVE0TvqUOlCnPNPdeaQACnYGHfFG3PfmlAobAFUkjO4gjB5pyRjPT9KFb3qQEZpNK5UW7DhEMEUeVxTg49aHkGOtS2kO19SLyxRTTMMnmipuPlMiKJsKC3I7+tWrazDJukO41QtryJ2XYRgVoRXaRrhmGMZrpT1MiTbHECqqMj2qJ5FQ7s8VXub0s2IxVceZO209KtMhrU0GuIxEw9q47VpA9w+D3FdKbVkhKtkkCuZ1WNYZix7jFQtJFdDl/igP+KKucHpIhz+Jrm/hmSvlMP4iw/LFdN47Ky+B71Sw+XbyR6GuY+GpAWJm/56OvXvgGhbSRfoek3T80xWIbrSuAx5ph6ZHNcxqrFmJwpyT+FLLz/unmq3vzip1O6Pn0oa0GS2ty1urRmMSQsMNGwyDmuf8R+DP7Uxf+GLhrS8i+fyQ2Bn2rZcFicHFMSZ4JA8b7GHcVUJuOqEzO8OeO7S4mTRfG1uNO1WMeWl6i7Vc9tw7fWuva4WGf7FqAUPt3Ryrysgx1BrD1fSdK8YWbWupIkd8P8AV3CgAk1xmkazf+AtQ/sfxjbS3mhlsxTryY+wKn09q6bQrJuOjJd18J6U4COCSWyMg0qfOeK5yfxTpkcoOnXK3dmx3Kwb5gPpWtba5pzw70c5PQYrnnSnHoCnfcb4ulRPD08ZPMo2LisPSUIgto/mygANWNbim1xomhn8mKI7sY61c0G0PLTNvP8AeqZXjBJ9TWD0ZtQgqmOtNlztyeMVMOFqvIS2ck4rJIpDeWBI6jpUayleD1pxIwdp5pm3IyeKYupbs5HF1GyDJBDfiK5/QryW+vNVmnYGK4v2Jjx8uQAuR+ArpdHC2y3l3Of3VpbvM2focVi6DZG20/RImAEs6fapSP7zEnmt6btTkyHrKxxPxN8JT6NqK+IPDUHkyR83MMS/KR/eA/mK1vBfiu21SwTe4GMKVP3kP+FerSRJcwlZUDDoMjNeHfETwXcaJfNr/hZWCAlrm2XoPUgent2rCnUU04vc0aPTNowDGQw+8KSRlaQA4IcHj8K4vwH4th1S12klGH30JyYz/hXbBRuVhjkggj09a0impq5nNe6zz4sRr8bKPlGoRde26Nx/Ssfx9optbkXcI2xyEEsD91h0P+e1autfuNXnOwvLHc28m/n5QHYH+YrqtXs47+xkhmVSr+v061ti1+8XojLDv3PvKvwp8SZuktZyR5oETg9AQPlb6ZBX8Vr1WV/cV80WUd3pOrSWysVniO+Mn/log7Y9cfyFe+6FqSato1reRMHDr8xHQN3rCUrFcvKaTuDUW/nIFP8ALJoaM8EcU436iE3+vWo2ftTijd6YynNVcmw5SOtPWTFR7eMA0w5FDkNRJTLxUbz5FQk8HikAyRWLuzVWQvmH0op+w+gooGUotKER+Xle3NSyWWxgWBz05NX43KruK8GkmKyIdhJ/pXZY5jJ+ymNjzn2q3YxMrAk8elSsG3gbefWnBWxkUxMszuAvGM4rjPEUZkDtjJHPFdEzNk+Y34CsXWGwp4yCMVEnfYSdzgfEkn2jw1qSHlWi3Y9wea5n4dMPsikclZlPX/Zrq7lVktb+32jDRnb+XNcJ8PJWhe5jPVXBx9G6fkau1jSKu2j19PmQfnQU4p1mSyD27VYCDHvXMaIrNwp4OaamR977pq0yZGORVaRSh6nHpQ9hoV8KeDnNQTgjBHNP3bgDTCNxHPSoGMySQTwc8YrTklh1PT2s9YtkuoSMZYciqJG7IHFTREkenaqvbUTRz5+F+iXDvJpdzLbS9VVjwDVW58MahoXlrPd+YpbAfPFdlbBlcY65rC+Kk8i6dp4Rmwz4bmtqdeXMokyhdaiWstjbOsM9/H8/Ubuc10tg8fkoInBWuB0nwdZ6ppUU8kkkN23zI5ORn3rQtLy50KUWmpL5YH3JeqSfj2p1Eqj90dPRWO5LHGM5qNicVUs7+GccHBIHWrLHaGySRXK9HZmqEjUAMSOc1Io34H8VRK2eO3Y+tSK21gRQMr6zcLF4eurTIEuoTR2wOf4Sw3D8hWhO6HXJimPKt4xGoHbAA/xrm9ZlE+vaVbSgGOAPP079q1LIkwXEjdXbFbS0pJdzJPmlc6jTrhZLU5U+YehBziszVmMFz5igbXBBB5Bpmk3G1WQ8gHIq5qSCWPBHuMVw25Z6HR0PG/HHg+fT7l/EPhQlGB3XFoBx7kDuPatv4eeLIdXgERbYVwrxt96I/wCBrrzuViB1xxnkGvLPH+gzeGdTTxLoKFYHbFzCOVBPU/Q12RfNuZvY6fxGkM2v65axsYpRpgYAkYeWJlcnPuP61v2sy3ESyKBtdQw49RmvPWvZb670/X7VfPjaMxzqxzwVIwfbBxXaeFnZtEsWcDcqbPyJH41piZKSjbdHPSTTaZm+L9Ekv7dLqzwl9Ad6E9CPQ1N8MNZksdWXS7oqI75TMsKnJt5P4lPoD1FdOIw4JAz7etcX4g0qSwvY7u0BheA+dGyfxjPIb15pU4KY6krHtIQCh9uMVn6RfC+sY5Q3JUE59CMirLnIo2RNriMRzimqPamkGnx+lS3fYpIXZ1xUDKcZq2v3TUTdKEBUCknpUiR9PrTh1BpwO2mok3EIGT1/KigyjPQUUWRV2Qs5JKnORSxzxRcHv0zVRplEvU+lQHDqcnJFatkrc0pLlRlzxjNU5NQG07OaqXMm1MDOKS0MbIV2nPrTTImSxyNJKoIPWodZjAXPH0rSQARjOF7isjVj5gJz8p4qajVrIIRtucPqf7m6jkRcKTg46YPBrz3Sz9h8SX8HQhy6+4P+RXqN7b+fbyJ6DIryXxQTZ63FdRnl1KH8qVO7jY0Wkj2XS5w9rFIcZIGcetasIBwRXJ+Drk3GkwEknPFdVbsMKMGocbGltCUpnPWqs8JYd89hV5eemOtcr478VQeGrZFwzXc/3AB9xR1NSlzaCNOSJouSrY6dKhUfM3tXGeHvHkl3PicebEPvgj5l9/eu6zHNEJ4TuR8HjtVToyhuKMr6EaE1MnC+9RIMk+1TqAeO9ZNlkkZ/er6Zrmfiu4+waavczbq6i3UmQZHQ1xPxVffeaZbqPU/rVUleYzrvDy7NJsVxyUzWlcW8NzEYrmMSxnqrjIqrpqbLe2UjG2ID9K0O1Tdp6DSTOP1HQLmwYy6O3mwDk27nlfoaTR9fUuYnLLMOGgl4YfT1rqpj/Os3V9Gs9XiH2hDHOPuzpwwq1NSVpE2s9C1a3cNxgRMFbvGeoq306155fR6j4dnH24tPaMfkuU7f7w7V1Oj6zHOYYrl0xJjZKOh+tKVN6W1HzdzNe5L+MbkAZ8uJUA9PWurQFLRBjGea4ywWRfG2quEYx+YBux8p7V20g2ooAq8RpYdLVMbaN5U/A+U8VuriRcEe9c8x27SOoNbGnzb4+vfB9q4qnc2WplzKUlKnjGR/hTbiKK5t5IZ41kidCjIwyGBq7qkW2YsOAe9U0b8x1q4O+pL7Hl2jeFhpHiXWraxnluLCGBZWVXAWIswALKeuK0PCGurDrdzo8krMsUhTY45VvVT3Brcnu1tviJIBbR7brTPs0hAwW3Hhz6nIH5V5z8RNNfwh41e5sQxt/lbcDkEY6g+xzXfUppxu9NDni1do9vtfvgAAe3tTdatkudHlJUboSST32Hg/l1rH8Fa9b6/pkcq4WdFAdQc7c9CP9k4/A5BrqIhmdomx5cymNvTBFYwfJLUJJSRieAb8nTTHMf3lnL9mm/3f4T/IV2jEAYrzXwyWs/Fr2lwfkvo2tpOw8xeA36Cu4sJWeMxScTREo49CKqsuWVhQa5S8zAYpi9abgg0/b6VktAZI0g24FR7hjFM5yaUCjmYWuICe3Wmuze1ShTTWQk0+Zg0V9x96Kf5be1FK7Gc8krFgqk5Yc55qysTybTk/WkazJTfjHpVuziZUGTnjpXRa5gOTTkIy75pm3yHG3AXPIq4UIGQevaqVxG4kBPSiO45bEc9w8km1c1WvUfyT6Yq4gCNkDrxUl4qrCwOOnerlHlJUrnFsxWZuOa88+JmnpbC3uI1JDyAge/cV6ZfsqsxA4z1rnPFgFxo7yBcyWx8xcDPHesFO0jS2l0Vvhu7nTRvXB6gGu6jzwwNebeG72OzlEhkZ4ZT94nvXoMU4kjG05GMg1rUhZ3QqdS6LiSHABPvXlnx0RWbSJv7wdRXpCP7+9eafGuVZLnR4iC2EZsDjv/8AWrOOsrGqepY8P+HI9Y8KWF3YFYNUgiIjk7SdeG/lTdC8Q3elXLWV4jxXCt88DDAcf3lPce1dN8No1h8OWgAOCu7Ddea19f8ADtjrlsY7pcSYyky8PGfUGrVflk4y1QnT5tUTWVxa6lD5lvIpbuBUvllXIIPFeZynVPCl/HFqTjyGb93eqPlcej+hr1PR/N1DRxe4R0B2s0bZ2n3HaprUeVc0NhRm72YW64cHJrgvH583xpYW5GQEX8ya9AjGJFOQRu7V5trcn2z4lkggpG6ID6etRR+L5Gh6Wf3Z24+6AKeJODRL1PeoCwBHHNZDsx5yWPfinqckDvVdXJkz7dKkVwB70DTux00aSxSQXEYlifhkcdRXA63p8nhqQzRxPdaM7ZKZ+aEnpivQRk9TWD453nw3cBeVypYe2RWlKbUlHoxTinqGkaoJbKO3t7dEtw4lkY8u57ZPp7VuwSrcR7lOCD0NcVpuljUbS5gt7iSKUxBo2UkbTxipPC2rSpcPZal+7vIcq6n+LHcetVWs9EOnodbKcdQauae5SXaxwr9PrUbIJ03R8g0iBhjnaykEZrinsaI19TjZ7UE8kHt2rCYEEkf5NdNb4ubNk6bqw5IiJAnJYnFTSlbQbWhyEqib4mQow6QpkEfnWr8VtLtdU0VWljGEPysBymeD/SqOlv5nxD1aQLvSONUyB93A9a6PxcBLoU3HKrz9RXqYhtUl3scMF77Z88aVfaj4G8Rqk+5FHKN1Vkb+akdR689q+gND1201azguoH/dSHbgsCYn/un+YPcVy0/hy08XaClnefJKBuhuAMtE39Qe4rz6xudV8AeIZNF16Mm3bAB3YSWP+Fgf5HqDwfblpyU0rnRNdUen+O0Nlra3sB2KXS6RuwPRx9e9dVc6iI9YsLzH+iajHgkdn7/qM/jXIaTqNv4msW0m4cNPhjbTt1cj+Ej1xWp4XikuNEazmfzHt33J7YGM111lojng1c7wDOMUpXjiq9k7taxGVSHxg1MXwDzXP0NBmKeig0zNKrYPWlcEWBgKRTOM1G0nvTN5A4NJsG7kpAyaKg3gUVNx2M6fAXgkmpLWRmwqjIpJJUP3QCKbHNsnyuMfyrqckzFQLMruq/MDkc/Wq1xKCqknoc1Jc3G4gnis24Yk/L0qFJ3LlHQtmcBTxkHmoJXWRRuOR6UKEEIDZzWdfSGPBU8VrKWhmlYZfQoycDJrDZULvHIMp0b3HpVyW8LREg8dKykZvNZmJ59q5J7nTFaHATwHR9Yns5SWt+oz3XsR7iu00DUSqpBIwK4/duOjD0rL8Z2ZuLaO+jX97bnaxA5Kf/rqnYAQ2UVwpzZyHBI6wSdv+An9K7qFVVI8kjnqR5JXiehxvnGBjivKPi7P5niq1gzxFbqD+PP9a9B0q8L7opceYnv1ry/x6xu/HV4AMhNqAH6Cs1Bwm7lwkmrnq/hJPI0OyQgDEajOPbrXRq6kcDHtWJpi+XYWyeiL/KtBHxxnmuR7s0WxNfWkF7avBcRJLE4wUcZFctZPd+ApJDDJJLoEx2+aE3yWRPqD96P1B6dRXVoxIyPWpdiyIyOodGGGVhkEVdOo6ZTs1YxdH1qO4vXtJGjeTOVdDkOOuR7YrgZpDb/Ea9EoH+uVhTfF+l3PhTUBdaaJlsS2+F4xkQnqyH/ZrD0zV5dY8StfTFd7Fd5UYA5611KKbc4bNGUbrRnvjKDniqkoKnOKs27pJArIwZSOCKbMuUIHeuE6E9CowIwy0j5GCMkHip1UhcEdqPLBUjFFyUrEayHpmqXidd/hu/APITNWzHgdKpeIHEfhvUWPQRgfmaqCvNWG9ip4QX54zjnyAD+lS+LtAbUdl9ZSeRqMA+V8ffA7Go/CbqJlGRkQKP0rcv5wkDsT2yM06raqNoIHH+G/FRE4sr1fIvI+GRjw/uK720uI5x5keCe6k15a2mQ+INWl8xDGy5Kyp95D2IqxFqOp+FblYdY3yWecRXi8gezVm5Qqepdj1+ymhQbc7W9zRPAjSNMjcDH51gabqkF/bq6yRsG5DK3DVrWs2zMTnhuR9axVNqQdLHE+FGM3iDxHOMczCMY79ql1bWknGp2bMCyu6Y9O1P8AA7wW9hqt1OCZJL84HqAay9c8OTX+oy32nkqlwd+Pqa9SvZLU5IXRp/D2TzYIlz7A/St/4g+FbTxjoT2lwFjuowWtZ8cxv7/7J7iq3hHQ30mFN5GQK6lH55rggrI3cru58v6F/b2ja7DYyQOLyOXbErd3U+v+eK9s8L6Te/2rd3SyyW0cgSWSBhkI55YKe4P9a6mXSdNlvDdzWUL3Gd29hkg+o9Kv5Cj5QoHtXQ6spKxk4K90Nkwp44Hb2qIsTTZW5qPJNQwJtx7GnDJJxUKE1MMYp8oriHJpAPepMjFNUcc1JQza1FPwfQ0UWGYrwMPlBOe1VbkTIi7citliFYMBzTXRZwOMcVso2Mr31KIZ5IlZuT0NOSPATvk1aaDYpx09KjVgAB6dKlblS2BrdZEzyKqXNorR4XJ+taNpJuYqeeainKqW/lWrVjFPmObuLNACuBnPSs2SIoxBHFdDdSxhs/xVi3sgO481zzOiOpQMSzxvE4yj8MK5/wAOKLLV7vS7sZhcFdrfxDtXQRSYzk1i+KYzBLbalHw8Z2N7j3qIvU0cVYfNF/Y1zJBNukcKXtZweGX0PuBwa4e6Jv8AxPe3A5BKt+FepX1r/wAJB4eR7fBnQeZCVPfHT6EV5TptvqM+s3cOn2kk0ix5kQKflC9z6Y5r0ef2kL9Ucihyy8j2S1YNbx9vlX8OKsOPl4PPY1S0oh7CCQMrFkGSpyOlW8c9a897nSmuhYhY8c8VeiYZ+orOU4JA71Zib1pMaK/ih/L8Mam5QSAW7ko3IPFeHeBfD1/q6391plwkVxbpuWJ03CQHtXu2sbToGpbugtpP5GuC+BjPKt62BgRqM+hyauE5Qi7DcbjvAfiMxFrO/do2Xgh/+WZ/HnFelTKwQEjgjI965bxl4JF9MdU0nZFqK8tH/BKPQiqHhPxjLabtM1aF50i4a3Y/vofdCfvD2rRqNZOUdyFeG+x2arjmpMZIxU8EMF9afbNKnW4tTySD8yezDqDUHIxlSD71g046M0unsIyZBHeud8Z5i8MzqWx5kqIB6811GK5T4gEnT7GEfx3QP5Cro6zQpbaGXpckllcec+djIAKuatqqzQeWhyzDirVvYefpyFlzknFVIdE/0lcggA0qk7tiSdy34T04xxGZlwX9R0rfubaOdHinjR424ZWGQaktIkijVFqZsYPFcLve5seaar4dvPDd19v0OQyadu3S2mc7R6rXR6L4ttbmJS75ZfThh7YrfkwzBWyUPBGKoHRNNZXT7JEVLbgSOn0rop1Lq0hGV4Vkd7+5j2kwSTmVQvPFdnoVnJZ2ZhlYP87FSOMAnOKh061htYxHbxqqj0HNaiNge9aOfPuZuNtiVeMj0oNIpNPA6U1qJoaDz3owSDU6Rg9aUqMZp2IuUnBzT0jyae4GTzTkbGKS3AURYprcCpWlx1qvJLls9K0chKN2G6jcfWoi/ShjgVmtRsn8z3oqpvHqaKrUYjsmFyCeKiVyh2gHJqD7Sithjz71IlzHgtj5qbnqQoaEo83OWyRTZolPODk80iyPN32ipsAfeYfnVKdhOm31IcrFk9DjtVQurlt5qe6wSctk9sVTKfIfWhyuCjylO98vkDrjisi6JCMOc4ragty0o3Lk0t7aqFPyDoetS1cqDOQ3HPQ1NNapfWT28oyrqRg+tTzQiJvbNPQkBWUdOeKxb5Tos2VPh+7RW0tk5G6FztHoK5q6d9L8f35VLlNu6WX7OSN8Tcnofc8VsSu2l+IY5wCsU+Nx6Dmrl+Ui8b2kr/Ml3ZMnJx8ykEH8q6oy5VzI5uW8rM2lk05dRMWlgjTpY1e2yMAnHzAfjzT3IP3VHPvXFa3BPod0SpH9kyzFkZelu+c49lIre0jVkvRtcgTL1APB9xWkqSnBVI69yFNQk4yNxOcH3qcd6rwtnIFWI87sN0zXHe50RdzK8b3P2TwXqspOGMRRcdyayfgvai00GeR12vIyg++B/wDXqt8ZLkQ+GLSyB/eXVwO/YVpeGrSfSfDFmVJYON5b2PSqb5YX7s0O/DLszmuI1/QLXW78Fl8u4U5SaPhgatJro2FSDmrOiI01wZjnHuayjdO8Qepxs82teEbzz9Q84x5+XUbdd2R/00Xv9a7LSPGWm6pCxvWRJCPkng5jkPv/AHT7V07QRyqySqHQjBDcg/hXAeJfh1CGlu/DkgtLhvmeAnMcv4Vv7VS92aMWuXY7CNg6hlIIPcGuR+IUqxvpCFwMys31wK5jSvEOraBem1vYHUp96CQ8H3VvSrviTVk1+6sGSBolhJbZnPJHarjTUJKSd0OLO/0RFk0S2PcqTTzFtY8c+1O0tPI02CLuqCnSOOT3rklNNuxrYEBBpzdKg80jGDUynIGaxaGRMOKavWpJOtQu208VNwLUMm361djlz9ayFfJqxDJ1zWid0BrI+alEgwKpxNlamC5HNbQbM5MtLLxQZOOaqKCCfSnEn0Na3ZktBxYk5pcnbTRUjfdpWsHMiAkkk800A9akfpgUi0WuClYci5HSnFcDmnpz0pxIx71duVBzXIdn0opSxzRUlHLwnzT8/Wr0UJAB7dKlSzGAwGCecVMVIcADjjNDixKZEI3IATtTJBLjB4961YYgBnHvSvGHXoKFEbkZDDI+YgGhULjAq60aI+SOvrUM7xQtlT+BrS1lqRe6JIYQnJBz61S1Igg46U2S9LHCn8arSS7wazlIcEYtwu4sPQ0sCAqR6VPPGd2QMg0kcZU8A81zSkzoWhkeK7MzaTvQEvCdw+lc/qt2biLw5dnIdJ3gLAeq/wD1q76W3MsDK33GBBzXk3iVpLJ0tlZikN0kig8exroovmi0Y1E4zUj0CxniurOWzvFEiyqdyOQSymuLv7ZvDt+I0kc2LHMMpPMR9D7Vn6jqUuj6pYXK8K2UlU9wK6W/mh1JrfaBLHLjj1FXhq7hLyCtTU4+ZuaDrQuGVJSqznjb0BHqK6Y/f9O9eYa1pt34feOYM02mNjbIPvQH0b2966bw7rhuCsdw6bz91h/Hmta1KM17SmZU5uL5JHO/E+4F5420jTy3ywRhiMfxMelerbES1jt1HyIoUD8MV483/E0+Ld05I2xzrGpP+yP/AK1evE/Metcta9lE6r9zIbRF+0+Zn5Cc4NbNoiW4KrSMxCjHNOTPYVmlqTzGjBJxVnG5eD9Kz4zgCrccmAKtIl6mdqmlW16n+lQpJjoSOlZdroGnWknmR24L54Lndj6V0UpJzVOTg5NDuloKO4DABNMfDJ0pjE59qVMMOtYpam10VypB6cVNkinhQAaYVO72ocbhew0nnrUExq15Q71FMnGKnkHuVt5DACrUJPHvVRwc4FWYckDimlYaNW3NXkAIrOgbaBV6OTgV0RdjGSbJvLzQU59qVXHrQX4OKu5nZkTLg04HIpCc0oPzUSdwUbbiOoIpFAA5qTaOtMZeKSdhco3dg8dKTeSaCpApuDk0N3Hy9Q3Gil3H0NFFwuVll44phnAYjHNSRW6lQTk0otVSXeDx0xWi0epO6Lbyh7dQBjAquHI6GoZpCvGQBTVmTrkE/Wob1NLEjb5HwVODTXsQ4O5qe1xg4BzTJJm29SBT5kLlKc1qkcZ2jcap7eD2q48pB61XlIkcYGM1LdyopIrKmeO1S+UAuSKlhiCn5jinMvPqK55msdRgxs56V5j8U7Q7RdxqCrD5uP4hXpsoAQgVzPiLT11HTZ7Y/fYbkx61NKXK7hNcysclrOkwapoMTxSAzHO1SMHoM896r+BtFvvtCJOzhYjkA+lWtDsNZlurVrstDFBj74+8Rx/KvTtPREA2KoJ5yKuzUuZMTGz2sc1m1vPGHiZdrIwyCK8q17wtrWi3Im0Hfc2yndGvHmR+3uK9jkXeMiq0kZJzkg+xrenKUNYszmk3qecfDjwpqK30mp62ksFwZfNwxGWPvXpkq4PNRwuygKc8d6kdg2fpUu7d2U3fYjDccVZt15qsqHGasKcdOtIosd6miwTyM1AqlsYzUwUg8U4mciYrkH+VVpYs5JqyrYqKVsn2pk2uylKmF7VEo2jAqW5bB4qJCvc0uW4OSuPTcalVMk0sQBHFTqMZFCVjTdEBUqKilUEVNM3PSoXf5enNTJlR2Kxj+bNSxkLgCoXc5oQnOTWHUotpJgHirMcwAGOtZobnvU0ROetWBpo/eplkyKpRfe9RVuMDmt4mMmLv9qATnmnFOKaUwaZPNclQk1IcbSO9Qxtgc08vnNAldsMcCk2Uu6hWpFt6B5Z96KXd9PzoqjPmRmGU5wDSecWz16VWGScA+1PEZAOOtK7Zd0hZT5i7c9BVaNWLY/lViCIsx3ZBqy0YUY4/Ghphz3IoF3DAH5VK0D7Sc/hT7VFX73fpUkjqrgZPNN2EmZzxMf4c5pIrUxk7uc1qgIQSBSMgYZFUo21Id7ma8THtgdqhf5ePatTZjNZd0uZBjNZTRrTZGy/KSazXQFifetKR9sZHOaphQXyehrnejNivKqjJ61LZyFNoJqveN8xC1HFIQQM1UdhNanQpNxjNNklwD0qlBJ0z2qwYfMIPOKtXJaGRy7pMGr8SK6ZGPxqk0AjIOKsRzhDjb+Iq2KKLAjA4p2xfTiq7XHOQDipIJC56cUrhIuRbVHQUjOuOKruTmmF+KpuyISJGcjvUq4Zfeqq8kZqVG29alXLlsR3SAqazGYRt7itOZtwx2rNvIxyRxmtlZI5pJvYsW84Pp+dXt/HWsS2YDjPNaCv0rKSudEHoPlOeaqyEgdCasscjFQScdOKyehoiGMEtk1LjFN3gcUoKkdKzbsMcuM1LF1AqAsBT439KqMriauaEbAVajYVmJLzipUk+bFbpmNjWBBHWkP1qmkpx1pxkJ74FVe4nGy0HluaA/pj86gduetKnNICcEk80rHaODmkQHtSsMCnFCk+ggY4opMH1H50VWgWRFsVGBI61JsBPCjFQOWbaT0qXOCQfSk5dhxhoKm0KeBxUExLjhaA/5U3zFVcH9KLti9mSQMcYY1FICZtxOQO1QSSbNxp1vIJFJ5zSHdPQtRzAnIHFDSMF+UVFAo3Yq00QK8UXYio1yQpyareerMTgZqW5tmAJArPIkL420nqVB2ElbLEUFD5eQR9Kd5BByafgKvzVjKDuap3MWaOTzicHFIflwD6VqTx5BzVaOAE8ipV0MktEJ5B4rQjdulQwJsU4qdELc5FX6AMmZj2qr87P04zWmY930qMx7Tzg1oloRJvoRJCxUdfpV+2TA96rK+DirMT80xWbJ9inr1pphz2pm/k+1TxOdtTdMLWIfJwc8Uxxwc1ZkPGapO+CQT1qk0iXfoNbnpUEseeasoN3el8r5etRKfYqEDL8kKwanNIRjrVuSMDvzVaQAnpU8+hfKhVkOOKGYnrmowMHipkBJrK9yiuQcmnKSBUxXmmMBTsgI+WNWE+6MCoVQ545FWIhjG6nFAKo5zU0aNnJ6ULgYqZDyPStkiGkSxpwKkKc0I44p7SAVa0M2iu6c8UICKV39KVTlfekT1JkJpz9KZGakZlyBRcpxuR5+tFSbfaii4WZUjfHBNOd8Keeazml3jg06IsBySR70FpqxMGVjwfwpxGR7etMhjy2R3q8iLtwRxTWhL1M4wGRiM4BqeK3KEgU+TgnbwKRZxnGfarurGSjqT2ybDhuvapScdaiilyeookf5vaodjRRZLINyVQZMuQcVaEo24zUUoAINF7Cs2QsgAGRUEwG3oKmckgiqM8mwfNUSbsaxshzKCKhK7Gz2pBNzz92hxvPXj61ipMsGnG7A4qWGb35qm8YByc0rSqBkZBxVqXQRo+fj0qOSUMM1miZnYdSKv28fydcmmmwG72z04qZZSgBJp5hz/DxUEy4AGMYpNNglYkNwCRyTVuCcHjpWMWYuQDwKuWr8DP60tRs02f5BzVGWTJIp0khK4FQ1S0FYsQuFzmrCMGFUdwHtmlWb04qGBPOnoaqlOal3k96BgntRZDIdvOamUDbzTCBmlzjvQ7W0AVqjK55p5YGgYxjvWN9QGqMCpU6ioyQDTgeODWqYEwGW5qUcCoUbjrzUh3eoqoydxNDt2D1wacHz1NV3JBz1oQknB4/CtE2TpYsjmpFGAahjBz1qwikimnch2Qx2wBigNzzSupB6UgQ/SmwTH7j6n86KjL4OKKku6P/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Strange, C, Herth, FJ, Kovitz, KL, et al. Design of the Endobronchial Valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reduction. BMC Pulm Med 2007; 7:10. Copyright &copy; 2010 BioMed Central Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_43_17078=[""].join("\n");
var outline_f16_43_17078=null;
var title_f16_43_17079="Pruritus ani";
var content_f16_43_17079=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F88892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F88892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Pruritus ani",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 443px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Perianal erythema with mild lichenification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_43_17079=[""].join("\n");
var outline_f16_43_17079=null;
var title_f16_43_17080="Computed tomographic and positron emission tomographic scanning of pulmonary nodules";
var content_f16_43_17080=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Computed tomographic and positron emission tomographic scanning of pulmonary nodules",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/43/17080/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/43/17080/contributors\">",
"     Paul Stark, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/43/17080/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/43/17080/contributors\">",
"     Nestor L Muller, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/43/17080/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/43/17080/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/43/17080/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) is an important tool in the evaluation of solitary and multiple pulmonary nodules. It determines the morphology and attenuation characteristics of nodules, defines additional nodules that may not be visible on plain radiography, and detects additional intrathoracic abnormalities, such as enlarged mediastinal lymph nodes. CT provides clues to the nature of the nodule(s), as well as global thoracic assessment that may help guide patient management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Positron emission tomography (PET) is a nuclear imaging technique that provides insight into the metabolic activity of a pulmonary lesion and, by inference, yields information about the probability of malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28102?source=see_link\">",
"     \"Thoracic positron emission tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of CT and PET in the evaluation of solitary or multiple pulmonary nodules will be presented here. General issues related to the differential diagnosis and evaluation of the solitary pulmonary nodule are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=see_link\">",
"     \"Diagnostic evaluation and management of the solitary pulmonary nodule\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COMPUTED TOMOGRAPHY (CT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT is the imaging modality most often used to evaluate pulmonary nodules. In this section, we review technical aspects of CT and the use of CT in the evaluation of pulmonary nodules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Technical aspects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Helical CT (ie, spiral CT) has several technical advantages in the evaluation of pulmonary nodules, compared to conventional step and shoot CT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Helical CT performed with sustained respiration (ie, a breath hold), eliminates the misalignment associated with respiratory motion and assures contiguity from section to section. As a result, helical CT detects up to 40 percent more nodules than conventional CT [",
"      <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/1-3\">",
"       1-3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Helical CT nearly eliminates respiratory motion artifacts that are seen in up to 10 percent of conventional CT scans.",
"     </li>",
"     <li>",
"      Reconstruction of axial sections (0.5 mm to 2 mm in thickness from the helical data set with overlapping intervals, at least half the section thickness) facilitates the densitometric analysis of nodules, thereby eliminating partial volume effects and improving the detection of fat or calcium in nodules. The accuracy of CT attenuation is thus enhanced if the detector width is less than one half the diameter of the nodule [",
"      <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Complex pulmonary masses, like arteriovenous malformations or rounded atelectasis, can be well characterized by three-dimensional volume rendering of the helical data set. Nonenhanced three-dimensional reformatting of arteriovenous malformations facilitates analysis of the angioarchitecture. Contrast-enhanced CT studies are important as well, since they allow exclusion of thrombi in the arteriovenous malformation.",
"     </li>",
"     <li>",
"      Peridiaphragmatic pathology can be imaged advantageously using multislice CT reformatted images with near isotropic resolution in the sagittal and coronal planes. The images are free of respiratory motion and devoid of the step-like artifacts that can be seen in conventional CT [",
"      <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rapid and sequential cine viewing of multiple helical CT sections, also called stack mode, enhances the radiologist's ability to detect peripheral nodules smaller than 3 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/4\">",
"     4",
"    </a>",
"    ]. Cine viewing activates the motion processing channel in the human visual system and helps the radiologist differentiate tubular structures, such as blood vessels, from spherical structures, such as tumors. The cine display also helps the viewer assimilate information from a large number of images generated in a helical CT mode, leading to a considerable savings in time when compared with interpretation of hard copy, film display, or the so-called shingles mode. [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional technical issues related to CT scanning (eg, radiation dose) are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17032?source=see_link\">",
"     \"Principles of computed tomography of the chest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Solitary pulmonary nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, solitary pulmonary nodules are single, rounded opacities on conventional chest radiographs that are completely surrounded by aerated lung parenchyma and measure up to 3 cm in diameter. Rounded opacities that are more than 3 cm in diameter are defined as pulmonary masses. Solitary pulmonary nodules can be further characterized by CT scans according to size, calcification, attenuation, border, morphology, and growth rate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions larger than 3 cm (masses) are particularly likely to be malignant. In one study, 80 percent of solitary masses were found to be malignant, compared to 20 percent of nodules less than 2 cm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/8\">",
"     8",
"    </a>",
"    ]. Other studies using CT have demonstrated that more than 90 percent of lesions larger than 3 cm are malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A lesion of any size that is detected on imaging studies must be considered malignant until proven otherwise. However, lung cancer screening trials have clearly demonstrated a relationship between nodule diameter and the likelihood of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/11\">",
"     11",
"    </a>",
"    ]. This is illustrated by the results of one such trial [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nodules &le;3 mm had a 0.2 percent likelihood of malignancy",
"     </li>",
"     <li>",
"      Nodules 4 to 7 mm had a 0.9 percent likelihood of malignancy",
"     </li>",
"     <li>",
"      Nodules 8 to 20 mm had a 18 percent likelihood of malignancy",
"     </li>",
"     <li>",
"      Nodules &gt;20 mm had a 50 percent likelihood of malignancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, fewer than 1 percent of nodules smaller than 5 mm turned out to be malignant in patients without a history of cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Lesions exceeding 3 cm in diameter have a 90 percent likelihood of malignancy. Such estimates are difficult because up to 40 percent of diagnosed lung cancers have a diameter less than 2 cm.",
"   </p>",
"   <p>",
"    The recommended frequency of follow-up, according to the size of a nodule, is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=see_link&amp;anchor=H12#H12\">",
"     \"Diagnostic evaluation and management of the solitary pulmonary nodule\", section on 'Serial CT scans'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain patterns of calcification of a solitary nodule are strongly suggestive that a lesion is benign (",
"    <a class=\"graphic graphic_figure graphicRef74580 \" href=\"UTD.htm?27/20/27969\">",
"     figure 1",
"    </a>",
"    ) including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse, homogeneous calcification (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75030 \" href=\"UTD.htm?8/47/8944\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Central calcification (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75964 \" href=\"UTD.htm?39/16/40207\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69188 \" href=\"UTD.htm?18/61/19423\">",
"       image 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Laminated (concentric) calcification (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80141 \" href=\"UTD.htm?38/35/39487\">",
"       image 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      \"Popcorn\" calcification (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80219 \" href=\"UTD.htm?42/54/43887\">",
"       image 5",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other patterns of calcification should not be considered suggestive of a benign lesion (",
"    <a class=\"graphic graphic_figure graphicRef79216 \" href=\"UTD.htm?18/19/18737\">",
"     figure 2",
"    </a>",
"    ). As an example, reticular, punctate, amorphous, or eccentric calcifications are seen in up to 6 percent of malignant nodules (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64021 \" href=\"UTD.htm?3/34/3616\">",
"     image 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74827 \" href=\"UTD.htm?1/42/1711\">",
"     image 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Attenuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The attenuation coefficient of a pulmonary nodule is a measure of its electron density in relation to the attenuation of water, expressed in Hounsfield units (HU) (",
"    <a class=\"graphic graphic_table graphicRef82257 \" href=\"UTD.htm?7/52/8011\">",
"     table 1",
"    </a>",
"    ). At the extremes, air has the lowest attenuation, followed by fat, while calcium and bone have high attenuation. Fat within a nodule is suggestive of a hamartoma. Calcium can be present primarily in benign nodules, although rare malignant nodules can display calcifications as well. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Calcification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Noncalcified nodules are classified as ground-glass, partially solid (ie, sub-solid, semi-solid, or mixed), or solid nodules. The previously used threshold of 164 HU to differentiate benign from malignant nodules has not proven useful in recent years, primarily due to difference in calibration of scanners in different institutions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nodules composed predominantly of ground glass opacification can be seen in atypical alveolar hyperplasia (usually with a diameter of &le;5 mm) or bronchioloalveolar carcinoma (usually with a diameter of &gt;5 mm). Bronchioloalveolar carcinoma is also called adenocarcinoma in situ.",
"     </li>",
"     <li>",
"      Partially solid nodules can be seen in the mixed subtype adenocarcinoma, which is also called minimally invasive adenocarcinoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This radiographic characterization strongly correlates with a pathological classification system known as Noguchi Classification: Ground glass lesions that are &le;5 mm in diameter usually represent atypical alveolar hyperplasia, ground glass lesions that are between 5 and 10 mm in diameter are suspicious for bronchioloalveolar carcinoma, and partially solid lesions may represent the mixed subtype of adenocarcinoma (",
"    <a class=\"graphic graphic_picture graphicRef83407 \" href=\"UTD.htm?17/30/17892\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Border",
"    </span>",
"    &nbsp;&mdash;&nbsp;A smooth border has a 20 percent likelihood of representing a malignant nodule (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61692 \" href=\"UTD.htm?29/16/29967\">",
"     image 8",
"    </a>",
"    ). The likelihood of malignancy increases to 60 percent with a scalloped border (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78150 \" href=\"UTD.htm?28/0/28687\">",
"     image 9",
"    </a>",
"    ), 90 percent with spiculations (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69840 \" href=\"UTD.htm?7/29/7632\">",
"     image 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63489 \" href=\"UTD.htm?13/11/13491\">",
"     image 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51731 \" href=\"UTD.htm?26/1/26641\">",
"     image 12",
"    </a>",
"    ), and 95 percent in the presence of a corona radiata (",
"    <a class=\"graphic graphic_figure graphicRef62360 \" href=\"UTD.htm?20/61/21457\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A corona radiata describes fine linear striations that extend perpendicular to the surface of the nodule into the surrounding lung for a distance of 4 to 5 mm, like the spokes of a wheel (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59449 \" href=\"UTD.htm?39/39/40575\">",
"     image 13",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional characteristics of the nodule&rsquo;s shape may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nodular lesions with tails toward the hilum include rounded atelectasis, arteriovenous malformations, and, occasionally, bronchogenic cysts (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54773 graphicRef66530 graphicRef81990 \" href=\"UTD.htm?24/41/25242\">",
"       image 14A-C",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef78745 \" href=\"UTD.htm?2/20/2383\">",
"       image 15",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Peripheral carcinomas may have pleural tags extending to the periphery, away from the hilum.",
"     </li>",
"     <li>",
"      Lesions that are connected to blood vessels include nodular pulmonary infarcts, occasional solitary metastatic lesions, bronchopulmonary sequestrations, and arteriovenous malformations (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56072 \" href=\"UTD.htm?3/22/3426\">",
"       image 16",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Multiple peripheral triangular or rounded lesions with cavitation suggest septic embolization, aspiration, or vasculitis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70040 \" href=\"UTD.htm?28/33/29203\">",
"       image 17",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Nodules that are smooth, attached to the pleura, attached to fissures, located in close apposition to vessels, or smaller than 10 mm in diameter are likely benign [",
"      <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/20\">",
"       20",
"      </a>",
"      ]. Such nodules are usually intrapulmonary lymph nodes, nodular scars, granulomas, nodular pleural plaques, or bronchi.",
"     </li>",
"     <li>",
"      Cavitated nodules with a thin wall are more likely to be benign than cavitated nodules with a thick wall. In one study, cavitated nodules with a thin wall (&le;4 mm) were benign in 95 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/21\">",
"       21",
"      </a>",
"      ]. Cavitated nodules with a wall thickness of 5 to 15 mm were benign in 73 percent of cases, while cavitated nodules with a wall thickness &ge;16 mm were benign in only 16 percent of cases. Among the benign cavitary lesions, abscesses or infected emphysematous bullae have to be considered (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56201 \" href=\"UTD.htm?33/18/34080\">",
"       image 18",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef77861 \" href=\"UTD.htm?39/18/40225\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Thin-walled cysts or pneumatoceles may be seen with coccidioidomycosis, pneumocystis pneumonia, staphylococcal pneumonia, and metastases from transitional carcinoma of the bladder (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53339 \" href=\"UTD.htm?1/28/1474\">",
"       image 19",
"      </a>",
"      ). They may also be seen following traumatic pulmonary laceration.",
"     </li>",
"     <li>",
"      A halo may be seen surrounding a nodule in the setting of angioinvasive aspergillosis, zygomycosis (mucormycosis), lymphoma, bronchioloalveolar carcinoma, coccidioidomycosis, or (rarely) bacterial infections.",
"     </li>",
"     <li>",
"      Nodules surrounded by small satellite lesions are benign 90 percent of the time.",
"     </li>",
"     <li>",
"      Crescent signs (ie, a thin, curvilinear lucent line) are seen in cavitating necrotic lung lesions (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77137 \" href=\"UTD.htm?23/18/23841\">",
"       image 20",
"      </a>",
"      ). They can be simulated by small fungus balls within preexisting cavities (ie, Monod sign). These entities can be distinguished by imaging the patient in different positions: necrotic lung balls are fixed to the wall of the cavities and do not move with positional maneuvers, whereas true fungus balls change their position on decubitus views, for instance, since they are mobile (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64248 graphicRef77086 \" href=\"UTD.htm?7/56/8071\">",
"       image 21A-B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Review of available prior chest radiographs is a critical part of the diagnostic evaluation. Lesions that are malignant tend to have a doubling time (the time necessary for the lesion to double its volume) between 30 and 480 days (ie, between one month and sixteen months), while benign lesions generally have a doubling time that is either less than 30 days (some infectious causes) or greater than 480 days (chronic granulomatous lesions) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/22\">",
"     22",
"    </a>",
"    ]. Exceptions to this rule can be found with occasional bronchioloalveolar carcinomas, which exhibit a doubling time of up to 900 days.",
"   </p>",
"   <p>",
"    The fastest growing lung cancer, small cell carcinoma, has a median doubling time of about 30 days. Adenocarcinoma has a median doubling time of 180 days, while squamous cell carcinomas have a doubling time of 90 to 140 days.",
"   </p>",
"   <p>",
"    Using the growth rate to distinguish benign from malignant lesions has pitfalls:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small differences in the diameter can have a profound effect on the volume. This is illustrated by the formula for the volume of a sphere is [4&pi;]r",
"      <sup>",
"       3",
"      </sup>",
"      &divide; 3, where r represents the radius of the nodule. A nodule that has a diameter of 1 cm would be determined to have doubled in volume if its diameter increased by as little as 2.5 mm. Nodules with diameters of 2 and 3 cm would be determined to have doubled if their diameters increased 5 and 8 mm, respectively. Thus, the growth of smaller nodules is more difficult to substantiate and document. Volumetric three-dimensional rendering and advanced post-processing software can detect early changes in configuration and subtle growth in the longitudinal or z-axis that may elude conventional two dimensional measurements [",
"      <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exceptions to the range of doubling times for malignant lesions mentioned above exist. Low grade malignant lesions (eg, bronchial carcinoid with typical histology) may have a doubling time that exceeds 480 days, while bronchioloalveolar carcinoma may have a radiographic doubling time beyond 800 days. In contrast, Epstein-Barr virus (EBV)-associated lymphoma or lung cancer may have very fast doubling times in HIV positive patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a general guideline, two years of radiographic stability strongly suggests that a lesion is benign [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. When following up ground-glass or sub-solid nodules, three years of size stability are recommended with an initial early three month follow-up in order to detect clearing of potential benign, inflammatory processes, which would obviate long-term surveillance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2985669\">",
"    <span class=\"h2\">",
"     Multiple nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple pulmonary nodules detected by CT scanning, frequently turn out to represent metastatic disease. Such lesions are in the 5 mm range or smaller, subpleural, hidden by cardiomediastinal structures and the domes of the diaphragm, and easily missed by chest radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with pulmonary metastases will display multiple nodules on CT (ie, CT has high sensitivity); however, many patients without metastatic disease will also show multiple pulmonary lesions (ie, CT has low specificity). The specificity is higher in children than in adult patients, owing to the fact that adults have had more exposure to infectious and granulomatous agents during their life.",
"   </p>",
"   <p>",
"    Nonmalignant causes of multiple pulmonary nodules include, granulomatous infections, intrapulmonary lymph nodes, septic emboli, sarcoidosis, granulomatosis with polyangiitis (formerly called Wegener's granulomatosis), amyloidosis, and rheumatoid arthritis-associated pulmonary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/34/14888?source=see_link\">",
"     \"Differential diagnosis and evaluation of multiple pulmonary nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     POSITRON EMISSION TOMOGRAPHY (PET)",
"    </span>",
"    &nbsp;&mdash;&nbsp;PET allows functional imaging of structures by virtue of their ability to metabolize glucose and concentrate specific molecules that have been labeled with a positron-emitting radionuclide [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/28\">",
"     28",
"    </a>",
"    ]. It is usually performed in a patient with a known or suspected malignancy using a glucose analog that has been tagged with a positron-emitting isotope of fluorine, (18)F-2-deoxy-2-fluoro-D-glucose (FDG). Metabolically active cells (eg, malignant cells) utilize and import more glucose than other tissues and, thus, take up FDG more avidly (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79380 \" href=\"UTD.htm?21/7/21631\">",
"     image 22",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/29\">",
"     29",
"    </a>",
"    ]. Technical aspects of PET are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28102?source=see_link\">",
"     \"Thoracic positron emission tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Test characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;FDG-PET is more accurate than CT in differentiating benign from malignant lesions as small as 0.7 to 1 cm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/30\">",
"     30",
"    </a>",
"    ]. It is estimated that 96 percent of patients with lung cancer will have an abnormal FDG-PET (ie, sensitivity) and 79 percent of patients without lung cancer will have a normal FDG-PET (ie, specificity), a diagnostic accuracy of 91 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FDG-PET correctly excludes cancer in most cases (ie, good negative predictive value) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/30,33\">",
"     30,33",
"    </a>",
"    ]. However, it is not uncommon for an FDG-PET positive nodule to be infectious, inflammatory, or granulomatous in origin (ie, moderate positive predictive value) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    False-negative results can occur with tumors that have low metabolic activity (eg, bronchioloalveolar carcinomas, carcinoids, and some well-differentiated adenocarcinomas), small lesions (a critical mass of metabolically active malignant cells is required for detection by PET), and uncontrolled hyperglycemia, which leads to glucose saturation and subsequent delayed uptake of FDG since glucose competes with deoxy-2-fluoro-D glucose for the transmembrane transport into the cell [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. False-positive results can occur in inflammatory conditions and granulomatous diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28102?source=see_link&amp;anchor=H5#H5\">",
"     \"Thoracic positron emission tomography\", section on 'Sources of error'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Metabolic activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A tumor's metabolic activity can be measured using the standardized uptake value (SUV, formerly called standard uptake ratio). A high SUV indicates robust FDG uptake due to high metabolic glycolytic activity, which suggests malignancy (or active inflammation).",
"   </p>",
"   <p>",
"    The SUV can be interpreted visually in a qualitative fashion or quantitatively, with comparable accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Qualitative assessment &ndash; FDG uptake by the tumor is compared to background activity by visual inspection.",
"     </li>",
"     <li>",
"      Quantitative assessment &ndash; a numerical value is determined from the PET scan. An SUV exceeding 2.5 is generally considered highly suggestive of malignancy or active inflammation. Each institution must establish its own cutoff value because the SUV depends upon multiple parameters, including the activity of the FDG, the timing between injection and scanning, and the size and location of the lesion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The SUV may provide additional prognostic information in patients with lung cancer and help in the assessment of the response to treatment, as well as in the detection of tumor recurrence. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the initial evaluation, treatment and prognosis of lung cancer\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PET/CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Integrated computed tomography and positron emission tomography",
"    <span class=\"nowrap\">",
"     (PET/CT)",
"    </span>",
"    appears to more accurately characterize solitary pulmonary nodules (SPNs) as benign or malignant than either modality alone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. This was illustrated by an observational study of 42 patients with a SPN [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/36\">",
"     36",
"    </a>",
"    ]. CT, PET, and",
"    <span class=\"nowrap\">",
"     CT/PET",
"    </span>",
"    correctly characterized 74, 74, and 93 percent of SPNs, respectively, as benign or malignant.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    is similarly accurate at characterizing SPNs in patients who have a history of cancer. In one observational study that included 56 such patients, malignant SPNs were diagnosed by visual criteria with a sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 96, 83, 84, 96, and 89 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/37\">",
"     37",
"    </a>",
"    ]. Malignant SPNs were diagnosed by semiquantitative criteria with a sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 89, 93, 92, 90, and 91 percent, respectively.",
"   </p>",
"   <p>",
"    False negative",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scans have occurred in patients with bronchioloalveolar carcinoma, carcinoid, tuberculosis, and renal cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17080/abstract/37\">",
"     37",
"    </a>",
"    ]. False positive CT-PET have occurred in patients with fungal infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/23/24946?source=see_link\">",
"       \"Patient information: Multiple pulmonary nodules (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/1/23570?source=see_link\">",
"       \"Patient information: Single pulmonary nodule (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2984967\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary nodules are rounded opacities that are completely surrounded by aerated lung parenchyma and measure up to 3 cm in diameter. They can be solitary or multiple. In contrast, rounded opacities that are more than 3 cm in diameter are labeled as pulmonary masses. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Solitary pulmonary nodules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Computed tomography (CT) is an important tool in the evaluation of pulmonary nodules. It characterizes nodules on the basis of size, calcification, attenuation, border, morphology, and growth rate. CT detects additional nodules that elude chest radiography and delineates other intrathoracic abnormalities, such as enlarged mediastinal lymph nodes. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Size'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Calcification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Attenuation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Border'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Morphology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Growth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Positron emission tomography (PET) is a nuclear imaging technique that provides insight into the metabolic activity of a pulmonary lesion and, by inference, yields information about the probability of malignancy. It is more accurate than CT in differentiating benign from malignant lesions as small as 0.7cm to 1 cm in diameter. PET correctly excludes cancer in most cases (ie, it has good negative predictive value), but it is possible for a nodule with a positive PET to be infectious, inflammatory, or granulomatous in nature (ie, it has moderate positive predictive value). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Positron emission tomography (PET)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Integrated positron emission tomography and CT scanning",
"      <span class=\"nowrap\">",
"       (PET/CT)",
"      </span>",
"      appears to more accurately characterize pulmonary lesions as benign or malignant than either modality alone. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'PET/CT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/1\">",
"      Costello P, Anderson W, Blume D. Pulmonary nodule: evaluation with spiral volumetric CT. Radiology 1991; 179:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/2\">",
"      Remy-Jardin M, Remy J, Giraud F, Marquette CH. Pulmonary nodules: detection with thick-section spiral CT versus conventional CT. Radiology 1993; 187:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/3\">",
"      Costello P. Spiral CT of the thorax. Semin Ultrasound CT MR 1994; 15:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/4\">",
"      Seltzer SE, Judy PF, Adams DF, et al. Spiral CT of the chest: comparison of cine and film-based viewing. Radiology 1995; 197:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/5\">",
"      Winer-Muram HT. The solitary pulmonary nodule. Radiology 2006; 239:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/6\">",
"      Erasmus JJ, Connolly JE, McAdams HP, Roggli VL. Solitary pulmonary nodules: Part I. Morphologic evaluation for differentiation of benign and malignant lesions. Radiographics 2000; 20:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/7\">",
"      Erasmus JJ, McAdams HP, Connolly JE. Solitary pulmonary nodules: Part II. Evaluation of the indeterminate nodule. Radiographics 2000; 20:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/8\">",
"      STEELE JD. THE SOLITARY PULMONARY NODULE. REPORT OF A COOPERATIVE STUDY OF RESECTED ASYMPTOMATIC SOLITARY PULMONARY NODULES IN MALES. J Thorac Cardiovasc Surg 1963; 46:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/9\">",
"      Zerhouni EA, Stitik FP, Siegelman SS, et al. CT of the pulmonary nodule: a cooperative study. Radiology 1986; 160:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/10\">",
"      Siegelman SS, Khouri NF, Leo FP, et al. Solitary pulmonary nodules: CT assessment. Radiology 1986; 160:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/11\">",
"      MacMahon H, Austin JH, Gamsu G, et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 2005; 237:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/12\">",
"      Midthun, DE, Swensen, SJ, Jett, JR. Evaluation of  nodules detected by screening for lung cancer with low dose spiral computed tomography. Lung Cancer 2003; 41:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/13\">",
"      Godoy MC, Naidich DP. Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management. Radiology 2009; 253:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/14\">",
"      Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/15\">",
"      Rigler LG. An overview of cancer of the lung. Semin Roentgenol 1977; 12:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/16\">",
"      Henschke CI, Yankelevitz DF, Mirtcheva R, et al. CT screening for lung cancer: frequency and significance of part-solid and nonsolid nodules. AJR Am J Roentgenol 2002; 178:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/17\">",
"      Winer-Muram HT, Jennings SG, Tarver RD, et al. Volumetric growth rate of stage I lung cancer prior to treatment: serial CT scanning. Radiology 2002; 223:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/18\">",
"      Tsubamoto M, Kuriyama K, Kido S, et al. Detection of lung cancer on chest radiographs: analysis on the basis of size and extent of ground-glass opacity at thin-section CT. Radiology 2002; 224:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/19\">",
"      Remy J, Remy-Jardin M, Wattinne L, Deffontaines C. Pulmonary arteriovenous malformations: evaluation with CT of the chest before and after treatment. Radiology 1992; 182:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/20\">",
"      Xu DM, van der Zaag-Loonen HJ, Oudkerk M, et al. Smooth or attached solid indeterminate nodules detected at baseline CT screening in the NELSON study: cancer risk during 1 year of follow-up. Radiology 2009; 250:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/21\">",
"      Woodring JH, Fried AM. Significance of wall thickness in solitary cavities of the lung: a follow-up study. AJR Am J Roentgenol 1983; 140:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/22\">",
"      Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988; 96:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/23\">",
"      Honda O, Johkoh T, Sumikawa H, et al. Pulmonary nodules: 3D volumetric measurement with multidetector CT--effect of intravenous contrast medium. Radiology 2007; 245:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/24\">",
"      Williams DE, Pairolero PC, Davis CS, et al. Survival of patients surgically treated for stage I lung cancer. J Thorac Cardiovasc Surg 1981; 82:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/25\">",
"      Midthun DE, Swensen SJ, Jett JR. Approach to the solitary pulmonary nodule. Mayo Clin Proc 1993; 68:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/26\">",
"      Libshitz HI, North LB. Pulmonary metastases. Radiol Clin North Am 1982; 20:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/27\">",
"      Chang AE, Schaner EG, Conkle DM, et al. Evaluation of computed tomography in the detection of pulmonary metastases: a prospective study. Cancer 1979; 43:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/28\">",
"      Lowe VJ, Naunheim KS. Positron emission tomography in lung cancer. Ann Thorac Surg 1998; 65:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/29\">",
"      Nolop KB, Rhodes CG, Brudin LH, et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987; 60:2682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/30\">",
"      Vansteenkiste JF, Stroobants SS. PET scan in lung cancer: current recommendations and innovation. J Thorac Oncol 2006; 1:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/31\">",
"      Vansteenkiste JF, Stroobants SG. The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology. Eur Respir J 2001; 17:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/32\">",
"      Fischer BM, Mortensen J, H&oslash;jgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol 2001; 2:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/33\">",
"      Vansteenkiste JF. Nodules, CT-scans and PET-scans: a good partnership. Lung Cancer 2004; 45:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/34\">",
"      Lowe VJ, Hoffman JM, DeLong DM, et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994; 35:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/35\">",
"      Yi CA, Lee KS, Kim BT, et al. Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med 2006; 47:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/36\">",
"      Kim SK, Allen-Auerbach M, Goldin J, et al. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med 2007; 48:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17080/abstract/37\">",
"      Bar-Shalom R, Kagna O, Israel O, Guralnik L. Noninvasive diagnosis of solitary pulmonary lesions in cancer patients based on 2-fluoro-2-deoxy-D-glucose avidity on positron emission tomography/computed tomography. Cancer 2008; 113:3213.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6977 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-14B9D587E9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_43_17080=[""].join("\n");
var outline_f16_43_17080=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2984967\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COMPUTED TOMOGRAPHY (CT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Technical aspects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Solitary pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Calcification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Attenuation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Border",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2985669\">",
"      Multiple nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      POSITRON EMISSION TOMOGRAPHY (PET)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Test characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Metabolic activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PET/CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2984967\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/6977\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6977|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/47/8944\" title=\"diagnostic image 1\">",
"      Calcified granuloma CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/16/40207\" title=\"diagnostic image 2\">",
"      Central calcification on CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/61/19423\" title=\"diagnostic image 3\">",
"      Central calcification on CT II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/35/39487\" title=\"diagnostic image 4\">",
"      Solitary pulmonary granuloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/54/43887\" title=\"diagnostic image 5\">",
"      Hamartoma CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/34/3616\" title=\"diagnostic image 6\">",
"      Bronchogenic carcinoma CT VII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/42/1711\" title=\"diagnostic image 7\">",
"      Bronchogenic carcinoma CT VIII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/16/29967\" title=\"diagnostic image 8\">",
"      Carcinoid tumor CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/0/28687\" title=\"diagnostic image 9\">",
"      Calcified pleural plaque CT I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/29/7632\" title=\"diagnostic image 10\">",
"      Solitary pulmonary nodule CT I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/11/13491\" title=\"diagnostic image 11\">",
"      Spiculated nodule CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/1/26641\" title=\"diagnostic image 12\">",
"      Spiculated carcinoma CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/39/40575\" title=\"diagnostic image 13\">",
"      Spiculated pulmonary nodule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/8/29826\" title=\"diagnostic image 14A\">",
"      Arteriovenous malformation I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/12/36037\" title=\"diagnostic image 14B\">",
"      Arteriovenous malformation II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/49/30483\" title=\"diagnostic image 14C\">",
"      Arteriovenous malformation III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/20/2383\" title=\"diagnostic image 15\">",
"      Rounded atelectasis CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/22/3426\" title=\"diagnostic image 16\">",
"      Arteriovenous malformation CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/33/29203\" title=\"diagnostic image 17\">",
"      Septic emboli",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/18/34080\" title=\"diagnostic image 18\">",
"      Abscess cavity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/28/1474\" title=\"diagnostic image 19\">",
"      Post traumatic lung cyst CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/18/23841\" title=\"diagnostic image 20\">",
"      Lung gangrene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/38/40545\" title=\"diagnostic image 21A\">",
"      Saprophytic aspergillus CT I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/7/35953\" title=\"diagnostic image 21B\">",
"      Saprophytic aspergillus CT II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/7/21631\" title=\"diagnostic image 22\">",
"      Solitary pulmonary nodule FDG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6977|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/20/27969\" title=\"figure 1\">",
"      Pattern of benign calcification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/19/18737\" title=\"figure 2\">",
"      Malignant calcification pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/61/21457\" title=\"figure 3\">",
"      Margin of pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6977|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/30/17892\" title=\"picture 1\">",
"      Ground glass nodule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/18/40225\" title=\"picture 2\">",
"      Infected bulla",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6977|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8011\" title=\"table 1\">",
"      Attenuation coefficient nodule",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=related_link\">",
"      Diagnostic evaluation and management of the solitary pulmonary nodule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/34/14888?source=related_link\">",
"      Differential diagnosis and evaluation of multiple pulmonary nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=related_link\">",
"      Overview of the initial evaluation, treatment and prognosis of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/23/24946?source=related_link\">",
"      Patient information: Multiple pulmonary nodules (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/1/23570?source=related_link\">",
"      Patient information: Single pulmonary nodule (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17032?source=related_link\">",
"      Principles of computed tomography of the chest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28102?source=related_link\">",
"      Thoracic positron emission tomography",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_43_17081="Nephrocalcinosis";
var content_f16_43_17081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nephrocalcinosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/43/17081/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/43/17081/contributors\">",
"     Sidney M Kobrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/43/17081/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/43/17081/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/43/17081/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/43/17081/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/43/17081/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrocalcinosis is characterized by the deposition of calcium in the kidney parenchyma and tubules [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/1\">",
"     1",
"    </a>",
"    ]. Nephrocalcinosis may cause acute or chronic kidney injury, or be incidentally detected radiographically in a patient with normal renal function. Nephrocalcinosis is caused by multiple different conditions and the renal prognosis is determined by the underlying cause; whereas most patients with nephrocalcinosis do not progress to end-stage renal disease, certain underlying conditions, if not effectively treated, may be associated with progressive kidney dysfunction. The pathogenesis, clinical presentation, causes and treatment of nephrocalcinosis are discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term nephrocalcinosis is used to describe the deposition of both calcium oxalate and calcium phosphate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Some experts limit the definition of nephrocalcinosis to the deposition of calcium phosphate and refer to the deposition of calcium oxalate as oxalosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. For the purposes of this review, we retain the broader definition of nephrocalcinosis to include both calcium phosphate and calcium oxalate. The term oxalosis will refer exclusively to calcium oxalate deposition.",
"   </p>",
"   <p>",
"    The defining characteristic of nephrocalcinosis is generalized calcium deposition in the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Localized calcium deposition that occurs with focal renal injury is not included in this definition.",
"   </p>",
"   <p>",
"    Nephrocalcinosis is classified as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Molecular or chemical &mdash; A measurable increase in intracellular calcium concentration exists but is not visible microscopically or via radiographic imaging.",
"     </li>",
"     <li>",
"      Microscopic &mdash; Mineral deposits are visible by light microscopic examination of tissue obtained by biopsy but not by radiographic imaging.",
"     </li>",
"     <li>",
"      Macroscopic &mdash; Calcification is visible by radiographic imaging.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Molecular nephrocalcinosis is most often observed in patients with overt hypercalcemia and is completely reversed upon correction of the hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link\">",
"     \"Clinical manifestations of hypercalcemia\"",
"    </a>",
"    .) Microscopic nephrocalcinosis is a precursor of macroscopic nephrocalcinosis but can also be associated with acute kidney injury as occurs in acute phosphate nephropathy following bowel cleansing with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7032?source=see_link\">",
"     \"Acute phosphate nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nephrocalcinosis can involve the renal medulla or, much less often, the cortex. In the largest reported series of 375 patients with macroscopic nephrocalcinosis, 97 percent involved the medulla [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/1\">",
"     1",
"    </a>",
"    ]. Cortical nephrocalcinosis accounted for less than 3 percent of cases and was usually due to severe underlying cortical disease, such as renal cortical necrosis (often associated with pregnancy) or chronic glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Other causes of cortical nephrocalcinosis include primary and secondary oxalosis (which can also cause medullary nephrocalcinosis) and renal allograft rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33479?source=see_link&amp;anchor=H7#H7\">",
"     \"Acute kidney injury (acute renal failure) in pregnancy\", section on 'Renal cortical necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrocalcinosis is caused by an increase in the urinary excretion of calcium, phosphate,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    oxalate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. The most common cause of nephrocalcinosis is increased urinary calcium excretion with or without hypercalcemia. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These metabolic abnormalities are also closely associated with nephrolithiasis, and patients frequently present with both conditions. However, for reasons that are not clear, nephrocalcinosis is not always associated with nephrolithiasis, and nephrolithiasis often occurs in the absence of nephrocalcinosis. In addition, nephrocalcinosis often suggests a serious metabolic defect, whereas nephrolithiasis is commonly observed in otherwise healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calcium oxalate and calcium phosphate crystals form when the concentration of the reactants exceeds the saturation limit. In a careful histologic study of intraoperative renal biopsy specimens from idiopathic calcium oxalate stone formers, calcium phosphate (hydroxyapatite) deposits (Randall's plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/10\">",
"     10",
"    </a>",
"    ]) were primarily noted in the inner medullary (papillary) interstitium in the basement membranes of the thin limbs of the loop of Henle [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/9,11\">",
"     9,11",
"    </a>",
"    ] where tubular fluid is saturated even under normal circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/4,9\">",
"     4,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These calcium phosphate plaques can enlarge into the surrounding interstitial tissue, or rupture into the tubule lumen serving as a nidus for luminal calcium oxalate stone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/2\">",
"     2",
"    </a>",
"    ]. In vitro studies have shown that calcium phosphate can promote calcium oxalate crystallization. Randall's plaques are also seen in patients with calcium phosphate stones [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the intraoperative biopsy study cited above, the histologic findings were different in patients who had undergone intestinal bypass (bariatric) surgery for obesity and subsequently developed calcium oxalate nephrolithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/9\">",
"     9",
"    </a>",
"    ]. Crystal deposition was not present in the papillary interstitium as in idiopathic calcium oxalate stone formers. However crystals were attached to the apical surface of collecting tubule cells or completely filled the tubular lumen, appearing to obstruct a number of inner medullary collecting ducts.",
"   </p>",
"   <p>",
"    A later series from the same group described the endoscopic findings in the renal papillae in 23 stone formers undergoing percutaneous nephrolithotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/13\">",
"     13",
"    </a>",
"    ]. All kidneys had papillary plaque, which was found in over 90 percent of papillae. Eleven patients had attached stones, which appeared to occur on Randall's plaques.",
"   </p>",
"   <p>",
"    Oxalate crystals are either homogeneous (composed exclusively of calcium and oxalate) or heterogeneous (composed of calcium, oxalate and phosphate). In general, homogeneous calcium oxalate crystals form only in the setting of marked hyperoxaluria, such as that which occurs in primary hyperoxaluria or ethylene glycol toxicity. Heterogeneous crystals form in the setting of milder degrees of hyperoxaluria [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link\">",
"     \"Primary hyperoxaluria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=see_link\">",
"     \"Methanol and ethylene glycol poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary histologic finding on renal biopsy in patients with nephrocalcinosis is tubular, intracellular and interstitial basophilic calcifications. Calcium phosphate deposits are distinguished from calcium oxalate by positive staining with the von Kossa stain (",
"    <a class=\"graphic graphic_picture graphicRef55578 \" href=\"UTD.htm?9/39/9848\">",
"     picture 1",
"    </a>",
"    ) and by the absence of birefringence under polarized light. Tubular atrophy, interstitial fibrosis, and interstitial inflammation with a lymphocytic infiltrate may accompany chronic calcium phosphate or calcium oxalate deposition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrocalcinosis is associated with conditions that cause hypercalcemia, hyperphosphatemia, and the increased excretion of calcium, phosphate,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    oxalate in the urine. Hypocitraturia also may contribute, particularly in patients with distal (type 1) renal tubular acidosis. Citrate normally inhibits crystal formation by forming a soluble complex with calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link&amp;anchor=H9#H9\">",
"     \"Risk factors for calcium stones in adults\", section on 'Hypocitraturia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A high urine pH is also observed in patients who have calcium phosphate nephrocalcinosis.",
"   </p>",
"   <p>",
"    Underlying conditions that have been associated with calcium phosphate crystal formation may be categorized into those that cause the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypercalciuria with hypercalcemia",
"     </li>",
"     <li>",
"      Hypercalciuria without hypercalcemia",
"     </li>",
"     <li>",
"      Hyperphosphaturia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Such categories are useful in determining the specific diseases that underlie newly diagnosed nephrocalcinosis in the individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hypercalcemia and hypercalciuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following conditions can cause nephrocalcinosis in association with hypercalcemia with hypercalciuria:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary hyperparathyroidism",
"     </li>",
"     <li>",
"      Sarcoidosis",
"     </li>",
"     <li>",
"      Vitamin D therapy",
"     </li>",
"     <li>",
"      Milk alkali syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27094?source=see_link\">",
"       \"The milk-alkali syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Williams' syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5287?source=see_link\">",
"       \"Williams-Beuren syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Congenital hypothyroidism (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link\">",
"       \"Clinical features and detection of congenital hypothyroidism\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Primary hyperparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrocalcinosis and nephrolithiasis are the most common renal manifestations of primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/15\">",
"     15",
"    </a>",
"    ]. The reported incidence of nephrocalcinosis among patients with primary hyperparathyroidism is between 16 and 22 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations of primary hyperparathyroidism\", section on 'Nephrolithiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrocalcinosis is common in chronic sarcoidosis and other granulomatous disorders associated with hypercalcemia and hypercalciuria. Nephrocalcinosis is reported in 13 percent of patients with sarcoidosis and in 50 percent of those with known renal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=see_link&amp;anchor=H3#H3\">",
"     \"Renal disease in sarcoidosis\", section on 'Hypercalciuria and hypercalcemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Vitamin D therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrocalcinosis may occur secondary to the administration of vitamin D preparations, which increase both the absorption of ingested calcium and bone resorption, resulting in hypercalcemia and hypercalciuria [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/1\">",
"     1",
"    </a>",
"    ]. This is a particular problem when calcitriol is coadministered with oral phosphate supplements, both of which are commonly used to treat X-linked hypophosphatemic rickets [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/19-21\">",
"     19-21",
"    </a>",
"    ] and other disorders characterized by hyperphosphaturia and hypophosphatemia. In different series, nephrocalcinosis was detected radiologically in 19 of 24 and 11 of 23 children with X-linked hypophosphatemic rickets [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/19,21\">",
"     19,21",
"    </a>",
"    ], 3 of 11 children with vitamin D-dependent rickets type I [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/21\">",
"     21",
"    </a>",
"    ], and 26 of 41 children with nephropathic cystinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link&amp;anchor=H12#H12\">",
"     \"Etiology of hypercalcemia\", section on 'Hypervitaminosis D'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link&amp;anchor=H8#H8\">",
"     \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=see_link&amp;anchor=H12#H12\">",
"     \"Etiology and treatment of calcipenic rickets in children\", section on 'Vitamin D dependent rickets type I'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=see_link\">",
"     \"Cystinosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hypercalciuria without hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following conditions can cause nephrocalcinosis in association with hypercalciuria without hypercalcemia:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Distal renal tubular acidosis",
"     </li>",
"     <li>",
"      Medullary sponge kidney",
"     </li>",
"     <li>",
"      Neonatal nephrocalcinosis and loop diuretics",
"     </li>",
"     <li>",
"      Inherited tubulopathies",
"     </li>",
"     <li>",
"      Chronic hypokalemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Distal (type 1) renal tubular acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal (type 1) renal tubular acidosis (RTA) is the most common cause of nephrocalcinosis (particularly in children) due to hypercalciuria without hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/1,23\">",
"     1,23",
"    </a>",
"    ]. Distal RTA results in a systemic acidosis that requires increased buffering of acid by bone, with the subsequent release of bone calcium and phosphate. Metabolic acidosis is also associated with hypocitraturia, which can promote calcium precipitation in the tubules. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link&amp;anchor=H9#H9\">",
"     \"Risk factors for calcium stones in adults\", section on 'Hypocitraturia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reported prevalence of nephrocalcinosis in patients with distal RTA ranges from 60 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/1,24\">",
"     1,24",
"    </a>",
"    ]. However, it is difficult to interpret this estimate since nephrocalcinosis itself frequently causes defects in distal acidification. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/26/23973?source=see_link\">",
"     \"Nephrolithiasis in renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Medullary sponge kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrocalcinosis is observed radiographically in 30 to 50 percent of patients with medullary sponge kidney (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50100 graphicRef76195 \" href=\"UTD.htm?27/5/27732\">",
"     image 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition to hypercalciuria, medullary sponge kidney is characterized by hypocitraturia, which contributes to the development of nephrocalcinosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37206?source=see_link\">",
"     \"Medullary sponge kidney\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Neonatal nephrocalcinosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrocalcinosis is common in neonates of low birth weight, with a reported incidence that can exceed 60 percent in infants with a birth weight below 1500 g. The most common cause is the prolonged administration of a loop diuretic (most often",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    ). Less common causes include William's syndrome, renal tubular acidosis, and primary neonatal hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26356?source=see_link\">",
"     \"Nephrocalcinosis in neonates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Loop diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loop diuretics are widely used in adults and may cause nephrocalcinosis as described in neonates in the preceding section. The risk of nephrocalcinosis appears to be limited to patients taking very high doses for a prolonged period. This issue was addressed in a review of 18 consecutive adults who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    for 3 to 25 years because of weight gain or idiopathic edema [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/26\">",
"     26",
"    </a>",
"    ]. Nephrocalcinosis was detected on renal ultrasonography in 15 of the patients (all but one were women). The mean dose was 538 mg of furosemide per day (range 120 to 2800",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    compared to 40 to 80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in the three patients without nephrocalcinosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20981?source=see_link&amp;anchor=H5#H5\">",
"     \"Idiopathic edema\", section on 'Diuretic-induced edema'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Inherited tubulopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple inherited tubular disorders directly cause hypercalciuria. Whereas some disorders cause isolated hypercalciuria, others cause concurrent hypercalciuria and hyperphosphaturia.",
"   </p>",
"   <p>",
"    The following conditions cause isolated hypercalciuria but not hyperphosphaturia: (All are discussed elsewhere in UpToDate and links are provided).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bartter syndrome, which simulates a chronic low-dose infusion of a loop diuretic, since the defect involves the Na-K-2Cl cotransporter in the thick ascending limb which is the site of action of loop diuretics. Hypercalciuria is thought to be primarily responsible for the tendency to nephrocalcinosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/27\">",
"       27",
"      </a>",
"      ], but chronic hypokalemia also may contribute. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=see_link\">",
"       \"Bartter and Gitelman syndromes\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H16\">",
"       'Chronic hypokalemia'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Hypomagnesemic hypercalciuric nephrocalcinosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link\">",
"       \"Causes of hypomagnesemia\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Autosomal dominant hypocalcemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link\">",
"       \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following inherited diseases cause both hypercalciuria and hyperphosphaturia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dent's disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38616?source=see_link\">",
"       \"Dent's disease (X-linked recessive nephrolithiasis)\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Lowe's syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38616?source=see_link&amp;anchor=H4#H4\">",
"       \"Dent's disease (X-linked recessive nephrolithiasis)\", section on 'OCRL1 gene and the Lowe oculocerebrorenal syndrome'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Chronic hypokalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalciuria and nephrocalcinosis have been observed in chronic hypokalemic states including primary aldosteronism and Liddle's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Nephrocalcinosis and chronic hypokalemia are also seen in distal (type 1) renal tubular acidosis and Bartter syndrome but, as noted above, hypercalciuria is thought to be primarily responsible. Support for this hypothesis comes from the observation that chronic hypokalemia in Gitelman syndrome, which involves a mutation in the thiazide-sensitive sodium-chloride cotransporter in the distal tubule, is associated with hypocalciuria and the absence of nephrocalcinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Sarcoidosis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Distal (type 1) renal tubular acidosis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=see_link\">",
"     \"Bartter and Gitelman syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hyperphosphaturia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperphosphaturia with or without hypercalciuria is a risk factor for nephrocalcinosis. Hyperphosphaturia may occur with or without hyperphosphatemia. Hyperphosphaturia and hyperphosphatemia plus acute renal failure are observed in tumor lysis syndrome and after ingestion of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    bowel preparations. These acute disorders are typically characterized by microscopic nephrocalcinosis, and are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link&amp;anchor=H491579#H491579\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\", section on 'Hyperphosphatemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7032?source=see_link\">",
"     \"Acute phosphate nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperphosphaturia in the absence of hyperphosphatemia (ie, phosphate wasting), usually results from inherited tubulopathies, although acquired forms may be observed in the setting of malignancy or renal transplant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link&amp;anchor=H13#H13\">",
"     \"Causes of hypophosphatemia\", section on 'Primary renal phosphate wasting'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=see_link&amp;anchor=H5#H5\">",
"     \"Parathyroid and mineral metabolism after renal transplantation\", section on 'Hypophosphatemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hyperphosphaturia can occur as an isolated abnormality or with hypercalciuria in inherited tubulopathies (such as Dent's disease and Lowe's syndrome mentioned above). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Inherited tubulopathies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Inherited tubular defects that cause hyperphosphaturia but not hypercalciuria include X-linked hypophosphatemic rickets and autosomal dominant and autosomal recessive hypophosphatemic rickets. These disorders are discussed in detail elsewhere. Treatment of at least the first two consists of oral phosphate supplements, which increase phosphate excretion, and calcitriol, which increases calcium excretion, both of which can contribute to the development of nephrocalcinosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link\">",
"     \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Vitamin D therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hyperoxaluria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hyperoxaluria is the major risk factor for the development of oxalosis. Primary hyperoxaluria (PHO) is an autosomal recessive disorder that is characterized by the increased synthesis of oxalate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/7,32\">",
"     7,32",
"    </a>",
"    ]. In a series of 95 children with PHO reported to an international registry, 90 percent had nephrolithiasis at diagnosis and 48 percent had nephrocalcinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link\">",
"     \"Primary hyperoxaluria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperoxaluria may also be secondary to the increased enteric absorption of oxalate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/33\">",
"     33",
"    </a>",
"    ]. Fat malabsorption is the most common cause of increased oxalate absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/33\">",
"     33",
"    </a>",
"    ]. The mechanism by which fat malabsorption increases oxalate absorption is via the binding of calcium by free fatty acids in the colon. This decreases the amount of calcium that is available to bind to oxalate and form insoluble calcium oxalate and results in increased oxalate absorption since free oxalate is more easily absorbed compared to calcium-bound oxalate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fat malabsorption leading to hyperoxaluria and nephrocalcinosis can be seen in a variety of clinical settings, including pancreatic insufficiency, inflammatory bowel disease, bowel resection or jejunoileal or gastric bypass, use of the weight reduction drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/32/5638?source=see_link\">",
"     orlistat",
"    </a>",
"    , which causes fat malabsorption by inhibiting gastric and pancreatic lipases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/34-37\">",
"     34-37",
"    </a>",
"    ], and cystic fibrosis, which causes pancreatic insufficiency and in which other factors promoting calcium deposition (such as hypercalciuria) may also be present (",
"    <a class=\"graphic graphic_table graphicRef54743 \" href=\"UTD.htm?5/6/5229\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18007?source=see_link&amp;anchor=H8#H8\">",
"     \"Chronic complications of the short bowel syndrome in adults\", section on 'Hyperoxaluria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H16#H16\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Nephrolithiasis and nephrocalcinosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Secondary hyperoxaluria may also be due to the chronic ingestion of excessive amounts of oxalate precursors, such as vitamin C, or of foods rich in oxalic acid such as rhubarb, parsley, cocoa, nuts, or star fruit (carambola) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrocalcinosis is, in most cases, an asymptomatic, chronic, and slowly progressive disease that is discovered as an incidental finding during radiographic imaging of the abdomen or chest. Such imaging may be obtained as part of the evaluation of nephrolithiasis, which often coexists with nephrocalcinosis.",
"   </p>",
"   <p>",
"    However, occasional patients present with clinical symptoms that are related to nephrocalcinosis or to the causative process (eg, hypercalcemia). These include renal colic and polyuria and polydipsia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal colic is most often due to associated nephrolithiasis as may occur in patients with chronic hypercalciuria. A less common cause is extrusion of calcified nodules from the interstitium into the calyceal system [",
"      <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nocturia, polyuria, and polydipsia due to impaired urinary concentrating ability (ie, nephrogenic diabetes insipidus) as may occur in patients with hypercalcemia, medullary nephrocalcinosis of any cause, or in children with Bartter syndrome in whom the genetic defect impairs loop sodium chloride reabsorption, which is essential for concentrating ability [",
"      <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are several causes of nephrocalcinosis that are typically acute and present only with renal failure. These include tumor lysis syndrome, acute phosphate nephropathy, and occasional cases of enteric hyperoxaluria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7032?source=see_link\">",
"     \"Acute phosphate nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18007?source=see_link&amp;anchor=H8#H8\">",
"     \"Chronic complications of the short bowel syndrome in adults\", section on 'Hyperoxaluria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urinalysis in patients with nephrocalcinosis may be benign or reveal sterile pyuria or hematuria, especially in the setting of intraluminal stone formation and obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/1\">",
"     1",
"    </a>",
"    ]. Proteinuria is usually less than 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    except among patients with Dent's disease who often presents with significant proteinuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38616?source=see_link\">",
"     \"Dent's disease (X-linked recessive nephrolithiasis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several reports have described an association between erythrocytosis and nephrocalcinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Erythropoietin levels are increased in most of these patients, which has suggested a possible mechanism of nephrocalcinosis-induced regions of medullary hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Depending upon the underlying disease, serum calcium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    phosphate may be increased, and a 24-hour urine collection may show increased excretion of calcium, phosphate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    oxalate. However, 24-hour urine collections are not part of the routine work-up of patients with unexplained chronic kidney disease; they are usually obtained if there is a history of nephrolithiasis or after imaging has established the diagnosis of nephrocalcinosis in an attempt to identify treatable predisposing factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrocalcinosis should be included in the differential diagnosis of patients who present with chronic kidney disease, a benign urinalysis, and little or no proteinuria, particularly in those who are hypercalcemic or have a history of one of the above causes of nephrocalcinosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\", section on 'Urinalysis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H30#H30\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Correlation of urinary findings with kidney diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of chronic nephrocalcinosis can only be made by imaging or, much less often, renal biopsy. In addition to being part of the evaluation for chronic kidney disease, imaging may detect nephrocalcinosis as an incidental finding when performed for indications unrelated to the kidneys or as part of an evaluation for nephrolithiasis. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macroscopic nephrocalcinosis may be detected by multiple imaging techniques, including abdominal plain film, ultrasound (US), and CT imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/26,42-45\">",
"     26,42-45",
"    </a>",
"    ]. Calcification is poorly visualized by magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited data suggest that US and CT are more sensitive than abdominal plain film for the detection of nephrocalcinosis, particularly in patients without severe disease. One study, for example, evaluated 62 patients seen at a stone clinic in which an imaging test suggested either nephrocalcinosis or nephrolithiasis (pelvicalyceal calcifications) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/42\">",
"     42",
"    </a>",
"    ]. All patients underwent abdominal plain film, US, and CT. Nephrocalcinosis was considered present if at least two radiologists made the diagnosis on US",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CT. The sensitivity was 85 to 90 percent with US, 81 to 86 percent with CT scan, and 63 to 66 percent with abdominal plain film [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The highest sensitivity and specificity (92 and 89 percent) were attained when two of the radiologic tests suggested the presence of nephrocalcinosis, since there is not always concordance between US and CT. However this study had no independent gold standard for the diagnosis. Similar findings were noted in a series of 15 long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    abusers who had characteristic features of nephrocalcinosis on US; only 12 had positive findings on CT [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Loop diuretics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    These findings suggest that US and CT are the preferred imaging tests for the diagnosis of nephrocalcinosis. However, in the absence of a reason to suspect nephrocalcinosis (eg, hypercalcemia or a history of nephrolithiasis), US is usually the initial imaging test that is performed in patients who present with chronic kidney disease, a bland urinalysis, and little or no proteinuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=see_link&amp;anchor=H20#H20\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\", section on 'Radiologic studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once the diagnosis of nephrocalcinosis has been confirmed, the subsequent evaluation is directed at determining the underlying cause. This evaluation is important since the underlying condition may require treatment for reasons independent of its effect on renal function (such as primary hyperparathyroidism or sarcoidosis), and because the underlying condition generally determines the renal prognosis. Whereas some causes of nephrocalcinosis, such as primary hyperoxaluria, commonly result in end-stage renal disease, others, such as medullary sponge kidney, rarely cause progressive renal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link&amp;anchor=H4#H4\">",
"     \"Primary hyperoxaluria\", section on 'Clinical and laboratory manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37206?source=see_link&amp;anchor=H21853815#H21853815\">",
"     \"Medullary sponge kidney\", section on 'Prognosis and treatment'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H23\">",
"     'Evaluation subsequent to diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Evaluation subsequent to diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing is performed in an attempt to identify possible causes of nephrocalcinosis. Initial testing includes measurement of serum electrolytes, calcium, and phosphate, and the urine pH. If these tests do not suggest a cause (eg, hypercalcemia or distal renal tubular acidosis), two 24-hour urine collections should be obtained to measure the excretion of calcium, phosphate, oxalate, citrate, and, to assess the completeness of the collection, creatinine.",
"   </p>",
"   <p>",
"    Based upon the results of these laboratory tests, the following approaches are warranted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with hypercalcemia should be evaluated for the cause. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hypercalcemia and hypercalciuria'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link\">",
"       \"Etiology of hypercalcemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=see_link\">",
"       \"Diagnostic approach to hypercalcemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypercalciuria in the absence of hypercalcemia can be caused by a variety of disorders that are discussed above. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hypercalciuria without hypercalcemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperphosphaturia in the absence of hyperphosphatemia suggests a hereditary form of hypophosphatemic rickets in children, and an acquired form due to a tumor or following a renal transplant in adults. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Hyperphosphaturia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In infants, in addition to neonatal primary hyperparathyroidism, one should consider",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      -induced nephrocalcinosis, Williams' syndrome, and distal (type 1 RTA). The last disorder, which can also be caused by nephrocalcinosis, should be suspected in patients with an otherwise unexplained normal anion gap acidosis and a urine pH above 5.6. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26356?source=see_link\">",
"       \"Nephrocalcinosis in neonates\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5287?source=see_link\">",
"       \"Williams-Beuren syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/26/23973?source=see_link\">",
"       \"Nephrolithiasis in renal tubular acidosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=see_link\">",
"       \"Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperoxaluria suggests either primary or secondary hyperoxaluria (most often due to malabsorption). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Hyperoxaluria'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link\">",
"       \"Primary hyperoxaluria\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy is directed at the underlying cause of the nephrocalcinosis. Among patients with hypercalcemia, for example, treatment includes the correction of hypercalcemia by parathyroidectomy in primary hyperparathyroidism and glucocorticoid therapy in sarcoidosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link\">",
"     \"Management of primary hyperparathyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=see_link&amp;anchor=H3#H3\">",
"     \"Renal disease in sarcoidosis\", section on 'Hypercalciuria and hypercalcemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measures may be undertaken to reduce the urinary concentration and increase the solubility of the substances (calcium, phosphate or oxalate) contributing to nephrocalcinosis. Data that support such interventions are extrapolated from studies of patients with nephrolithiasis; no studies have demonstrated a beneficial effect among patients with established nephrocalcinosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increasing fluid intake to produce urine output of &gt; 2",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    may be beneficial for all patients with nephrocalcinosis.",
"   </p>",
"   <p>",
"    Among patients with hypercalciuria, urinary calcium excretion may be reduced by dietary modifications that include restriction of animal protein, restriction of sodium intake to &lt; 100",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    and liberalization of potassium intake.",
"   </p>",
"   <p>",
"    The administration of citrate may increase the solubility of calcium in urine and limit the development of nephrocalcinosis. Among patients who have hypocitraturia and a urine pH less than 7, we give potassium citrate to achieve a normal urinary citrate level. We do not give citrate to patients who have urine pH equal to or greater than 7.",
"   </p>",
"   <p>",
"    Specific management of the underlying causes of nephrocalcinosis is discussed elsewhere and links are provided above. Management of obstructing stones is similar to nephrolithiasis that is not associated with nephrocalcinosis and is discussed elsewhere. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27079?source=see_link\">",
"     \"Management of ureteral calculi\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30695?source=see_link\">",
"     \"Options in the management of renal and ureteral stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the specific therapies aimed at nephrocalcinosis, patients should receive general chronic kidney disease therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The renal prognosis of nephrocalcinosis is determined by the underlying cause. While most patients with nephrocalcinosis do not progress to end-stage renal disease, certain underlying causes, if not effectively treated, are more likely to be associated with progressive renal dysfunction. These include primary hyperoxaluria, hypomagnesemic hypercalciuric nephrocalcinosis and Dent's disease. On the other hand, patients with medullary sponge kidney or distal renal tubular acidosis rarely develop chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link\">",
"     \"Primary hyperoxaluria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link\">",
"     \"Causes of hypomagnesemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38616?source=see_link\">",
"     \"Dent's disease (X-linked recessive nephrolithiasis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once nephrocalcinosis is detected radiographically, it is unlikely to be reversed. However, partial reversal has been reported in patients who have had successful treatment of hypercalciuria and among patients with hyperoxaluria following corrective intestinal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17081/abstract/1\">",
"     1",
"    </a>",
"    ]. Complete resolution of neonatal nephrocalcinosis is generally observed after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    is stopped. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26356?source=see_link\">",
"     \"Nephrocalcinosis in neonates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nephrocalcinosis is characterized by the generalized deposition of either calcium phosphate or calcium oxalate in the kidney medulla or cortex. Patients who develop nephrocalcinosis may have acute or chronic kidney injury, or may have normal renal function. Nephrocalcinosis is often incidentally detected by imaging studies that are obtained for reasons unrelated to the kidney. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis of nephrocalcinosis depends on the underlying cause. While most patients do not progress to end-stage renal disease, patients with primary hyperoxaluria, hypomagnesemic hypercalciuric nephrocalcinosis and Dent's disease often result in end stage renal disease. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nephrocalcinosis may be detected by plain x-rays, ultrasound, and CT imaging but less often by magnetic resonance imaging. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The underlying cause of nephrocalcinosis should be determined and treated if possible since the renal prognosis is determined by the underlying disease. No specific treatment has been shown to prevent progression of nephrocalcinosis. Data extrapolated from studies of individuals with nephrolithiasis provide support for interventions that reduce the urinary concentration and increase solubility of the substances (calcium, phosphate or oxalate) that contribute to nephrocalcinosis. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"       \"Prevention of recurrent calcium stones in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among all patients with nephrocalcinosis, we suggest a liberal fluid intake to achieve a urine volume of 2",
"      <span class=\"nowrap\">",
"       L/day",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Among all patients with nephrocalcinosis and hypercalciuria we suggest modest restriction (approximately 0.7",
"      <span class=\"nowrap\">",
"       gram/kg)",
"      </span>",
"      of dietary intake of animal protein (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Among all patients with nephrocalcinosis and hypercalciuria we suggest restriction of dietary sodium intake to &lt; 100",
"      <span class=\"nowrap\">",
"       meq/day",
"      </span>",
"      (approximately 2.3 g of sodium) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Among patients with nephrocalcinosis who have hypocitraturia and urine pH less than 7, we suggest the administration of potassium citrate to achieve normal urinary citrate levels (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Citrate should not be given to patients who have a urine pH equal or greater than 7 even if hypocitraturia is present.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Wrong, O. Nephrocalcinosis. In: Oxford Textbook of Clinical Nephrology, Davison, AM, Cameron, JS, Gr&uuml;nfeld, J, et al (Eds), Oxford University Press, Oxford 2005. pp. 1375-1396.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/2\">",
"      Sayer JA, Carr G, Simmons NL. Nephrocalcinosis: molecular insights into calcium precipitation within the kidney. Clin Sci (Lond) 2004; 106:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/3\">",
"      Markowitz GS, Nasr SH, Klein P, et al. Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing. Hum Pathol 2004; 35:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/4\">",
"      Asplin JR, Mandel NS, Coe FL. Evidence of calcium phosphate supersaturation in the loop of Henle. Am J Physiol 1996; 270:F604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/5\">",
"      ARONS WL, CHRISTENSEN WR, SOSMAN MC. Nephrocalcinosis visible by x-ray associated with chronic glomerulonephritis. Ann Intern Med 1955; 42:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/6\">",
"      Schepens D, Verswijvel G, Kuypers D, Vanrenterghem Y. Images in Nephrology. Renal cortical nephrocalcinosis. Nephrol Dial Transplant 2000; 15:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/7\">",
"      Diallo O, Janssens F, Hall M, Avni EF. Type 1 primary hyperoxaluria in pediatric patients: renal sonographic patterns. AJR Am J Roentgenol 2004; 183:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/8\">",
"      Harrison RB, Vaughan ED Jr. Diffuse cortical calcification in rejected renal transplants. Radiology 1978; 126:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/9\">",
"      Evan AP, Lingeman JE, Coe FL, et al. Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 2003; 111:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/10\">",
"      Randall, R. Papillary pathology as precursors of primary renal calculus. J Urol 1940; 44:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/11\">",
"      Evan A, Lingeman J, Coe FL, Worcester E. Randall's plaque: pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int 2006; 69:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/12\">",
"      Low RK, Stoller ML. Endoscopic mapping of renal papillae for Randall's plaques in patients with urinary stone disease. J Urol 1997; 158:2062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/13\">",
"      Matlaga BR, Williams JC Jr, Kim SC, et al. Endoscopic evidence of calculus attachment to Randall's plaque. J Urol 2006; 175:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/14\">",
"      Hamm LL. Renal handling of citrate. Kidney Int 1990; 38:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/15\">",
"      Suh JM, Cronan JJ, Monchik JM. Primary hyperparathyroidism: is there an increased prevalence of renal stone disease? AJR Am J Roentgenol 2008; 191:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/16\">",
"      Lloyd HM. Primary hyperparathyroidism: an analysis of the role of the parathyroid tumor. Medicine (Baltimore) 1968; 47:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/17\">",
"      Muther RS, McCarron DA, Bennett WM. Renal manifestations of sarcoidosis. Arch Intern Med 1981; 141:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/18\">",
"      Bergner R, Hoffmann M, Waldherr R, Uppenkamp M. Frequency of kidney disease in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/19\">",
"      Verge CF, Lam A, Simpson JM, et al. Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 1991; 325:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/20\">",
"      Jequier S, Cramer B, Goodyer P, et al. Renal ultrasound in metabolic bone disease. Pediatr Radiol 1986; 16:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/21\">",
"      Goodyer PR, Kronick JB, Jequier S, et al. Nephrocalcinosis and its relationship to treatment of hereditary rickets. J Pediatr 1987; 111:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/22\">",
"      Theodoropoulos DS, Shawker TH, Heinrichs C, Gahl WA. Medullary nephrocalcinosis in nephropathic cystinosis. Pediatr Nephrol 1995; 9:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/23\">",
"      Cremin B, Wiggelinkhuizen J, Bonnici F. Nephrocalcinosis in children. Br J Radiol 1982; 55:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/24\">",
"      Brenner RJ, Spring DB, Sebastian A, et al. Incidence of radiographically evident bone disease, nephrocalcinosis, and nephrolithiasis in various types of renal tubular acidosis. N Engl J Med 1982; 307:217.",
"     </a>",
"    </li>",
"    <li>",
"     Yendt, ER. Medullary sponge kidney. In: Diseases of the Kidney, 5th ed, Schrier, RW, Gottschalk, CW (Eds), Little, Brown, Boston, 1993, pp. 525-532.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/26\">",
"      Kim YG, Kim B, Kim MK, et al. Medullary nephrocalcinosis associated with long-term furosemide abuse in adults. Nephrol Dial Transplant 2001; 16:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/27\">",
"      Vaisbich MH, Fujimura MD, Koch VH. Bartter syndrome: benefits and side effects of long-term treatment. Pediatr Nephrol 2004; 19:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/28\">",
"      Ogihara T, Maruyama A, Hata T, et al. A case of normoreninemic, normotensive primary aldosteronism associated with essential hypertension and nephrocalcinosis. Clin Exp Hypertens 1981; 3:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/29\">",
"      Yang CW, Kim SY, Kim YS, et al. Nephrocalcinosis associated with primary aldosteronism. Nephron 1994; 68:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/30\">",
"      Noblins M, Kleinknecht D, Dommergues JP, et al. [Liddle syndrome (or pseudo-hyperaldosteronism). Long-term development and erythrocyte potassium flow study in 4 cases]. Arch Fr Pediatr 1992; 49:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/31\">",
"      Resta N, Stella A, Susca FC, et al. Two novel mutations and a new STK11/LKB1 gene isoform in Peutz-Jeghers patients. Hum Mutat 2002; 20:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/32\">",
"      Lieske JC, Monico CG, Holmes WS, et al. International registry for primary hyperoxaluria. Am J Nephrol 2005; 25:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/33\">",
"      Chikos PM, McDonald GB. Regional enteritis complicated by nephrocalcinosis and nephrolithiasis. Case report. Radiology 1976; 121:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/34\">",
"      Nasr SH, D'Agati VD, Said SM, et al. Oxalate nephropathy complicating Roux-en-Y Gastric Bypass: an underrecognized cause of irreversible renal failure. Clin J Am Soc Nephrol 2008; 3:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/35\">",
"      Singh A, Sarkar SR, Gaber LW, Perazella MA. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis 2007; 49:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/36\">",
"      Karamadoukis L, Shivashankar GH, Ludeman L, Williams AJ. An unusual complication of treatment with orlistat. Clin Nephrol 2009; 71:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/37\">",
"      Hoppe B, Leumann E, von Unruh G, et al. Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria. Front Biosci 2003; 8:e437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/38\">",
"      Chen CL, Fang HC, Chou KJ, et al. Acute oxalate nephropathy after ingestion of star fruit. Am J Kidney Dis 2001; 37:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/39\">",
"      Procino G, Mastrofrancesco L, Mira A, et al. Aquaporin 2 and apical calcium-sensing receptor: new players in polyuric disorders associated with hypercalciuria. Semin Nephrol 2008; 28:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/40\">",
"      Feest TG, Proctor S, Brown R, Wrong OM. Nephrocalcinosis: another cause of renal erythrocytosis. Br Med J 1978; 2:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/41\">",
"      Agroyannis B, Koutsikos D, Tzanatos-Exarchou H, Yatzidis H. Erythrocytosis in type I renal tubular acidosis with nephrocalcinosis. Nephrol Dial Transplant 1992; 7:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/42\">",
"      Cheidde L, Ajzen SA, Tamer Langen CH, et al. A critical appraisal of the radiological evaluation of nephrocalcinosis. Nephron Clin Pract 2007; 106:c119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/43\">",
"      Glazer GM, Callen PW, Filly RA. Medullary nephrocalcinosis: sonographic evaluation. AJR Am J Roentgenol 1982; 138:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/44\">",
"      Alon US. Nephrocalcinosis. Curr Opin Pediatr 1997; 9:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/45\">",
"      Hoppe B, Kemper MJ. Diagnostic examination of the child with urolithiasis or nephrocalcinosis. Pediatr Nephrol 2010; 25:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17081/abstract/46\">",
"      LiPuma JP. Magnetic resonance imaging of the kidney. Radiol Clin North Am 1984; 22:925.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7209 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-87E8EA23DE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_43_17081=[""].join("\n");
var outline_f16_43_17081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hypercalcemia and hypercalciuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Vitamin D therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hypercalciuria without hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Distal (type 1) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Medullary sponge kidney",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Neonatal nephrocalcinosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Loop diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Inherited tubulopathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Chronic hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hyperphosphaturia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Evaluation subsequent to diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7209\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7209|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/29/18910\" title=\"diagnostic image 1A\">",
"      Calcifications in sponge kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/54/16226\" title=\"diagnostic image 1B\">",
"      Medullary sponge kidney CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7209|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/39/9848\" title=\"picture 1\">",
"      Acute phosphate nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7209|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/6/5229\" title=\"table 1\">",
"      Mechanisms of malabsorption",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33479?source=related_link\">",
"      Acute kidney injury (acute renal failure) in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7032?source=related_link\">",
"      Acute phosphate nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23226?source=related_link\">",
"      Bartter and Gitelman syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=related_link\">",
"      Causes of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=related_link\">",
"      Causes of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18007?source=related_link\">",
"      Chronic complications of the short bowel syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=related_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=related_link\">",
"      Cystinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38616?source=related_link\">",
"      Dent's disease (X-linked recessive nephrolithiasis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=related_link\">",
"      Diagnostic approach to hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18120?source=related_link\">",
"      Etiology and diagnosis of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28248?source=related_link\">",
"      Etiology and treatment of calcipenic rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=related_link\">",
"      Etiology of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=related_link\">",
"      Hereditary hypophosphatemic rickets and tumor-induced osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20981?source=related_link\">",
"      Idiopathic edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27079?source=related_link\">",
"      Management of ureteral calculi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37206?source=related_link\">",
"      Medullary sponge kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/3/4154?source=related_link\">",
"      Methanol and ethylene glycol poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26356?source=related_link\">",
"      Nephrocalcinosis in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/26/23973?source=related_link\">",
"      Nephrolithiasis in renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30695?source=related_link\">",
"      Options in the management of renal and ureteral stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=related_link\">",
"      Parathyroid and mineral metabolism after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=related_link\">",
"      Primary hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=related_link\">",
"      Renal disease in sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27094?source=related_link\">",
"      The milk-alkali syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5287?source=related_link\">",
"      Williams-Beuren syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_43_17082="Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria";
var content_f16_43_17082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/43/17082/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/43/17082/contributors\">",
"     Wendell F Rosse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/43/17082/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/43/17082/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/43/17082/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/43/17082/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/43/17082/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal nocturnal hemoglobinuria (PNH) is a disorder characterized by a defect in the glycosylphosphatidylinositol (GPI) anchor, due to an acquired abnormality in the PIG-A gene. This leads to partial or complete absence of all GPI-linked proteins, particularly CD59 (membrane inhibitor of reactive lysis) and CD55 (decay accelerating factor), resulting in an increased sensitivity of the affected cells to the action of complement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42392?source=see_link\">",
"     \"Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13593?source=see_link\">",
"     \"Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of PNH are primarily related to abnormalities in the hematopoietic system, including hemolytic anemia, a hypercoagulable state, and diminished hematopoiesis. Progression to aplastic anemia, myelodysplasia, and acute leukemia can also occur. In the past, the treatment of PNH had been largely empirical. As with most medical disorders, therapy is largely given to ameliorate the symptoms or complications rather than the cause of the disease. However, with improved understanding of the underlying pathogenesis, more rational therapies are emerging, such as the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Eculizumab'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The diagnosis and treatment of PNH will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The clinical manifestations of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14121?source=see_link\">",
"     \"Clinical manifestations of paroxysmal nocturnal hemoglobinuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical presentation of the classic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PNH should be considered in a patient with any of the following manifestations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evidence of acquired hemolysis, specifically with a negative direct antiglobulin (Coombs) test of the red cells.",
"     </li>",
"     <li>",
"      Evidence of intravascular hemolysis (eg, hemoglobinemia, hemoglobinuria, hemosiderinuria, elevation of plasma lactate dehydrogenase levels, reduction in plasma haptoglobin levels).",
"     </li>",
"     <li>",
"      Granulocytopenia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombocytopenia in the presence of an elevation in the reticulocyte count or evidence of intravascular hemolysis.",
"     </li>",
"     <li>",
"      Venous thrombosis, particularly of the abdominal or cerebral veins (eg, Budd-Chiari syndrome, mesenteric or portal vein thrombosis, thrombosis of cerebral or dermal veins) and signs of intravascular hemolysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H41#H41\">",
"       \"Overview of the causes of venous thrombosis\", section on 'Myeloproliferative neoplasms and PNH'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aplastic anemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=see_link&amp;anchor=H13#H13\">",
"       \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\", section on 'Clonal and genetic disorders'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myelodysplastic syndrome, refractory anemia variant. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H2816177#H2816177\">",
"       \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'PNH-positive cells'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Episodic dysphagia or abdominal pain with evidence for intravascular hemolysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14121?source=see_link\">",
"       \"Clinical manifestations of paroxysmal nocturnal hemoglobinuria\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the past, PNH was diagnosed indirectly based upon the sensitivity of PNH red cells to lysis by complement. The sucrose lysis test was used as a screening test and the diagnosis was confirmed by the Ham acid hemolysis test [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the sucrose lysis test, the patient's red cells are incubated with fresh serum diluted in an isotonic sucrose solution; complement is activated under these circumstances and hemolysis of the red cells indicates a positive test.",
"     </li>",
"     <li>",
"      In the Ham test, complement is activated by reduction of the pH of fresh serum to 6.4; hemolysis of red cells indicates a positive test.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the recognition of a deficiency of GPI-linked proteins in PNH has resulted in the development of flow cytometric methods for diagnosis, which have made the sucrose lysis and Ham tests entirely obsolete [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Expression of GPI anchored proteins'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Expression of GPI anchored proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least 20 GPI (glycosyl-phosphatidyl-inosityl)-linked proteins are missing from the surface of PNH hematopoietic cells (see above); the absence of any of them can be used as evidence of PNH. Red cells are most frequently analyzed, using monoclonal antibodies to the GPI-anchored proteins CD55 and CD59 followed by flow cytometry [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Deficient populations that comprise more than 1 percent of the red cells can be identified by this technique. Using special techniques, ever smaller numbers of cells can be identified, especially in patients with aplastic anemia and myelodysplastic syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Such patients are considered to have subclinical PNH [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=see_link&amp;anchor=H13#H13\">",
"     \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\", section on 'Clonal and genetic disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H2816177#H2816177\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'PNH-positive cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The abnormal red cells in PNH are either completely lacking the GPI-linked proteins (PNH III cells) or, less commonly, partially lacking (bearing about 10 percent of normal amounts of the protein, PNH II cells). Some patients have both types of abnormal PNH cells. Granulocytes can also be analyzed for the missing proteins; in addition to antibodies against CD55 and CD59, antibodies against a number of other GPI-linked antigens (CD14, CD16, CD24, CD48, CD52, and C66) may be used. A bacterial channel-forming toxin (proaerolysin) which binds specifically to the GPI anchor may be used with a fluorescence label (called FLAER) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/8,13\">",
"     8,13",
"    </a>",
"    ]. This reagent is more sensitive and more specific than the available monoclonal antibodies mentioned above. A consensus document on the optimal methods of flow cytometry for the diagnosis of PNH has been published [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, the population of PNH granulocytes detected is larger than the population of PNH red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/15\">",
"     15",
"    </a>",
"    ], and more closely measures the degree to which the abnormal clone has taken over in the bone marrow, since the abnormal red cells are lysed in the circulation while the abnormal granulocytes are not.",
"   </p>",
"   <p>",
"    To be certain of the diagnosis of PNH, if FLAER is not used, antibodies against two GPI-linked antigens and at least two cell lines should be used to be certain that rare genetic abnormalities of these antigens are not present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PNH is a chronic disease with significant morbidity and mortality. However, a substantial number of patients live for extended periods, and spontaneous recovery may occur. Three reviews have examined the natural history of patients with this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14121?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations of paroxysmal nocturnal hemoglobinuria\", section on 'Disease overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report of 80 patients, the median survival after the onset of the disease was approximately 10 years, with 28 percent of patients surviving 25 years or more [",
"      <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/16\">",
"       16",
"      </a>",
"      ]. Twelve of 35 patients who survived for longer than 10 years experienced a spontaneous recovery. Approximately 60 percent of deaths were due to venous thrombosis or bleeding; one or more episodes of venous thrombosis occurred in almost 40 percent of the patients. There were no cases of acute leukemia.",
"     </li>",
"     <li>",
"      A large retrospective study of 220 patients found that the median survival was 14.6 years with Kaplan-Meier survival estimates of 78, 65, and 48 percent at 5, 10, and 15 years after diagnosis, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/17\">",
"       17",
"      </a>",
"      ]. The eight-year rates of the major complications of PNH (pancytopenia, thrombosis, and myelodysplastic syndrome) were 15, 28, and 5 percent, respectively. Adverse prognostic factors included thrombosis, evolution to pancytopenia, myelodysplastic syndrome, or acute leukemia, and age &gt;55 years at onset of disease. Evidence of deficient hematopoiesis at disease onset, such as aplastic anemia or thrombocytopenia, was a less powerful predictor.",
"     </li>",
"     <li>",
"      A third large retrospective study of American and Japanese patients showed major differences between these two populations [",
"      <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/18\">",
"       18",
"      </a>",
"      ]. The onset of PNH among Japanese patients was more commonly in the setting of an aplastic or hypoplastic marrow than for the American patients. More strikingly, the prevalence of thrombosis was much greater among the American patients than among Japanese patients (38 versus 6 percent). Among the American patients, a large population of abnormal platelets was a likely indicator of thrombosis. The mean survival time for the Japanese patients was 32.1 years compared with 19.4 years for the American population, although the Kaplan-Meier survival curves were not different for the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT OF ANEMIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of PNH has been markedly changed by the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    to the therapeutic armamentarium. This monoclonal antibody stops the hemolysis characteristic of the disorder, resulting in marked improvement in the anemia in most cases. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Eculizumab'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Otherwise, the treatment of anemia among patients with PNH consists of supportive therapy, including the replacement of iron and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , and the administration of red blood cell transfusions if clinically required. In addition, suppression of ongoing red cell destruction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the stimulation of hematopoiesis may result from the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    androgens.",
"   </p>",
"   <p>",
"    Immunosuppression with antithymocyte serum may be effective, particularly when signs of hematopoietic deficiency are present (eg, granulocytopenia, thrombocytopenia, reticulocytopenia). Inhibition of the lytic effect of complement by an antibody to C5 has been very successful in the treatment of the symptoms of PNH (eg, fatigue, esophageal spasm, abdominal pain, erectile dysfunction, pulmonary hypertension, renal dysfunction). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Eculizumab'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Severe hematopoietic dysfunction leading to marked cytopenias can be successfully treated with hematopoietic cell transplantation (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Hematopoietic cell transplantation'",
"    </a>",
"    below), or immunosuppression by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antithymocyte globulin.",
"   </p>",
"   <p>",
"    For transfusion-dependent patients with severe hemolytic anemia and disabling symptoms (eg, fatigue, thromboses, frequent paroxysms of pain, end-organ damage), treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    has been successfully employed. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Eculizumab'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Asymptomatic patients, especially those with a PNH clone &lt;10 percent, or those with only mild symptoms should not be treated unless thrombosis supervenes or symptoms are severe. PNH clone size should be determined every 6 to 12 months in order to monitor for disease progression prior to the onset of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Iron",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even when gross hemoglobinuria is not observed, the urinary loss of iron in PNH is significant because of hemosiderinuria from ongoing intravascular hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/19\">",
"     19",
"    </a>",
"    ]. In this setting, urinary losses may be as much as 10 to 20 times normal, leading to the development of iron deficiency anemia. Even larger amounts of iron are lost by individuals with hemoglobinuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\", section on 'Intravascular hemolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, patients with PNH usually require supplemental iron unless they are receiving frequent red blood cell transfusions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link\">",
"     \"Treatment of anemia due to iron deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The administration of iron occasionally precipitates a hemoglobinuric episode, because of the outpouring of reticulocytes from the marrow. This event can be suppressed with the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or a red blood cell transfusion (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Red blood cell transfusions'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Folic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    is usually recommended for all patients with chronic hemolytic anemia (eg, sickle cell anemia) because of the expected increased need of the hyperplastic marrow for this cofactor.",
"   </p>",
"   <p>",
"    This vitamin is almost routinely prescribed, although there are no reports of patients with PNH who have become",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    deficient if folic acid supplementation had not been prescribed. The reutilization of red blood cell folate that is released into the plasma with hemolysis may result in a lower requirement for folic acid supplementation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Red blood cell transfusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any anemic patient, those with PNH may be transfused if clinically necessary. However, transfusions may result in transient hemoglobinuria due to hemolysis of the patient's complement sensitive red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/21\">",
"     21",
"    </a>",
"    ]. The reaction is usually fairly mild, but may be sufficiently severe to cause acute renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transfusion-associated hemolysis in PNH occurs most frequently when whole blood is transfused, is seen less often when packed red cells are transfused, and is seen rarely when washed red cells are employed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Removal of white blood cells from the transfused product also lessens the occurrence of this event.",
"   </p>",
"   <p>",
"    It is thought that this reaction results from minor immunologic incompatibilities that activate complement on the abnormal PNH cells. Such reactions are now sufficiently rare as to permit the use of the usual preparation of packed red cells without washing in most cases, particularly if the cells have been leukocyte depleted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Glucocorticoids and ACTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of ACTH has been abandoned because of toxicity resulting from the relatively high doses required to provide any possible benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/27\">",
"     27",
"    </a>",
"    ]. In addition, the overall beneficial effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is a subject of disagreement among experts [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/2,28,29\">",
"     2,28,29",
"    </a>",
"    ]. Anecdotally, prednisone has been most effective in patients with anemia due to hemolysis without alterations in hematopoiesis. Prednisone may act by diminishing complement activation, thereby halting hemolysis.",
"   </p>",
"   <p>",
"    The effective dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is generally higher than can be easily tolerated if given on a daily basis. As a result, moderate doses (15 to 30 mg) are usually administered on alternate days. During marked hemolytic episodes, however, higher doses given daily may help allay the paroxysm. The effect of prednisone can be rapid. As an example, in patients with nightly hemolysis, a dose of prednisone will suppress the hemolysis for that night, particularly if given in the evening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Androgenic hormones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgenic hormones are effective in diminishing the anemia of PNH in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/30\">",
"     30",
"    </a>",
"    ]. Derivatized androgens (such as danocrine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    ) with less masculinizing effect are also effective. The mechanism by which these agents work is not entirely clear. They may increase hematopoiesis or downregulate the activation of complement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Eculizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     Eculizumab",
"    </a>",
"    is a humanized monoclonal antibody that binds to the C5 component of complement and inhibits terminal complement activation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/31\">",
"     31",
"    </a>",
"    ]. This agent reduced hemolysis and transfusion requirements in an open-label pilot study of 11 transfusion-dependent patients with PNH [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Following this pilot study, eculizumab was compared with placebo in a double-blind, randomized, multicenter phase III trial (the TRIUMPH study) in 87 patients with PNH who had received at least 4 red cell transfusions during the previous 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/34\">",
"     34",
"    </a>",
"    ]. Eculizumab (600 mg) or placebo was given by infusion every week for four weeks, followed one week later by 900 mg given every two weeks through week 26.",
"   </p>",
"   <p>",
"    The following significant benefits were seen in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    -treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher rate of stabilization of hemoglobin levels in the absence of transfusion (49 versus zero percent with placebo).",
"     </li>",
"     <li>",
"      Fewer packed red cell transfusion (median of zero versus 10 units with placebo).",
"     </li>",
"     <li>",
"      Less intravascular hemolysis, as shown by an 86 percent decrease in the median area under the curve for serum lactate dehydrogenase concentrations plotted against time.",
"     </li>",
"     <li>",
"      An improvement in the quality of life, including improvement in fatigue and the symptoms of nitric oxide (NO) depletion (eg, esophageal spasm, abdominal pain, erectile dysfunction, renal dysfunction, and pulmonary hypertension) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There were no treatment-related serious adverse events. A follow-up one-year phase III study (the SHEPHERD study) in 97 patients receiving long-term treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    showed similar significant reductions in hemolysis (87 percent), decreases in the degree of anemia and transfusion requirement (52 percent), increased transfusion independence (51 percent), and improvement in fatigue and quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In all PNH studies using eculizumab to date, there has been a marked reduction in thromboembolic event rates while taking this medication, as compared with rates prior to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Comparable reductions were seen in patients who were or were not taking antiplatelet agents or anticoagulants.",
"   </p>",
"   <p>",
"    The reduction in intravascular hemolysis in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    -treated subjects resulted in a significant increase in PNH type III red cells (ie, red cells with a complete absence of GPI-linked proteins) from a mean of 28 percent at baseline to 57 percent at week 26 and week 52, compared with 34 to 36 percent at these time points with placebo. These cells completely lack GPI-linked proteins and might be prone to hemolysis if eculizumab were discontinued. However, 19 patients reported to date have discontinued treatment with this agent, which was not associated with serious hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13593?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins\", section on 'Erythrocytes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By contrast, the median proportions of PNH granulocytes did not change during the course of the study (96 percent at baseline and 97 percent at 52 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a preliminary report,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    was found to be equally effective in patients with PNH and a prior history of myelodysplastic syndrome or aplastic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/40\">",
"     40",
"    </a>",
"    ]. Although experience is limited (approximately 30 patients), eculizumab appears to be completely safe when used during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. As pregnancy markedly increases the complications of PNH, the use of this drug may become standard in this setting.",
"   </p>",
"   <p>",
"    The United States FDA has approved the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    (Soliris&trade;, Alexion Pharmaceuticals, Inc.) for the reduction of hemolysis in patients with PNH. The cost of treatment with this medication has been estimated to be in the range of 400,000 US dollars and 300,000 Euros per year [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/31,43\">",
"     31,43",
"    </a>",
"    ]. Since this agent has no effect on the underlying cellular abnormality in PNH, treatment, once started, may require prolonged administration in order to control the intravascular hemolysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombosis.",
"   </p>",
"   <p>",
"    Other drugs that control complement and its activation are under study [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1145380961\">",
"    <span class=\"h3\">",
"     Extravascular hemolysis after eculizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;While dramatic decreases in",
"    <strong>",
"     intravascular",
"    </strong>",
"    hemolysis have been noted following treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    , many patients still have persistent anemia, reticulocytosis, positive direct antiglobulin tests (ie, positivity for C3d), and biochemical evidence of hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. That this persistence of hemolysis might be due to immune-mediated",
"    <strong>",
"     extravascular",
"    </strong>",
"    hemolysis was shown in one study in 41 eculizumab-treated subjects, in whom a substantial fraction of red cells had C3 bound on their surface [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/46\">",
"     46",
"    </a>",
"    ]. C3 binding was entirely restricted to red cells with the PNH phenotype (ie, CD59 negative) and correlated directly with the reticulocyte count and indirectly with the hematologic response to eculizumab. In three of these patients, Cr-51 labeling of red cells demonstrated reduced in vivo survival, with excess tracer uptake in spleen and liver, consistent with extravascular hemolysis. This accumulation of C3 on the affected red cells is due to the fact that these cells lack CD55, a cell-bound inhibitor of C3 activation. The prolongation of circulating life span by eculizumab allows the accumulation to occur.",
"   </p>",
"   <p>",
"    In most cases, this phenomenon has relatively little clinical relevance and requires no additional therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/47\">",
"     47",
"    </a>",
"    ]. However, in single case reports in which hemolysis worsened in conjunction with a positive direct antiglobulin (Coombs) test, or in which transfusions were still required, addition of glucocorticoids (initial dose 75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/48\">",
"     48",
"    </a>",
"    ], or performance of splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/49\">",
"     49",
"    </a>",
"    ], reduced the degree of hemolysis. The use of a monoclonal antibody specific for the",
"    <span class=\"nowrap\">",
"     C3/C5",
"    </span>",
"    convertase may ultimately be of value in patients in whom this phenomenon becomes clinically important [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Neisserial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients enrolled in the TRIUMPH study discussed above were vaccinated against N. meningitidis, due to the observation that persons with a genetic deficiency of terminal complement proteins have an increased risk of neisserial infections, including N. meningitidis and N. gonorrhoeae. In all clinical studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    , meningococcal sepsis developed in 2 of 196 patients (1.0 percent) receiving the drug. Both had previously received meningococcal vaccination.",
"   </p>",
"   <p>",
"    Accordingly, patients should be told that there is a 0.5",
"    <span class=\"nowrap\">",
"     percent/year",
"    </span>",
"    risk of neisserial sepsis even after vaccination; they should be re-vaccinated every three to five years after starting treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    , and should seek immediate medical attention if they develop signs and symptoms of such infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link\">",
"     \"Inherited disorders of the complement system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology of Neisseria meningitidis infection\", section on 'Complement deficiency and meningococcemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prescribing information for this agent includes a boxed warning describing the risk for serious meningococcal infection and the need for meningococcal vaccination at last two weeks prior to treatment and revaccinations according to current medical guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with diminished erythropoiesis derive benefit from high doses of erythropoietin (40,000",
"    <span class=\"nowrap\">",
"     units/week)",
"    </span>",
"    or darbepoetin, particularly if renal impairment is present [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/52\">",
"     52",
"    </a>",
"    ]. Recombinant granulocyte stimulating factor (G-CSF) has been used to increase the granulocyte count in granulocytopenic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recombinant modified CD59 (Prodaptin) capable of binding to the red cell membrane has been shown to reduce complement-mediated red cell lysis in vivo in a mouse model [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/54\">",
"     54",
"    </a>",
"    ]. This approach for the potential treatment of PNH has not yet been tested in human subjects.",
"   </p>",
"   <p>",
"    A patient with concurrent intermediate grade non-Hodgkin lymphoma and PNH (hemoglobin 8.1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    with normal white blood cell and platelet counts) has been presented, who went into complete remission from both conditions following treatment with chemotherapy (R-CHOP) followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/30/40422?source=see_link\">",
"     ibritumomab",
"    </a>",
"    tiuxetan consolidation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/28/12741?source=see_link\">",
"     pegfilgrastim",
"    </a>",
"    support [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/55\">",
"     55",
"    </a>",
"    ]. It was assumed that the chemotherapy eradicated the abnormal PNH clone along with the lymphoma. This case notwithstanding, we do not recommend chemotherapy as a treatment for PNH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT OF THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute thrombosis in PNH is treated similarly to venous thrombosis occurring in other settings [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/56\">",
"     56",
"    </a>",
"    ]. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is also used, since complement activation probably initiates thrombosis in patients with PNH. The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    in the treatment of acute thrombosis is under consideration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Thrombolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombolysis should be instituted in the patient with PNH and large vein or life-threatening thrombosis if the clot is less than three to four days old and in whom there are no contraindications [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/4,57-59\">",
"     4,57-59",
"    </a>",
"    ]. In patients who develop Budd-Chiari syndrome, such therapy may decrease the probability of long-term complications. However, fibrinolysis may be dangerous in those with cerebral vein thrombosis, since it may convert a thrombotic stroke into a hemorrhagic one. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3434?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation for an acute episode of thrombosis should be instituted with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . Heparin appears to be effective when given in full therapeutic doses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any patient with a significant thrombosis, particularly intra-abdominal or intracerebral, should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    . Most patients who have had significant thrombosis also receive continuing anticoagulation following the acute event, using agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"      heparin",
"     </a>",
"     /low",
"    </span>",
"    molecular weight (LMW) heparin, although the necessity for this is not clear. For the first episode, they are generally managed as other patients with a similar thrombotic event. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H42#H42\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with recurrent episodes are managed as other patients with a clinically manifested hypercoagulable state, using, in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    , LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for an indefinite period. In the absence of concomitant treatment with eculizumab, antithrombotic therapy alone had not been completely effective in preventing further episodes of thrombosis. In a preliminary report of three patients with prior episodes of recurrent thrombosis, treatment with eculizumab was effective in eliminating subsequent episodes of thrombosis even after treatment with anticoagulants had been discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Eculizumab'",
"    </a>",
"    above.) In the long-term follow-up of approximately 190 patients for up to nine years, thrombosis occurred in only three: one on an indwelling catheter and two in patients with previous thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Prophylactic anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombosis in PNH appears to be related to the size of the abnormal platelet clone; those patients with large numbers of abnormal platelets are at greater risk. In one study, the 10-year risk of thrombosis was 44 percent in those with large PNH clones (ie, PNH granulocytes &gt;50 percent of the total), and was 5.8 percent in those with small clones [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/61\">",
"     61",
"    </a>",
"    ]. Accordingly, in one medical center, patients with large PNH clones and no contraindication to anticoagulation were offered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    prophylaxis (target INR 2.0 to 3.0). At a median follow-up of six years, the following observations were made [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were no thrombotic episodes in the 39 patients who received primary prophylaxis.",
"     </li>",
"     <li>",
"      The 56 patients not taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      had a 10-year thrombosis rate of 36.5 percent.",
"     </li>",
"     <li>",
"      There were only two serious bleeding episodes in more than 100 patient-years of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these retrospective observations need to be confirmed, they suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    prophylaxis is effective in patients with PNH if the granulocyte clone size is &gt;50 percent, the platelet count is",
"    <span class=\"nowrap\">",
"     &gt;100,000/microL,",
"    </span>",
"    and there are no contraindications to anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (7500 to 10,000 units twice a day) or LMW heparin should be instituted in any perioperative period, during immobilization, or when an indwelling intravenous catheter is used. Such prophylaxis should also be started in the first trimester of pregnancy and continued until four to six weeks post-partum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link&amp;anchor=H9#H9\">",
"     \"Anticoagulation during pregnancy\", section on 'Management of specific conditions requiring anticoagulation'",
"    </a>",
"    .) The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    in these settings is under consideration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Prednisone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since activation of complement may be involved in thrombotic episodes, moderate to high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) can be given, although the effectiveness of this agent has been questioned. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Glucocorticoids and ACTH'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     HEMATOPOIETIC CELL TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identical twin (syngeneic) and HLA identical sibling hematopoietic cell transplantation (HCT) have been used successfully in selected patients with PNH [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/63-67\">",
"     63-67",
"    </a>",
"    ]. Marrow ablative conditioning regimens are commonly administered to eliminate the PNH clone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/63,65,66\">",
"     63,65,66",
"    </a>",
"    ]. In one syngeneic transplant, the absence of conditioning was associated with gradual loss of the transplanted cells and symptom recurrence at 17 months, suggesting a survival advantage for the PNH clone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/68\">",
"     68",
"    </a>",
"    ]. Matched unrelated HCT has also been successfully used in some patients. Complications with this procedure appear to be no more frequent in PNH than in other disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/64-66\">",
"     64-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A report from the International Bone Marrow Transplant Registry described the outcome in 57 patients with PNH who received HCT between 1978 and 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/66\">",
"     66",
"    </a>",
"    ]. Forty-eight of the donors were HLA-identical siblings, two were identical twins, one was a phenotypically HLA-identical parent, and six were unrelated HLA-matched donors. The median age at transplant was 28 years (range 10 to 47 years) and the median interval from the time of diagnosis to transplant was 26 months (range 2 to 240 months). Severe aplastic anemia was present pretransplant in 32 percent. The following results were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/66\">",
"     66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sustained engraftment occurred in 77 percent of the evaluable patients; acute (&ge; grade II) and chronic graft versus host disease were present in 34 and 33 percent, respectively.",
"     </li>",
"     <li>",
"      Overall survival following HLA-matched sibling transplantation was 56 percent at a median follow-up of 44 months. Of the seven patients receiving HCT from a parent or a matched unrelated donor, only one was alive at five years.",
"     </li>",
"     <li>",
"      Two patients received identical twin transplants, one with prior conditioning, resulting in engraftment and complete recovery at more than eight years. The one who received no prior conditioning had graft failure; a second transplant preceded by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and total body irradiation resulted in complete recovery and survival at more than 12 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The largest report, from the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation and the French Society of Hematology, described results in 211 patients with PNH who received allogeneic HCT between 1978 and 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/43\">",
"     43",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PNH had been present before HCT for a median time of 30 months; the average age at the time of HCT was 30 years (range: 23 to 39). Indications for HCT included severe aplastic anemia, recurrent severe hemolytic anemia, thrombosis, and",
"      <span class=\"nowrap\">",
"       MDS/AML.",
"      </span>",
"     </li>",
"     <li>",
"      Engraftment failure was noted in 7 percent; only one patient had a documented recurrence of PNH post-HCT. At a median follow-up of 61 months the five-year probability of overall survival was 68 percent.",
"     </li>",
"     <li>",
"      Five-year overall survivals were 86, 69, and 54 percent for those whose indication for HCT was recurrent hemolytic anemia, aplastic anemia, or thromboembolism, respectively. These data, along with matched pair comparisons with those not receiving HCT, indicated that only thromboembolism as the indication for HCT was associated with worse outcome. It was concluded that allogeneic HCT is probably not a suitable treatment option for life-threatening thromboembolism in patients with PNH, especially given the efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"       eculizumab",
"      </a>",
"      in preventing such complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The observation of graft failure or relapse after syngeneic transplants has been observed in other patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/65,68\">",
"     65,68",
"    </a>",
"    ]. Although HCT might be expected to cure PNH, one review of 17 patients found that relapse of PNH occurred in all five recipients of syngeneic transplants without conditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/69\">",
"     69",
"    </a>",
"    ]. In one patient, polymerase chain reaction analysis of the PIG-A gene showed that relapse was due to the emergence of a new clone, rather than persistence of the original clone [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/69\">",
"     69",
"    </a>",
"    ]. This finding supports the hypothesis that the bone marrow environment may create selective conditions favoring the emergence of PNH clones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candidates for HCT generally include those with life-threatening disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since there is considerable experience with the successful use of HCT for aplastic anemia, HCT is indicated in the patient with PNH, significant degrees of neutropenia and thrombocytopenia, and severe bone marrow hypoplasia, as demonstrated on bone marrow aspiration and biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29930?source=see_link\">",
"       \"Aplastic anemia: Prognosis and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe thrombotic events, particularly involving the hepatic veins, carry such a serious prognosis that consideration for transplantation is warranted in patients eligible for this procedure (eg, having an HLA matched sibling donor, age less than 45 to 50 years). By reversing the thrombotic tendency, HCT can lead to reversal of the Budd-Chiari syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/63\">",
"       63",
"      </a>",
"      ]. The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"       eculizumab",
"      </a>",
"      may effectively prevent further thrombosis, thus eliminating thrombosis as a reason for undergoing HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transplantation early in the course of the disease has been suggested for children, since transplantation is better tolerated in children than in adults and the long-term prognosis of children with PNH is somewhat limited [",
"      <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/70,71\">",
"       70,71",
"      </a>",
"      ]. In one report of 26 PNH patients &le;21 years of age, only 4 (15 percent) survived more than 15 years after diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/71\">",
"       71",
"      </a>",
"      ]. As noted above, the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"       eculizumab",
"      </a>",
"      may alter the need for such HCT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In many patients, however, clear indications for HCT are not present. Although many of these patients do well over a long period of time, PNH is associated with appreciable morbidity and mortality. The potential benefits of HCT in this setting must be balanced against the untoward consequences of this procedure, such as its 15 percent mortality rate. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Since peripheral blood progenitor cells can be harvested by leukocytapheresis, some investigators have suggested that the \"normal\" GPI-positive stem cell population can be separated and reinfused. If this approach were to be successful, it would probably be necessary to \"condition\" the marrow by chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation, since GPI-positive cells do not grow well in the marrow environment. This approach has not yet been attempted.",
"   </p>",
"   <p>",
"    However, autologous transplantation is unlikely to be successful because of the difficulty in obtaining sufficient numbers of normal stem cells. In one study, the majority of the most primitive peripheral blood stem cells were of normal phenotype in patients with PNH; however, the cells that were mobilized into the peripheral blood with G-CSF were phenotypically similar to mature neutrophils, ie, mainly PNH cells [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TREATMENT OF APLASIA OTHER THAN TRANSPLANTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a small number of patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    has been tried as an alternative to HCT for aplastic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. The rationale for the use of cyclosporine is the hypothesis that immune-mediated bone marrow damage in PNH is primarily directed against the normal GPI-positive cells, producing a growth advantage for the GPI-negative PNH cells. One report of three such patients noted a complete response in two after 6 and 24 months, and a partial response in the third after 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/73\">",
"     73",
"    </a>",
"    ]. The PNH clone and hemolysis persisted, suggesting that cyclosporine acted via immune mechanisms and not on the PNH cells. The disease relapsed in two patients in whom cyclosporine was withdrawn.",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    for marrow aplasia in PNH remains to be determined in a larger number of patients. Cyclosporine does not appear to be beneficial in patients without aplasia in whom the hematologic and PNH characteristics are not changed [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Antithymocyte globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one series, seven patients with PNH and aplastic anemia received antithymocyte globulin (ATG, 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for eight days along with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    to prevent or control serum sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/75\">",
"     75",
"    </a>",
"    ]. Three patients experienced a sustained improvement in at least one peripheral blood cytopenia, including one patient who had a complete trilineage response. These patients had hypoproliferative features and low-grade hemolysis which persisted at the same rate after therapy, whereas the degree of hemolysis was more pronounced in the nonresponders.",
"   </p>",
"   <p>",
"    In one series of 100 patients with aplastic anemia, the response to treatment with ATG in patients with normal and GPI-anchored protein-deficient granulocytes was 71 percent and 82 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/76\">",
"     76",
"    </a>",
"    ]. No statistically significant evidence of expansion in the size of the PNH clone was seen during long-term follow-up of these patients.",
"   </p>",
"   <p>",
"    These preliminary observations suggest that impaired hematopoiesis in PNH may respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or ATG treatment. However, the hemolytic component of the disease is not affected but may be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     eculizumab",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The defective PIG-A gene in PNH has been cloned. It is therefore theoretically possible to correct the defect in the abnormal stem cells using gene therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42392?source=see_link\">",
"     \"Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At present, the mechanism that enables the PNH clone to expand in the bone marrow is not understood since PIG-A inactivation alone does not confer a proliferative advantage to the hematopoietic stem cell. In view of the relationship between PNH and aplastic anemia, it may be that the cause of the failure of normal hematopoiesis in aplastic anemia enables the PNH clone to proliferate. Correcting the PNH cell defect may allow exposure to the insult causing bone marrow failure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/79\">",
"     79",
"    </a>",
"    ]. For these reasons, a better understanding of the problems of hematopoiesis will be required prior to such an attempt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Protein transfer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cell-to-cell transfer of GPI proteins has been demonstrated in a variety of systems. Transfer of GPI-linked proteins has been shown to be feasible using high density lipoproteins or washed RBC microvesicles [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/80\">",
"     80",
"    </a>",
"    ], or an alternative artificial glycolipid anchor (Prodaptin) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/43/17082/abstract/54\">",
"     54",
"    </a>",
"    ]. The PNH red cells exposed to these soluble preparations manifested both increased cell-associated CD55 and CD59 levels and decreased in vitro complement-mediated hemolysis. The advantage of these preparations over red blood cell transfusions is that they can be sterilized and do not result in iron overload.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Suspecting the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) should be suspected in patients with",
"    <strong>",
"     one or more",
"    </strong>",
"    of the following presentations. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical presentation of the classic disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Coombs negative acquired hemolytic anemia",
"     </li>",
"     <li>",
"      Intravascular hemolysis with or without hemoglobinuria",
"     </li>",
"     <li>",
"      Granulocytopenia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombocytopenia in the presence of an elevated reticulocyte count",
"     </li>",
"     <li>",
"      Aplastic anemia",
"     </li>",
"     <li>",
"      Myelodysplastic syndrome (refractory anemia and hypoplastic variants)",
"     </li>",
"     <li>",
"      Episodic dysphagia or abdominal pain",
"     </li>",
"     <li>",
"      Venous thrombosis along with evidence of hemolysis, particularly thrombosis of the abdominal or cerebral veins (eg, Budd-Chiari syndrome, mesenteric or portal vein thrombosis, thrombosis of cerebral or dermal veins)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following laboratory tests are helpful in assessing the patient with a presumptive diagnosis of PNH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count with white blood cell differential, platelet count, red cell indices (ie, MCV, MCH, MCHC), and reticulocyte count",
"     </li>",
"     <li>",
"      For anemic patients &mdash; direct antiglobulin (Coombs) test, serum lactate dehydrogenase (LDH), direct and indirect bilirubin, haptoglobin, urinalysis for the presence of hemoglobin and hemosiderin, serum iron, total iron binding capacity, ferritin",
"     </li>",
"     <li>",
"      Bone marrow aspiration and biopsy for subjects with pancytopenia, granulocytopenia, thrombocytopenia, or reticulocytopenia, in order to assess for the presence of bone marrow hypoplasia or aplasia. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Treatment of aplasia other than transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Making the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;To be certain of the diagnosis of PNH, the absence or near-absence of two glycosyl-phosphatidyl-inosityl (GPI)-linked antigens (eg, CD55, CD59) in at least two cell lines (eg, red cells, granulocytes), or the absence of the GPI anchor by the FLAER technique, should be demonstrated. This is performed using flow cytometric methods. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Expression of GPI anchored proteins'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only potentially curative treatment for PNH is allogeneic hematopoietic cell transplantation. All other treatments are supportive and are directed against the major manifestations of the disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic patients, especially those with a PNH clone &lt;10 percent, or those with only mild symptoms should not be treated. PNH clone size should be determined every 6 to 12 months in order to monitor for disease progression.",
"     </li>",
"     <li>",
"      Because hemoglobinuria is a prominent complication of PNH, all patients with PNH should be evaluated for the presence of iron deficiency. If found, iron deficiency should be treated with an oral iron preparation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Iron'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment of anemia due to iron deficiency\", section on 'Oral iron therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As a general precaution, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      supplementation (1",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      should be given prophylactically to those with hemolytic anemia in order to avoid the development of folic acid deficiency. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Folic acid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with symptomatic anemia due to PNH, supportive treatment with periodic blood transfusions or the use of erythropoiesis-stimulating agents, androgens,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      glucocorticoids have all been helpful in alleviating the signs and symptoms of anemia. There are no randomized studies that give guidance on the selection of an appropriate agent for this complication of PNH. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment of anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For selected transfusion-dependent patients or patients with disabling symptoms (eg, fatigue, thromboses, frequent paroxysms of pain, end-organ damage), we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"       eculizumab",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Any patient with a history of thrombosis of abdominal or cerebral veins should be treated with eculizumab; the necessity of additional anticoagulation therapy has not been established. Enthusiasm for this agent is reduced because of its expense, potential need for indefinite treatment, and increased risk for Neisserial infection. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Eculizumab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients, regardless of clone size, who have evidence of thrombosis without other cause should be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"       eculizumab",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      probably should be used acutely, but their continued use or discontinuation is not established.",
"     </li>",
"     <li>",
"      The prophylaxis of thrombosis in PNH is not well established. Although both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      are useful, their ability to prevent thrombosis is not complete.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"       Eculizumab",
"      </a>",
"      is likely to provide such prophylaxis, but this needs to be established by further data.",
"     </li>",
"     <li>",
"      For patients with severe aplastic anemia or cytopenia due to PNH, available choices include allogeneic hematopoietic cell transplantation or immunosuppressive regimens, depending upon patient age and the availability of an HLA-matched donor. These important issues are discussed in depth separately. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Hematopoietic cell transplantation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Treatment of aplasia other than transplantation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18217?source=see_link\">",
"       \"Hematopoietic cell transplantation in aplastic anemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29930?source=see_link\">",
"       \"Aplastic anemia: Prognosis and treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/1\">",
"      Rosse WF. Paroxysmal nocturnal hemoglobinuria as a molecular disease. Medicine (Baltimore) 1997; 76:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/2\">",
"      Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005; 106:3699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/3\">",
"      Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. Br J Haematol 2007; 137:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/4\">",
"      Luzzatto L, Gianfaldoni G, Notaro R. Management of paroxysmal nocturnal haemoglobinuria: a personal view. Br J Haematol 2011; 153:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/5\">",
"      Hartmann RC, Jenkins DE. The \"sugar-water\" test for paroxysmal nocturnal hemoglobinuria. N Engl J Med 1966; 275:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/6\">",
"      Ham TH, Dingle JH. STUDIES ON DESTRUCTION OF RED BLOOD CELLS. II. CHRONIC HEMOLYTIC ANEMIA WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: CERTAIN IMMUNOLOGICAL ASPECTS OF THE HEMOLYTIC MECHANISM WITH SPECIAL REFERENCE TO SERUM COMPLEMENT. J Clin Invest 1939; 18:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/7\">",
"      Rosse WF. Dr Ham's test revisited. Blood 1991; 78:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/8\">",
"      Brodsky RA. Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia. Ann Intern Med 2008; 148:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/9\">",
"      Hall SE, Rosse WF. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood 1996; 87:5332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/10\">",
"      Shichishima T, Terasawa T, Saitoh Y, et al. Diagnosis of paroxysmal nocturnal haemoglobinuria by phenotypic analysis of erythrocytes using two-colour flow cytometry with monoclonal antibodies to DAF and CD59/MACIF. Br J Haematol 1993; 85:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/11\">",
"      Mukhina GL, Buckley JT, Barber JP, et al. Multilineage glycosylphosphatidylinositol anchor-deficient haematopoiesis in untreated aplastic anaemia. Br J Haematol 2001; 115:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/12\">",
"      Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci U S A 1999; 96:5209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/13\">",
"      Brodsky RA, Mukhina GL, Li S, et al. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am J Clin Pathol 2000; 114:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/14\">",
"      Borowitz MJ, Craig FE, Digiuseppe JA, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom 2010; 78:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/15\">",
"      Hern&aacute;ndez-Campo PM, Almeida J, Acevedo MJ, et al. Detailed immunophenotypic characterization of different major and minor subsets of peripheral blood cells in patients with paroxysmal nocturnal hemoglobinuria. Transfusion 2008; 48:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/16\">",
"      Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/17\">",
"      Soci&eacute; G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 1996; 348:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/18\">",
"      Nishimura J, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) 2004; 83:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/19\">",
"      Sears DA, Anderson PR, Foy AL, et al. Urinary iron excretion and renal metabolism of hemoglobin in hemolytic diseases. Blood 1966; 28:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/20\">",
"      Rosse WF, Gutterman LA. The effect of iron therapy in paroxysmal nocturnal hemoglobinuria. Blood 1970; 36:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/21\">",
"      Dacie JV, Firth D. Blood transfusion in nocturnal haemoglobinuria. Br Med J 1943; i:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/22\">",
"      HEFFERNAN CK, JASWON N. A case of paroxysmal nocturnal haemoglobinuria associated with secondary haemochromatosis, a lower nephron nephrosis, and a megaloblastic anaemia. J Clin Pathol 1955; 8:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/23\">",
"      HEITZMAN EJ, CAMPBELL JS, STEFANINI M. Paroxysmal nocturnal hemoglobinuria with hemosiderin nephrosis. Am J Clin Pathol 1953; 23:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/24\">",
"      HIRSH J, UNGAR B, ROBINSON JS. PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA: AN ACQUIRED DYSHAEMOPOIESIS. Australas Ann Med 1964; 13:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/25\">",
"      DACIE JV. Transfusion of saline-washed red cells in nocturnal haemoglobinuria (Marchiafava-Micheli disease). Clin Sci (Lond) 1948; 7:65.",
"     </a>",
"    </li>",
"    <li>",
"     Dacie JV. Paroxysmal nocturnal hemoglobinuria. In: The Haemolytic Anaemias &mdash; Congenital and Acquired, 2nd ed, Dacie JV (Ed), Grune &amp; Stratton, New York 1967. p.1128.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/27\">",
"      FUNDENBERG H, PALMER WL, KIRSNER JB. Paroxysmal nocturnal hemoglobinuria; report of a case with rare hemoglobinuria treated with corticotropin. Am J Med Sci 1954; 227:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/28\">",
"      Firkin F, Goldberg H, Firkin BG. Glucocorticoid management of paroxysmal nocturnal haemoglobinuria. Australas Ann Med 1968; 17:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/29\">",
"      Rosse WF. Treatment of paroxysmal nocturnal hemoglobinuria. Blood 1982; 60:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/30\">",
"      Hartmann RC, Jenkins DE Jr, McKee LC, Heyssel RM. Paroxysmal nocturnal hemoglobinuria: clinical and laboratory studies relating to iron metabolism and therapy with androgen and iron. Medicine (Baltimore) 1966; 45:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/31\">",
"      Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet 2009; 373:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/32\">",
"      Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/33\">",
"      Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 2005; 106:2559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/34\">",
"      Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/35\">",
"      Hill A, Rother RP, Wang X, et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2010; 149:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/36\">",
"      Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008; 111:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/37\">",
"      Schubert J, Hillmen P, R&ouml;th A, et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2008; 142:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/38\">",
"      Hillmen P, Muus P, D&uuml;hrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007; 110:4123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/39\">",
"      Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011; 117:6786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/40\">",
"      Brodsky RA, Hillmen P, Schubert J, et al. Safety and efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria evolving from patients with myelodysplastic syndrome and aplastic anemia (abstract). J Clin Oncol 2007; 25:365s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/41\">",
"      Kelly R, Arnold L, Richards S, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol 2010; 149:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/42\">",
"      Marasca R, Coluccio V, Santachiara R, et al. Pregnancy in PNH: another eculizumab baby. Br J Haematol 2010; 150:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/43\">",
"      Peffault de Latour R, Schrezenmeier H, Bacigalupo A, et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica 2012; 97:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/44\">",
"      Lindorfer MA, Pawluczkowycz AW, Peek EM, et al. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood 2010; 115:2283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/45\">",
"      Hill A, Rother RP, Arnold L, et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica 2010; 95:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/46\">",
"      Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 2009; 113:4094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/47\">",
"      Risitano AM, Notaro R, Luzzatto L, et al. Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab. N Engl J Med 2010; 363:2270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/48\">",
"      Berzuini A, Montanelli F, Prati D. Hemolytic anemia after eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2010; 363:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/49\">",
"      Risitano AM, Marando L, Seneca E, Rotoli B. Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab. Blood 2008; 112:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/50\">",
"      Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2009; 113:6522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/51\">",
"      Dmytrijuk A, Robie-Suh K, Cohen MH, et al. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist 2008; 13:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/52\">",
"      Balleari E, Gatti AM, Mareni C, et al. Recombinant human erythropoietin for long-term treatment of anemia in paroxysmal nocturnal hemoglobinuria. Haematologica 1996; 81:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/53\">",
"      Schubert J, Scholz C, Geissler RG, et al. G-CSF and cyclosporin induce an increase of normal cells in hypoplastic paroxysmal nocturnal hemoglobinuria. Ann Hematol 1997; 74:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/54\">",
"      Hill A, Ridley SH, Esser D, et al. Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy. Blood 2006; 107:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/55\">",
"      Lai S, Venugopal P, Leslie W. Long-term remission of paroxysmal nocturnal hemoglobinuria following chemoimmunotherapy for non-Hodgkin lymphoma. Clin Adv Hematol Oncol 2012; 10:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/56\">",
"      Ray JG, Burows RF, Ginsberg JS, Burrows EA. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient. Haemostasis 2000; 30:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/57\">",
"      McMullin MF, Hillmen P, Jackson J, et al. Tissue plasminogen activator for hepatic vein thrombosis in paroxysmal nocturnal haemoglobinuria. J Intern Med 1994; 235:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/58\">",
"      Sholar PW, Bell WR. Thrombolytic therapy for inferior vena cava thrombosis in paroxysmal nocturnal hemoglobinuria. Ann Intern Med 1985; 103:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/59\">",
"      Araten DJ, Notaro R, Thaler HT, et al. Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature. Haematologica 2012; 97:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/60\">",
"      Emadi A, Brodsky RA. Successful discontinuation of anticoagulation following eculizumab administration in paroxysmal nocturnal hemoglobinuria. Am J Hematol 2009; 84:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/61\">",
"      Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 2003; 102:3587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/62\">",
"      Baglin TP, Keeling DM, Watson HG, British Committee for Standards in Haematology. Guidelines on oral anticoagulation (warfarin): third edition--2005 update. Br J Haematol 2006; 132:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/63\">",
"      Graham ML, Rosse WF, Halperin EC, et al. Resolution of Budd-Chiari syndrome following bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. Br J Haematol 1996; 92:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/64\">",
"      Antin JH, Ginsburg D, Smith BR, et al. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria: eradication of the PNH clone and documentation of complete lymphohematopoietic engraftment. Blood 1985; 66:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/65\">",
"      Kawahara K, Witherspoon RP, Storb R. Marrow transplantation for paroxysmal nocturnal hemoglobinuria. Am J Hematol 1992; 39:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/66\">",
"      Saso R, Marsh J, Cevreska L, et al. Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. Br J Haematol 1999; 104:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/67\">",
"      Santarone S, Bacigalupo A, Risitano AM, et al. Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Haematologica 2010; 95:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/68\">",
"      Endo M, Beatty PG, Vreeke TM, et al. Syngeneic bone marrow transplantation without conditioning in a patient with paroxysmal nocturnal hemoglobinuria: in vivo evidence that the mutant stem cells have a survival advantage. Blood 1996; 88:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/69\">",
"      Nafa K, Bessler M, Deeg HJ, Luzzatto L. New somatic mutation in the PIG-A gene emerges at relapse of paroxysmal nocturnal hemoglobinuria. Blood 1998; 92:3422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/70\">",
"      Flotho C, Strahm B, Kontny U, et al. Stem cell transplantation for paroxysmal nocturnal haemoglobinuria in childhood. Br J Haematol 2002; 118:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/71\">",
"      Ware RE, Hall SE, Rosse WF. Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. N Engl J Med 1991; 325:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/72\">",
"      Johnson RJ, Rawstron AC, Richards S, et al. Circulating primitive stem cells in paroxysmal nocturnal hemoglobinuria (PNH) are predominantly normal in phenotype but granulocyte colony-stimulating factor treatment mobilizes mainly PNH stem cells. Blood 1998; 91:4504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/73\">",
"      Stoppa AM, Vey N, Sainty D, et al. Correction of aplastic anaemia complicating paroxysmal nocturnal haemoglobinuria: absence of eradication of the PNH clone and dependence of response on cyclosporin A administration. Br J Haematol 1996; 93:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/74\">",
"      van Kamp H, van Imhoff GW, de Wolf JT, et al. The effect of cyclosporine on haematological parameters in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995; 89:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/75\">",
"      Paquette RL, Yoshimura R, Veiseh C, et al. Clinical characteristics predict response to antithymocyte globulin in paroxysmal nocturnal haemoglobinuria. Br J Haematol 1997; 96:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/76\">",
"      Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 1999; 131:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/77\">",
"      Nishimura J, Smith CA, Phillips KL, et al. Paroxysmal nocturnal hemoglobinuria: molecular pathogenesis and molecular therapeutic approaches. Hematopathol Mol Hematol 1998; 11:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/78\">",
"      Phillips KL, Ware RE, Hall S, et al. Efficient retrovirus-mediated PIG-A gene transfer and stable restoration of GPI-anchored protein expression in cells with the PNH phenotype. Blood 2001; 97:3004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/79\">",
"      Bessler M, Hillmen P. Somatic mutation and clonal selection in the pathogenesis and in the control of paroxysmal nocturnal hemoglobinuria. Semin Hematol 1998; 35:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/43/17082/abstract/80\">",
"      Sloand EM, Maciejewski JP, Dunn D, et al. Correction of the PNH defect by GPI-anchored protein transfer. Blood 1998; 92:4439.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7163 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-E9F4F161E5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_43_17082=[""].join("\n");
var outline_f16_43_17082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical presentation of the classic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Expression of GPI anchored proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT OF ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Iron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Folic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Red blood cell transfusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Glucocorticoids and ACTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Androgenic hormones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Eculizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1145380961\">",
"      - Extravascular hemolysis after eculizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Neisserial infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT OF THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Prophylactic anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Prednisone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      HEMATOPOIETIC CELL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TREATMENT OF APLASIA OTHER THAN TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Antithymocyte globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Protein transfer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Suspecting the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Making the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=related_link\">",
"      Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29930?source=related_link\">",
"      Aplastic anemia: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14121?source=related_link\">",
"      Clinical manifestations of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3434?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=related_link\">",
"      Epidemiology of Neisseria meningitidis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18217?source=related_link\">",
"      Hematopoietic cell transplantation in aplastic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=related_link\">",
"      Inherited disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42392?source=related_link\">",
"      Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/17/13593?source=related_link\">",
"      Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=related_link\">",
"      Treatment of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=related_link\">",
"      Treatment of intermediate, low, or very low risk myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_43_17083="Risks kidney stones PI";
var content_f16_43_17083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F64849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F64849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dietary factors and medical problems that increase the risk of kidney stones",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Not drinking enough fluid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diet with low levels of calcium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use of calcium supplements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diet with high levels of animal protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diet with high levels of sugars (sucrose, fructose)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diet with low levels of phytate (found in wheat, rice, rye, barley, and bean products)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High sodium diet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequent spinach consumption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other medical conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary hyperparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gout",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes mellitus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obesity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crohn's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric or intestinal bypass surgery",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_43_17083=[""].join("\n");
var outline_f16_43_17083=null;
var title_f16_43_17084="Causes secondary iron overload";
var content_f16_43_17084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of iron overload states",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Classification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Hereditary hemochromatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        HH: HFE related",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        C282Y homozygosity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        C282Y/H63D compound heterozygosity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Other mutations of HFE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        HH: non-HFE related; other gene mutations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Juvenile hemochromatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Autosomal dominant hemochromatosis (Solomon Islands)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Secondary iron overload",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Iron-loading anemias &plusmn; transfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Thalassemia major",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Sideroblastic anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Chronic hemolytic anemias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dietary iron overload",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Chronic liver diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hepatitis C and B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Alcohol-induced liver disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Porphyria cutanea tarda",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Fatty liver disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Miscellaneous causes of iron overload",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        African iron overload",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neonatal iron overload",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aceruloplasminemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital atransferrinemia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the American Association for the Study of Liver Diseases. Tavill, AS, Hepatology 2001; 33:1321.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_43_17084=[""].join("\n");
var outline_f16_43_17084=null;
var title_f16_43_17085="Pharmacology nonbenzodiazepines";
var content_f16_43_17085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F83292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F83292&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nonbenzodiazepine hypnotics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"7\" width=\"14%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Nonbenzodiazepine hypnotics",
"       </td>",
"       <td class=\"subtitle1\">",
"        US trade name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adult dose",
"        <br/>",
"        (usual)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preparation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Indication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Half-life",
"        <br/>",
"        (hours)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential for drug interactions",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zaleplon",
"       </td>",
"       <td>",
"        Sonata",
"       </td>",
"       <td>",
"        5 to 15 mg",
"       </td>",
"       <td>",
"        Capsule",
"       </td>",
"       <td>",
"        Sleep onset insomnia",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Zolpidem",
"       </td>",
"       <td>",
"        Ambien",
"       </td>",
"       <td rowspan=\"3\">",
"        5 to 10 mg",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Tablet",
"       </td>",
"       <td rowspan=\"3\">",
"        Sleep onset insomnia",
"       </td>",
"       <td>",
"        1.4 to 4.5",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         Low to moderate",
"        </p>",
"        <p>",
"         Zolpidem is metabolized in part by CYP3A4",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Edluar",
"       </td>",
"       <td>",
"        Sublingual tablet",
"       </td>",
"       <td>",
"        1.6 to 6.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zolpimist",
"       </td>",
"       <td>",
"        Oral liquid (each spray delivers 5 mg)",
"       </td>",
"       <td>",
"        1.7 to 8.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zolpidem controlled release",
"       </td>",
"       <td>",
"        Ambien CR",
"       </td>",
"       <td>",
"        6.25 to 12.5 mg",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Coated tablet",
"       </td>",
"       <td>",
"        Sleep onset insomnia or sleep maintenance insomnia",
"       </td>",
"       <td>",
"        1.4 to 4.5, sustained release preparation",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zolpidem middle of night administration",
"       </td>",
"       <td>",
"        Intermezzo",
"       </td>",
"       <td>",
"        1.75 to 3.5 mg",
"       </td>",
"       <td>",
"        Dissolvable tablet (sublingual)",
"       </td>",
"       <td>",
"        Sleep maintenance insomnia (middle night dose)",
"       </td>",
"       <td>",
"        1.4 to 6.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eszopiclone",
"       </td>",
"       <td>",
"        Lunesta",
"       </td>",
"       <td>",
"        1 to 3 mg",
"       </td>",
"       <td>",
"        Tablet",
"       </td>",
"       <td>",
"        Sleep onset insomnia or sleep maintenance insomnia",
"       </td>",
"       <td>",
"        6 to 9",
"       </td>",
"       <td>",
"        <p>",
"         Moderate",
"        </p>",
"        Eszopiclone is metabolized in part by CYP3A4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Other FDA-approved hypnotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ramelteon",
"       </td>",
"       <td>",
"        Rozerem",
"       </td>",
"       <td>",
"        8 mg",
"       </td>",
"       <td>",
"        Tablet",
"       </td>",
"       <td>",
"        Sleep onset insomnia",
"       </td>",
"       <td>",
"        1 to 2.6 (drug); 2 to 5 (active metabolite)",
"       </td>",
"       <td>",
"        <p>",
"         Moderate",
"        </p>",
"        <p>",
"         Ramelteon is metabolized in part by CYP1A2",
"        </p>",
"        Strong inhibitors of CYP1A2, including most fluoroquinolones, may interact. Use with fluvoxamine contraindicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxepin",
"       </td>",
"       <td>",
"        Silenor",
"       </td>",
"       <td>",
"        3 to 6 mg",
"       </td>",
"       <td>",
"        Tablet",
"       </td>",
"       <td>",
"        Sleep maintenance insomnia",
"       </td>",
"       <td>",
"        15 (drug); 31 (active metabolite)",
"       </td>",
"       <td>",
"        <p>",
"         Moderate",
"        </p>",
"        Doxepin is metabolized in part by CYP2D6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Initiate treatment using lowest dose shown for women, older adults, those with low body weight, debilitated patients, or those receiving treatment with opioid analgesics or other central nervous system or cardiorespiratory depressants.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     For specific drug interactions, including management recommendations and combinations that should be avoided, see Lexi-Interact&trade; program included with UpToDate.",
"     <br/>",
"     &Delta; Recommended dose in women is 5 mg due to risk of impaired driving.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Recommended dose in women is 6.5 mg due to risk of impaired driving.",
"     <br/>",
"     &sect; Duration of effect longer than predicted by half-life due to sustained release.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_43_17085=[""].join("\n");
var outline_f16_43_17085=null;
var title_f16_43_17086="Contents: Peripheral artery disease";
var content_f16_43_17086=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/3/5182\">",
"       Cardiovascular Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Peripheral artery disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Peripheral artery disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/5/6231\">",
"           Acquired arteriovenous fistula of the lower extremity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/9/14486\">",
"           Clinical manifestations and evaluation of chronic critical limb ischemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/60/36810\">",
"           Estimation of cardiac risk prior to noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/16/37128\">",
"           Lower extremity peripheral artery disease in end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/16/10506\">",
"           Noninvasive diagnosis of arterial disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/62/8170\">",
"           Thromboangiitis obliterans (Buerger's disease)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Etiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/5/6231\">",
"           Acquired arteriovenous fistula of the lower extremity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/31/30201\">",
"           Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/9/14486\">",
"           Clinical manifestations and evaluation of chronic critical limb ischemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/16/37128\">",
"           Lower extremity peripheral artery disease in end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/62/8170\">",
"           Thromboangiitis obliterans (Buerger's disease)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Manifestations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/31/30201\">",
"           Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/9/14486\">",
"           Clinical manifestations and evaluation of chronic critical limb ischemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/61/12245\">",
"           Overview of upper extremity peripheral artery disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/5/6231\">",
"           Acquired arteriovenous fistula of the lower extremity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/3/13368\">",
"           Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/12/6344\">",
"           Elective noncardiac surgery after percutaneous coronary intervention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/21/44376\">",
"           Indications for surgery in the patient with lower extremity claudication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/16/37128\">",
"           Lower extremity peripheral artery disease in end-stage renal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/45/29402\">",
"           Management of cardiac risk for noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/21/32090\">",
"           Medical management of claudication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/61/12245\">",
"           Overview of upper extremity peripheral artery disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/0/38921\">",
"           Percutaneous interventional procedures in the patient with lower extremity claudication",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/17/29975\">",
"           Perioperative myocardial infarction after noncardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/62/8170\">",
"           Thromboangiitis obliterans (Buerger's disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/58/19370\">",
"           Treatment of chronic lower extremity critical limb ischemia",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-E1E90A8E79-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f16_43_17086=[""].join("\n");
var outline_f16_43_17086=null;
var title_f16_43_17087="CF vit preps other";
var content_f16_43_17087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Supplements of water-soluble vitamins and zinc for individuals with cystic fibrosis*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Age",
"      </td>",
"      <td class=\"subtitle1\">",
"       SourceCF&reg; (drops, chewables, softgels)",
"      </td>",
"      <td class=\"subtitle1\">",
"       ADEKs&reg; (chewables)",
"      </td>",
"      <td class=\"subtitle1\">",
"       AQUADEKs&reg; (drops, softgels)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Vitamax&reg; (drops, chewables)",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        Poly-Vi-Sol&reg; (drops)",
"       </p>",
"       <p>",
"        Centrum&reg; (chewable, tablet)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Thiamin B1 (mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       0.5 mg/1 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0.6 mg/1 mL",
"      </td>",
"      <td>",
"       0.5 mg/1 mL",
"      </td>",
"      <td>",
"       0.5 mg/1 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       1 mg/2 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       1.2 mg/2 mL",
"      </td>",
"      <td>",
"       1 mg/2 mL",
"      </td>",
"      <td>",
"       1 mg/2 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       1.5 mg/1 chewable",
"      </td>",
"      <td>",
"       1.2 mg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        1.5 mg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       1.5 mg/1 chewable",
"      </td>",
"      <td>",
"       1.5 mg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       3 mg/2 softgels",
"      </td>",
"      <td>",
"       2.4 mg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        3 mg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       3 mg/2 chewables",
"      </td>",
"      <td>",
"       3 mg/2 tablets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Riboflavin B2 (mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       0.6 mg/1 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0.6 mg/1 mL",
"      </td>",
"      <td>",
"       0.6 mg/1 mL",
"      </td>",
"      <td>",
"       0.6 mg/1 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       1.2 mg/2 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       1.2 mg/2 mL",
"      </td>",
"      <td>",
"       1.2 mg/2 mL",
"      </td>",
"      <td>",
"       1.2 mg/2 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       1.7 mg/1 chewable",
"      </td>",
"      <td>",
"       1.3 mg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        1.7 mg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       1.7 mg/1 chewable",
"      </td>",
"      <td>",
"       1.7 mg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       3.4 mg/2 softgels",
"      </td>",
"      <td>",
"       2.6 mg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        3.4 mg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       3.4 mg/2 chewables",
"      </td>",
"      <td>",
"       3.4 mg/2 tablets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Niacin (mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       6 mg/1 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       6 mg/1 mL",
"      </td>",
"      <td>",
"       6 mg/1 mL",
"      </td>",
"      <td>",
"       8 mg/1 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       12 mg/2 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       12 mg/2 mL",
"      </td>",
"      <td>",
"       12 mg/2 mL",
"      </td>",
"      <td>",
"       16 mg/2 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       10 mg/1 chewable",
"      </td>",
"      <td>",
"       10 mg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        20 mg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       20 mg/1 chewable",
"      </td>",
"      <td>",
"       20 mg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       40 mg/2 softgels",
"      </td>",
"      <td>",
"       20 mg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        40 mg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       40 mg/ 2 chewables",
"      </td>",
"      <td>",
"       40 mg/2 tablets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Pyridoxine B6 (mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       0.6 mg/1 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0.6 mg/1 mL",
"      </td>",
"      <td>",
"       0.6 mg/1 mL",
"      </td>",
"      <td>",
"       0.4 mg/1 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       1.2 mg/2 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       1.2 mg/2 mL",
"      </td>",
"      <td>",
"       1.2 mg/2 mL",
"      </td>",
"      <td>",
"       0.8 mg/2 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       1.9 mg/1 chewable",
"      </td>",
"      <td>",
"       1.5 mg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        1.9 mg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       2 mg/1 chewable",
"      </td>",
"      <td>",
"       2 mg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       3.8 mg/2 softgels",
"      </td>",
"      <td>",
"       3 mg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        3.8 mg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       4 mg/2 chewables",
"      </td>",
"      <td>",
"       4 mg/2 tablets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       B12 (mcg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       4 mcg/1 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"      <td>",
"       4 mcg/1 mL",
"      </td>",
"      <td>",
"       2 mcg/1 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       8 mcg/2 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"      <td>",
"       8 mcg/2 mL",
"      </td>",
"      <td>",
"       4 mcg/2 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       6 mcg/1 chewable",
"      </td>",
"      <td>",
"       12 mcg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        12 mcg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       6 mcg/1 chewable",
"      </td>",
"      <td>",
"       6 mcg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       12 mcg/2 softgels",
"      </td>",
"      <td>",
"       24 mcg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        24 mcg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       12 mcg/2 chewables",
"      </td>",
"      <td>",
"       12 mcg/2 tablets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Biotin (mcg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       15 mcg/1 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       15 mcg/1 mL",
"      </td>",
"      <td>",
"       15 mcg/1 mL",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       30 mcg/2 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       30 mcg/2 mL",
"      </td>",
"      <td>",
"       30 mcg/2 mL",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       100 mcg/1 chewable",
"      </td>",
"      <td>",
"       50 mcg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        100 mcg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       300 mcg/1 chewable",
"      </td>",
"      <td>",
"       45 mcg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       200 mcg/2 softgels",
"      </td>",
"      <td>",
"       100 mcg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        200 mcg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       600 mcg/2 chewables",
"      </td>",
"      <td>",
"       60 mcg/2 tablets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Folic Acid (mcg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"      <td>",
"       0 mcg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       200 mcg/1 chewable",
"      </td>",
"      <td>",
"       200 mcg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        200 mcg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       200 mcg/1 chewable",
"      </td>",
"      <td>",
"       400 mcg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       400 mcg/2 softgels",
"      </td>",
"      <td>",
"       400 mcg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        400 mcg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       400 mcg/2 chewables",
"      </td>",
"      <td>",
"       800 mcg/2 tablets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Ascorbic Acid C (mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       45 mg/1 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       45 mg/1 mL",
"      </td>",
"      <td>",
"       45 mg/1 mL",
"      </td>",
"      <td>",
"       35 mg/1 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       90 mg/2 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       90 mg/2 mL",
"      </td>",
"      <td>",
"       90 mg/2 mL",
"      </td>",
"      <td>",
"       70 mg/2 mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       100 mg/1 chewable",
"      </td>",
"      <td>",
"       60 mg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        75 mg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       60 mg/1 chewable",
"      </td>",
"      <td>",
"       60 mg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       200 mg/2 softgels",
"      </td>",
"      <td>",
"       120 mg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        150 mg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       120 mg/2 chewables",
"      </td>",
"      <td>",
"       120 mg/2 tablets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Pantothenic Acid (mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       3 mg/1 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       3 mg/1 mL",
"      </td>",
"      <td>",
"       3 mg/1 mL",
"      </td>",
"      <td>",
"       0 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       6 mg/2 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       6 mg/2 mL",
"      </td>",
"      <td>",
"       6 mg/2 mL",
"      </td>",
"      <td>",
"       0 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       12 mg/1 chewable",
"      </td>",
"      <td>",
"       10 mg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        12 mg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       10 mg/1 chewable",
"      </td>",
"      <td>",
"       10 mg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       24 mg/2 softgels",
"      </td>",
"      <td>",
"       20 mg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        24 mg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       20 mg/2 chewables",
"      </td>",
"      <td>",
"       20 mg/2 tablets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Zinc (mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infants",
"      </td>",
"      <td>",
"       5 mg/1 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       5 mg/1 mL",
"      </td>",
"      <td>",
"       7.5 mg/1 mL",
"      </td>",
"      <td>",
"       0 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1-3 years",
"      </td>",
"      <td>",
"       10 mg/2 mL",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       10 mg/2 mL",
"      </td>",
"      <td>",
"       15 mg/2 mL",
"      </td>",
"      <td>",
"       0 mg",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Children 4-8 years",
"      </td>",
"      <td>",
"       15 mg/1 chewable",
"      </td>",
"      <td>",
"       7.5 mg/1 chewable",
"      </td>",
"      <td>",
"       <p>",
"        For 4-10 yrs:",
"       </p>",
"       <p>",
"        10 mg/1 softgel",
"       </p>",
"      </td>",
"      <td>",
"       7.5 mg/1 chewable",
"      </td>",
"      <td>",
"       15 mg/1 chewable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       9 yrs to adults",
"      </td>",
"      <td>",
"       30 mg/2 softgels",
"      </td>",
"      <td>",
"       15 mg/2 chewables",
"      </td>",
"      <td>",
"       <p>",
"        For ages 10+:",
"       </p>",
"       <p>",
"        20 mg/2 softgels",
"       </p>",
"      </td>",
"      <td>",
"       15 mg/2 chewables",
"      </td>",
"      <td>",
"       22 mg/2 tablets",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The content of this table was confirmed with each company as of December 2008.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eurand Pharmaceuticals, Inc. All rights reserved. Available at: file://www.sourcecf.com/pdf/VitaminComparisonTablenew.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_43_17087=[""].join("\n");
var outline_f16_43_17087=null;
